

HUMAN ALPHA-GALACTOSIDASE VARIANTS

[0001] The present application claims priority to US Prov. Appln. Ser. No. 62/982,949, filed February 28, 2020, hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

[0002] The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, reduced immunogenicity, improved cellular uptake, and stability under both acidic (pH <4) and basic (pH >7) conditions, and improved globotriaosylceramide clearance from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

REFERENCE TO SEQUENCE LISTING, TABLE OR COMPUTER PROGRAM

[0003] The official copy of the Sequence Listing is submitted concurrently with the specification as an ASCII formatted text file via EFS-Web, with a filename of "CX7-203WO2_ST25.txt", a creation date of February 22, 2021, and a size of 4.43 megabytes. The Sequence Listing filed via EFS-Web is part of the specification and is incorporated in its entirety by reference herein.

BACKGROUND OF THE INVENTION

[0004] Human alpha galactosidase ("GLA"; EC 3.2.1.22) is a lysosomal glycoprotein responsible for hydrolyzing terminal alpha galactosyl moieties from glycolipids and glycoproteins. It works on many substrates present in a range of human tissues. Fabry disease (also referred to as angiokeratoma corporis diffusum, Anderson-Fabry disease, hereditary dystopic lipidosis, alpha-galactosidase A deficiency, GLA deficiency, and ceramide trihexosidase deficiency) is an X-linked inborn error of glycosphingolipid catabolism that results from deficient or absent activity of alpha-galactosidase A. Patients affected with Fabry disease accumulate globotriaosylceramide (referred to herein as "Gb₃" and "Gb3") and related glycosphingolipids in the plasma and cellular lysosomes of blood vessels, tissue and organs (See e.g., Nance et al., Arch. Neurol., 63:453-457 [2006]). As the patient ages, the blood vessels become progressively narrowed, due to the accumulation of these lipids, resulting in decreased blood flow and nourishment to the tissues, particularly in the skin, kidneys, heart, brain, and nervous system. Thus, Fabry disease is a systemic disorder that manifests as renal failure, cardiac disease, cerebrovascular disease, small-fiber peripheral neuropathy, and skin lesions, as well as other disorders (See e.g., Schiffmann, Pharm. Ther., 122:65-77 [2009]). Affected patients exhibit symptoms such as painful hands and feet, clusters of small, dark red spots on their skin, the decreased ability to sweat, corneal opacity, gastrointestinal issues, tinnitus, and hearing loss. Potentially life-threatening complications include progressive renal damage, heart attacks, and stroke. This disease

affects an estimated 1 in 40,000-60,000 males, but also occurs in females. Indeed, heterozygous women with Fabry disease experience significant life-threatening conditions including nervous system abnormalities, chronic pain, fatigue, high blood pressure, heart disease, kidney failure, and stroke, thus requiring medical treatment (See e.g., Want et al., Genet. Med., 13:457-484 [2011]). Signs of Fabry disease can start any time from infancy on, with signs usually beginning to show between ages 4 and 8, although some patients exhibit a milder, late-onset disease. Treatment is generally supportive and there is no cure for Fabry disease, thus there remains a need for a safe and effective treatment.

SUMMARY OF THE INVENTION

[0005] The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, reduced immunogenicity, improved cellular uptake, and stability under both acidic (pH <4) and basic (pH >7) conditions, and improved globotriaosylceramide clearance from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

[0006] The present invention provides recombinant alpha galactosidase A and/or biologically active recombinant alpha galactosidase A fragment comprising an amino acid sequence comprising at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to SEQ ID NO:8. The present invention provides recombinant alpha galactosidase A and/or biologically active recombinant alpha galactosidase A fragment comprising an amino acid sequence comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:8.

[0007] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 44, 44/217, 44/217/316, 44/217/322, 44/217/322/337, 44/247, 44/247/302, 44/247/302/322, 44/247/322, 44/247/337, 44/247/362, 44/302, 44/337, 44/373, 217/322, 217/373, 247/322, 247/362, 302/322/362/373, 302/337, 316, 316/337, 322, 322/337, 362/373, and 373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO:

8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 44L, 44L/217F, 44L/217F/316L, 44L/217F/322M, 44L/217F/322M/337A, 44L/247N, 44L/247N/302Q, 44L/247N/302Q/322M, 44L/247N/322M, 44L/247N/337A, 44L/247N/362K, 44L/302Q, 44L/337A, 44L/373R, 217F/322M, 217F/373R, 247N/322M, 247N/362K, 302Q/322M/362K/373R, 302Q/337A, 316L, 316L/337A, 322M, 322M/337A, 362K/373R, and 373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from R44L, R44L/R217F, R44L/R217F/D316L, R44L/R217F/I322M, R44L/R217F/I322M/P337A, R44L/D247N, R44L/D247N/K302Q, R44L/D247N/K302Q/I322M, R44L/D247N/I322M, R44L/D247N/P337A, R44L/D247N/Q362K, R44L/K302Q, R44L/P337A, R44L/K373R, R217F/I322M, R217F/K373R, D247N/I322M, D247N/Q362K, K302Q/I322M/Q362K/K373R, K302Q/P337A, D316L, D316L/P337A, I322M, I322M/P337A, Q362K/K373R, and K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0008] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10/39/44/47/92/166/206/217/247/261/271/302/316/322/337/362/368/373/392, 44/217/316, 44/217/322/337, 166/362, 217/373, and 362/373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10T/39M/44L/47S/92Y/166S/206K/217F/247N/261A/271H/302Q/316L/322M/337A/362K/368W/373R/392M, 44L/217F/316L, 44L/217F/322M/337A, 166A/362K, 217F/373R, and 362K/373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from

P10T/E39M/R44L/T47S/H92Y/P166S/A206K/R217F/D247N/G261A/A271H/K302Q/D316L/I322M/P337A/Q362K/A368W/K373R/T392M, R44L/R217F/D316L, R44L/R217F/I322M/P337A, P166A/Q362K, R217F/K373R, and Q362K/K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0009] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7, 7/48/68, 7/48/68/120/282/299, 7/48/130/282, 7/48/180, 7/68/130/282/365, 7/68/180, 7/88/120/305/365, 7/120, 7/130, 7/282, 7/305, 7/305/365, 7/365, 39, 47, 47/87/95/96/158/162, 47/95, 47/273, 47/343, 48, 48/68, 48/180/282, 48/282, 48/282/305, 67/180, 68, 68/299/300, 71, 87/91/95/96/158/162, 87/91/95/96/206/343, 87/96/155/273/343, 88, 91/95, 91/95/96, 92, 93, 96, 96/273, 96/312/343, 120, 120/299/305, 151, 158, 158/162/273, 162, 162/273, 162/343, 166, 178, 180, 181, 206, 217, 271, 273, 273/343, 282, 282/365, 293/391, 299/300, 299/300/305/365, 300, 301, 305, 305/365, 314, 333, 336, 337, 343, 345, 363, 365, 370, 389, 393, 394, 396/398, 397, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7L, 7L/48D/68E, 7L/48D/68E/120H/282N/299R, 7L/48D/130E/282N, 7L/48D/180G, 7L/68E/130E/282N/365V, 7L/68E/180G, 7L/88A/120H/305G/365V, 7L/120H, 7L/130E, 7L/282N, 7L/305G, 7L/305G/365V, 7L/365V, 39V, 47D, 47D/87K/95E/96L/158R/162H, 47D/95E, 47D/273P, 47D/343G, 47V, 48D, 48D/68E, 48D/180G/282N, 48D/282N, 48D/282N/305G, 67T/180G, 68E, 68E/299R/300I, 71P, 87K/91Q/95E/96L/158A/162K, 87K/91Q/95E/96L/206S/343G, 87K/96I/155N/273P/343G, 88A, 91Q/95E, 91Q/95E/96L, 92F, 92T, 93I, 96L, 96L/273P, 96L/312Q/343G, 120H, 120H/299R/305G, 151L, 158A, 158A/162K/273G, 158R, 162H/343D, 162K, 162K/273P, 162S, 166K, 178G, 178S, 180G, 180L, 180T, 180V, 181A, 206K, 206S, 217K, 271R, 273P, 273P/343G, 282N, 282N/365V, 293P/391A, 299R/300I, 299R/300I/305G/365V, 300I, 301M, 305G, 305G/365V, 314A, 333F, 333G, 336V, 337R, 343D, 343G, 345A, 345Q, 363Q, 365A, 365Q, 365V, 370G, 389K, 393V, 394K, 396G/398T, 397A, 398A, 398P, 398S, and 398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or

more positions selected from R7L, R7L/E48D/Q68E, R7L/E48D/Q68E/Y120H/D282N/Q299R, R7L/E48D/D130E/D282N, R7L/E48D/F180G, R7L/Q68E/D130E/D282N/F365V, R7L/Q68E/F180G, R7L/Q88A/Y120H/N305G/F365V, R7L/Y120H, R7L/D130E, R7L/D282N, R7L/N305G, R7L/N305G/F365V, R7L/F365V, E39V, T47D, T47D/R87K/S95E/K96L/L158R/R162H, T47D/S95E, T47D/S273P, T47D/K343G, T47V, E48D, E48D/Q68E, E48D/F180G/D282N, E48D/D282N, E48D/D282N/N305G, P67T/F180G, Q68E, Q68E/Q299R/L300I, S71P, R87K/N91Q/S95E/K96L/L158A/R162K, R87K/N91Q/S95E/K96L/A206S/K343G, R87K/K96I/H155N/S273P/K343G, Q88A, N91Q/S95E, N91Q/S95E/K96L, H92F, H92T, V93I, K96L, K96L/S273P, K96L/P312Q/K343G, Y120H, Y120H/Q299R/N305G, D151L, L158A, L158A/R162K/S273G, L158R, R162H/K343D, R162K, R162K/S273P, R162S, P166K, W178G, W178S, F180G, F180L, F180T, F180V, Q181A, A206K, A206S, R217K, A271R, S273P, S273P/K343G, D282N, D282N/F365V, L293P/Q391A, Q299R/L300I, Q299R/L300I/N305G/F365V, L300I, R301M, N305G, N305G/F365V, S314A, S333F, S333G, I336V, P337R, K343D, K343G, V345A, V345Q, L363Q, F365A, F365Q, F365V, S370G, T389K, S393V, L394K, D396G/L398T, L397A, L398A, L398P, L398S, and L398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58.

[0010] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24/202, 39/47, 39/47/217, 39/151, 39/282/337/398, 39/337/343/398, 39/393/398, 47/130, 47/151, 47/343/345/393, 48, 48/68, 48/68/217/333/391/393, 48/68/333, 48/217, 48/333, 48/345/393, 48/393, 59/143, 68, 68/345, 130, 130/158, 130/158/393, 130/345/393, 143/271, 143/333, 143/387, 151, 151/158/217/343/345/393, 151/206/282/337/343/345/398, 151/282/393, 151/345/393/398, 151/393, 158, 158/393, 202, 206, 206/217, 217, 217/333, 217/337/345/398, 271, 282/393, 333, 333/345, 337/343/345/398, 343, 343/345/393/398, 393, and 393/398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24S/202N, 39V/47D, 39V/47V/217K, 39V/151L, 39V/282N/337R/398A, 39V/337R/343G/398A, 39V/393V/398A, 47V/130E, 47V/151L, 47V/343D/345Q/393V, 48D, 48D/68E, 48D/68E/217K/333F/391A/393V, 48D/68E/333F, 48D/217K, 48D/333F, 48D/333G, 48D/345Q/393V, 48D/393V, 59A/143S, 68E, 68E/345Q, 130E, 130E/158R, 130E/158R/393V, 130E/345Q/393V, 143S/271N, 143S/333N,

143S/387N, 151L, 151L/158R/217K/343G/345Q/393V, 151L/206S/282N/337R/343D/345Q/398A, 151L/282N/393V, 151L/345Q/393V/398A, 151L/393V, 158R, 158R/393V, 202N, 206S, 206S/217K, 217K, 217K/333F, 217K/333G, 217K/337R/345Q/398A, 271N, 282N/393V, 333F/345Q, 333G, 333N, 337R/343G/345Q/398A, 343D, 343D/345Q/393V/398A, 393V, and 393V/398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D24S/D202N, E39V/T47D, E39V/T47V/R217K, E39V/D151L, E39V/D282N/P337R/L398A, E39V/P337R/K343G/L398A, E39V/S393V/L398A, T47V/D130E, T47V/D151L, T47V/K343D/V345Q/S393V, E48D, E48D/Q68E, E48D/Q68E/R217K/S333F/Q391A/S393V, E48D/Q68E/S333F, E48D/R217K, E48D/S333F, E48D/S333G, E48D/V345Q/S393V, E48D/S393V, C59A/C143S, Q68E, Q68E/V345Q, D130E, D130E/L158R, D130E/L158R/S393V, D130E/V345Q/S393V, C143S/A271N, C143S/S333N, C143S/E387N, D151L, D151L/L158R/R217K/K343G/V345Q/S393V, D151L/A206S/D282N/P337R/K343D/V345Q/L398A, D151L/D282N/S393V, D151L/V345Q/S393V/L398A, D151L/S393V, L158R, L158R/S393V, D202N, A206S, A206S/R217K, R217K, R217K/S333F, R217K/S333G, R217K/P337R/V345Q/L398A, A271N, D282N/S393V, S333F/V345Q, S333G, S333N, P337R/K343G/V345Q/L398A, K343D, K343D/V345Q/S393V/L398A, S393V, and S393V/L398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158.

[0011] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/39/44/322, 10/39/92/206/217/271, 10/39/92/247, 10/39/92/247/271/316, 10/44, 10/44/47/92/247, 10/44/47/261/302/322/368, 10/44/92/316/322, 10/44/261/302/316, 10/44/302/337/368, 10/47/217/247/316/392, 10/47/217/322, 10/47/271, 10/92, 10/92/206/217/247, 10/92/206/247/316/322/392, 10/92/206/247/322/368, 10/92/217/261/302/337, 10/206/217/271, 10/206/247, 10/206/261/271/316, 10/261, 10/271/302, 10/302, 10/302/316, 10/302/322/337, 10/316/322, 10/337/392, 10/368, 39/44/92/162/247/302/316/322, 39/44/92/217/322, 39/44/92/247/271/302, 39/47/92/247/302/316/322, 39/47/217/247/368, 39/47/247, 39/92/247/302/316/337/368, 39/92/316/322, 39/247/271, 39/247/271/316, 39/322, 44/47/92/206/217/316/322, 44/47/92/247/261/271/316/337/368, 44/47/206/217/247/271/322, 44/47/247/322/368, 44/47/302/316/322, 44/92/206/247/368, 44/206/337, 44/247/261/302/316,

44/247/261/302/316/322, 47/92/247/271, 47/217/302, 47/247, 47/247/271, 89/217/247/261/302/316, 92/217/271, 92/247, 92/247/271/322, 92/247/302/322/337, 92/271/337, 92/302, 92/316, 206/217/271/392, 217/247/316/322/337/368, 247, 247/271, 247/302, 271, 271/302/322, 271/316/322, 302/322/368, and 368, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10P, 10P/39E/44R/322I, 10P/39E/92H/206A/217R/271A, 10P/39E/92H/247D, 10P/39E/92H/247D/271A/316D, 10P/44R, 10P/44R/47T/92H/247D, 10P/44R/47T/261G/302K/322I/368A, 10P/44R/92H/316D/322I, 10P/44R/261G/302K/316D, 10P/44R/302K/337P/368A, 10P/47T/217R/247D/316D/392T, 10P/47T/217R/322I, 10P/47T/271A, 10P/92H, 10P/92H/206A/217R/247D, 10P/92H/206A/247D/316D/322I/392T, 10P/92H/206A/247D/322I/368A, 10P/92H/217R/261G/302K/337P, 10P/206A/217R/271A, 10P/206A/247D, 10P/206A/261G/271A/316D, 10P/261G, 10P/271A/302K, 10P/302K, 10P/302K/316D, 10P/302K/322I/337P, 10P/316D/322I, 10P/337P/392T, 10P/368A, 39E/44R/92H/162M/247D/302K/316D/322I, 39E/44R/92H/217R/322I, 39E/44R/92H/247D/271A/302K, 39E/47T/92H/247D/302K/316D/322I, 39E/47T/217R/247D/368A, 39E/47T/247D, 39E/92H/247D/302K/316D/337P/368A, 39E/92H/316D/322I, 39E/247D/271A, 39E/247D/271A/316D, 39E/322I, 44R/47T/92H/206A/217R/316D/322I, 44R/47T/92H/247D/261G/271A/316D/337P/368A, 44R/47T/206A/217R/247D/271A/322I, 44R/47T/247D/322I/368A, 44R/47T/302K/316D/322I, 44R/92H/206A/247D/368A, 44R/206A/337P, 44R/247D/261G/302K/316D, 44R/247D/261G/302K/316D/322I, 47T/92H/247D/271A, 47T/217R/302K, 47T/247D, 47T/247D/271A, 89I/217R/247D/261G/302K/316D, 92H/217R/271A, 92H/247D, 92H/247D/271A/322I, 92H/247D/302K/322I/337P, 92H/271A/337P, 92H/302K, 92H/316D, 206A/217R/271A/392T, 217R/247D/316D/322I/337P/368A, 247D, 247D/271A, 247D/302K, 271A, 271A/302K/322I, 271A/316D/322I, 302K/322I/368A, and 368A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from T10P, T10P/M39E/L44R/M322I, T10P/M39E/Y92H/K206A/F217R/H271A, T10P/M39E/Y92H/N247D, T10P/M39E/Y92H/N247D/H271A/L316D, T10P/L44R, T10P/L44R/S47T/Y92H/N247D, T10P/L44R/S47T/A261G/Q302K/M322I/W368A, T10P/L44R/Y92H/L316D/M322I,

T10P/L44R/A261G/Q302K/L316D, T10P/L44R/Q302K/A337P/W368A,
 T10P/S47T/F217R/N247D/L316D/M392T, T10P/S47T/F217R/M322I, T10P/S47T/H271A,
 T10P/Y92H, T10P/Y92H/K206A/F217R/N247D,
 T10P/Y92H/K206A/N247D/L316D/M322I/M392T, T10P/Y92H/K206A/N247D/M322I/W368A,
 T10P/Y92H/F217R/A261G/Q302K/A337P, T10P/K206A/F217R/H271A, T10P/K206A/N247D,
 T10P/K206A/A261G/H271A/L316D, T10P/A261G, T10P/H271A/Q302K, T10P/Q302K,
 T10P/Q302K/L316D, T10P/Q302K/M322I/A337P, T10P/L316D/M322I, T10P/A337P/M392T,
 T10P/W368A, M39E/L44R/Y92H/R162M/N247D/Q302K/L316D/M322I,
 M39E/L44R/Y92H/F217R/M322I, M39E/L44R/Y92H/N247D/H271A/Q302K,
 M39E/S47T/Y92H/N247D/Q302K/L316D/M322I, M39E/S47T/F217R/N247D/W368A,
 M39E/S47T/N247D, M39E/Y92H/N247D/Q302K/L316D/A337P/W368A,
 M39E/Y92H/L316D/M322I, M39E/N247D/H271A, M39E/N247D/H271A/L316D, M39E/M322I,
 L44R/S47T/Y92H/K206A/F217R/L316D/M322I,
 L44R/S47T/Y92H/N247D/A261G/H271A/L316D/A337P/W368A,
 L44R/S47T/K206A/F217R/N247D/H271A/M322I, L44R/S47T/N247D/M322I/W368A,
 L44R/S47T/Q302K/L316D/M322I, L44R/Y92H/K206A/N247D/W368A, L44R/K206A/A337P,
 L44R/N247D/A261G/Q302K/L316D, L44R/N247D/A261G/Q302K/L316D/M322I,
 S47T/Y92H/N247D/H271A, S47T/F217R/Q302K, S47T/N247D, S47T/N247D/H271A,
 L89I/F217R/N247D/A261G/Q302K/L316D, Y92H/F217R/H271A, Y92H/N247D,
 Y92H/N247D/H271A/M322I, Y92H/N247D/Q302K/M322I/A337P, Y92H/H271A/A337P,
 Y92H/Q302K, Y92H/L316D, K206A/F217R/H271A/M392T,
 F217R/N247D/L316D/M322I/A337P/W368A, N247D, N247D/H271A, N247D/Q302K, H271A,
 H271A/Q302K/M322I, H271A/L316D/M322I, Q302K/M322I/W368A, and W368A, wherein the
 amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372.

[0012] The present invention also provides recombinant alpha galactosidase A wherein said
 comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional
 fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one
 substitution or substitution set at one or more positions selected from 10/36/92/166/247/261/316/392,
 10/39, 10/39/44/47/92/206/217, 10/39/44/47/316, 10/39/44/47/337, 10/39/44/92/166/261/316/322,
 10/39/44/92/166/302/322, 10/39/44/92/166/392, 10/39/44/92/217/302/322, 10/39/44/92/302/322,
 10/39/44/166/261/271/316/322, 10/39/44/392, 10/39/47/92/337, 10/39/92/131/166/271/316/322,
 10/39/92/166/217/247/271, 10/39/92/217/316, 10/44/47/166/261/271, 10/44/47/166/271/322/368,
 10/44/47/217/271/316/322, 10/44/92, 10/44/92/217/247/271/302/316/392, 10/44/166/302,
 10/44/206/316/322, 10/47/92/166/271/316/337, 10/47/92/271/302, 10/47/92/316/322/392,
 10/47/166/271, 10/47/166/316, 10/92/166, 10/92/166/217/247/261/271, 10/92/166/261/271/392,
 10/92/166/261/316/322/337, 10/92/166/337/368, 10/92/302/337, 10/92/316/322, 10/206,

10/206/247/261, 10/217/322, 10/261, 10/261/337/392, 10/316/392, 10/368, 39/44/47/92/166/206/392, 39/44/47/92/206/247/261, 39/44/47/92/206/392, 39/44/47/206/337/368/392, 39/44/92/166/247/261/302/337, 39/44/166/271, 39/44/166/271/337/368/392, 39/47/92/316/322, 39/47/92/392, 39/47/166/217/261/392, 39/47/217/247/368, 39/47/247, 39/92/166/217/392, 39/92/261/302, 39/166/217/261/316/368, 39/322, 39/392, 44/47, 44/47/92/217/271, 44/47/92/217/316/322/392, 44/47/92/392, 44/47/166, 44/47/166/271, 44/47/247/271/392, 44/316/322/392, 44/337, 47/166/206/217/247/337, 47/166/217/271/337, 47/206, 47/217/247/261, 47/271, 52/217/302/316, 92/166/206/271/316, 92/166/217/261/271/392, 92/166/217/316/337/392, 92/166/247, 92/166/316, 92/206/322, 92/217, 92/217/271/337, 92/261/271, 92/271, 166/217/316/322/337, 166/247/271/316, 166/316/322/337, 206/217, 217/392, 247/316, 316/322/368, and 316/337/392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10T/36M/92Y/166S/247N/261A/316L/392M, 10T/39M, 10T/39M/44L/47S/92Y/206K/217F, 10T/39M/44L/47S/316L, 10T/39M/44L/47S/337A, 10T/39M/44L/92Y/166S/261A/316L/322M, 10T/39M/44L/92Y/166S/302Q/322M, 10T/39M/44L/92Y/166S/392M, 10T/39M/44L/92Y/217F/302Q/322M, 10T/39M/44L/92Y/302Q/322M, 10T/39M/44L/166S/261A/271H/316L/322M, 10T/39M/44L/392M, 10T/39M/47S/92Y/337A, 10T/39M/92Y/131G/166S/271H/316L/322M, 10T/39M/92Y/166S/217F/247N/271H, 10T/39M/92Y/217F/316L, 10T/44L/47S/166S/261A/271H, 10T/44L/47S/166S/271H/322M/368W, 10T/44L/47S/217F/271H/316L/322M, 10T/44L/92Y, 10T/44L/92Y/217F/247N/271H/302Q/316L/392M, 10T/44L/166S/302Q, 10T/44L/206K/316L/322M, 10T/47S/92Y/166S/271H/316L/337A, 10T/47S/92Y/271H/302Q, 10T/47S/92Y/316L/322M/392M, 10T/47S/166S/271H, 10T/47S/166S/316L, 10T/92Y/166S, 10T/92Y/166S/217F/247N/261A/271H, 10T/92Y/166S/261A/271H/392M, 10T/92Y/166S/261A/316L/322M/337A, 10T/92Y/166S/337A/368W, 10T/92Y/302Q/337A, 10T/92Y/316L/322M, 10T/206K, 10T/206K/247N/261A, 10T/217F/322M, 10T/261A, 10T/261A/337A/392M, 10T/316L/392M, 10T/368W, 39M/44L/47S/92Y/166S/206K/392M, 39M/44L/47S/92Y/206K/247N/261A, 39M/44L/47S/92Y/206K/392M, 39M/44L/47S/206K/337A/368W/392M, 39M/44L/92Y/166S/247N/261A/302Q/337A, 39M/44L/166S/271H, 39M/44L/166S/271H/337A/368W/392M, 39M/47S/92Y/316L/322M, 39M/47S/92Y/392M, 39M/47S/166S/217F/261A/392M, 39M/47S/217F/247N/368W, 39M/47S/247N, 39M/92Y/166S/217F/392M, 39M/92Y/261A/302Q, 39M/166S/217F/261A/316L/368W, 39M/322M, 39M/392M, 44L/47S, 44L/47S/92Y/217F/271H, 44L/47S/92Y/217F/316L/322M/392M,

44L/47S/92Y/392M, 44L/47S/166S, 44L/47S/166S/271H, 44L/47S/247N/271H/392M, 44L/316L/322M/392M, 44L/337A, 47S/166S/206K/217F/247N/337A, 47S/166S/217F/271H/337A, 47S/206K, 47S/217F/247N/261A, 47S/271H, 52N/217F/302Q/316L, 92Y/166S/206K/271H/316L, 92Y/166S/217F/261A/271H/392M, 92Y/166S/217F/316L/337A/392M, 92Y/166S/247N, 92Y/166S/316L, 92Y/206K/322M, 92Y/217F, 92Y/217F/271H/337A, 92Y/261A/271H, 92Y/271H, 166S/217F/316L/322M/337A, 166S/247N/271H/316L, 166S/316L/322M/337A, 206K/217F, 217F/392M, 247N/316L, 316L/322M/368W, and 316L/337A/392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10T/K36M/H92Y/P166S/D247N/G261A/D316L/T392M, P10T/E39M, P10T/E39M/R44L/T47S/H92Y/A206K/R217F, P10T/E39M/R44L/T47S/D316L, P10T/E39M/R44L/T47S/P337A, P10T/E39M/R44L/H92Y/P166S/G261A/D316L/I322M, P10T/E39M/R44L/H92Y/P166S/K302Q/I322M, P10T/E39M/R44L/H92Y/P166S/T392M, P10T/E39M/R44L/H92Y/R217F/K302Q/I322M, P10T/E39M/R44L/H92Y/K302Q/I322M, P10T/E39M/R44L/P166S/G261A/A271H/D316L/I322M, P10T/E39M/R44L/T392M, P10T/E39M/T47S/H92Y/P337A, P10T/E39M/H92Y/W131G/P166S/A271H/D316L/I322M, P10T/E39M/H92Y/P166S/R217F/D247N/A271H, P10T/E39M/H92Y/R217F/D316L, P10T/R44L/T47S/P166S/G261A/A271H, P10T/R44L/T47S/P166S/A271H/I322M/A368W, P10T/R44L/T47S/R217F/A271H/D316L/I322M, P10T/R44L/H92Y, P10T/R44L/H92Y/R217F/D247N/A271H/K302Q/D316L/T392M, P10T/R44L/P166S/K302Q, P10T/R44L/A206K/D316L/I322M, P10T/T47S/H92Y/P166S/A271H/D316L/P337A, P10T/T47S/H92Y/A271H/K302Q, P10T/T47S/H92Y/D316L/I322M/T392M, P10T/T47S/P166S/A271H, P10T/T47S/P166S/D316L, P10T/H92Y/P166S, P10T/H92Y/P166S/R217F/D247N/G261A/A271H, P10T/H92Y/P166S/G261A/A271H/T392M, P10T/H92Y/P166S/G261A/D316L/I322M/P337A, P10T/H92Y/P166S/P337A/A368W, P10T/H92Y/K302Q/P337A, P10T/H92Y/D316L/I322M, P10T/A206K, P10T/A206K/D247N/G261A, P10T/R217F/I322M, P10T/G261A, P10T/G261A/P337A/T392M, P10T/D316L/T392M, P10T/A368W, E39M/R44L/T47S/H92Y/P166S/A206K/T392M, E39M/R44L/T47S/H92Y/A206K/D247N/G261A, E39M/R44L/T47S/H92Y/A206K/T392M, E39M/R44L/T47S/A206K/P337A/A368W/T392M, E39M/R44L/H92Y/P166S/D247N/G261A/K302Q/P337A, E39M/R44L/P166S/A271H, E39M/R44L/P166S/A271H/P337A/A368W/T392M, E39M/T47S/H92Y/D316L/I322M, E39M/T47S/H92Y/T392M, E39M/T47S/P166S/R217F/G261A/T392M, E39M/T47S/R217F/D247N/A368W, E39M/T47S/D247N, E39M/H92Y/P166S/R217F/T392M,

E39M/H92Y/G261A/K302Q, E39M/P166S/R217F/G261A/D316L/A368W, E39M/I322M, E39M/T392M, R44L/T47S, R44L/T47S/H92Y/R217F/A271H, R44L/T47S/H92Y/R217F/D316L/I322M/T392M, R44L/T47S/H92Y/T392M, R44L/T47S/P166S, R44L/T47S/P166S/A271H, R44L/T47S/D247N/A271H/T392M, R44L/D316L/I322M/T392M, R44L/P337A, T47S/P166S/A206K/R217F/D247N/P337A, T47S/P166S/R217F/A271H/P337A, T47S/A206K, T47S/R217F/D247N/G261A, T47S/A271H, D52N/R217F/K302Q/D316L, H92Y/P166S/A206K/A271H/D316L, H92Y/P166S/R217F/G261A/A271H/T392M, H92Y/P166S/R217F/D316L/P337A/T392M, H92Y/P166S/D247N, H92Y/P166S/D316L, H92Y/A206K/I322M, H92Y/R217F, H92Y/R217F/A271H/P337A, H92Y/G261A/A271H, H92Y/A271H, P166S/R217F/D316L/I322M/P337A, P166S/D247N/A271H/D316L, P166S/D316L/I322M/P337A, A206K/R217F, R217F/T392M, D247N/D316L, D316L/I322M/A368W, and D316L/P337A/T392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0013] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2, 4, 5, 24/59, 24/143/144, 24/143/202/333, 24/143/202/352/390/391, 24/143/333/352/387/390/391, 24/143/390/391, 24/202, 24/202/271, 24/202/333/352, 24/271/352, 24/352/387/390/391, 24/387/391, 31, 40, 59, 59/143, 59/143/202, 59/143/202/271/333, 59/143/271, 59/143/333, 59/202, 59/202/333, 59/271/387/390, 73, 76, 80, 83, 84, 91/215/361, 122, 123, 143, 143/202, 143/271, 143/271/352/390, 143/333, 143/333/387/390, 143/387/391, 147, 155, 164, 165, 179, 186, 202, 202/333, 210, 215/218, 218, 218/361, 218/361/398, 218/398, 246, 254/398, 271, 271/333, 271/333/390/391, 271/333/391, 271/352/391, 273, 275, 277, 278, 280, 281, 283, 284, 287, 300, 303, 304, 325, 331, 332, 333/352, 333/390/391, 333/391, 334, 335, 336, 338, 339, 340, 341, 343, 359, 360, 361, 362, 367, 369, 371, 373, 375, 377, 382, 382/398, 385, 387/391, 390, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2S, 4L, 5M, 5V, 24S/59A, 24S/143S/144N, 24S/143S/202N/333N, 24S/143S/202N/352N/390N/391N, 24S/143S/333N/352N/387N/390T/391N, 24S/143S/390T/391N, 24S/202N, 24S/202N/271N, 24S/202N/333N/352N, 24S/271N/352N, 24S/352N/387N/390N/391N, 24S/387N/391N, 31F, 31H, 31L, 31T, 31W, 40Q, 59A, 59A/143S, 59A/143S/271N, 59A/202N, 59T, 59T/143S/202N, 59T/143S/333N, 59T/202N/333N, 59V/143S/202N/271N/333N, 59V/271N/387N/390T, 73A, 76A,

76F, 76M, 76S, 80T, 83R, 83S, 84G, 84K, 84R, 91S/215S/361T, 122E, 122N, 122S, 123Q, 123R, 123S, 123T, 143S, 143S/202N, 143S/271N, 143S/271N/352N/390N, 143S/333N, 143S/333N/387N/390T, 143S/387N/391N, 147L, 147S, 155A, 155D, 155F, 155L, 155R, 155T, 164E, 165I, 179H, 179L, 179R, 179W, 186E, 186F, 186M, 186P, 186R, 186S, 186Y, 202N, 202N/333N, 210I, 215S/218Y, 218Y, 218Y/361T, 218Y/361T/398F, 218Y/398F, 246Y, 254T/398F, 271N, 271N/333N, 271N/333N/390N/391N, 271N/333N/391N, 271N/352N/391N, 273L, 275A, 275G, 277Q, 277V, 278N, 278R, 278S, 280G, 281I, 281M, 283L, 283P, 283T, 283V, 284A, 284E, 284G, 284L, 284M, 284R, 284S, 287R, 300F, 303A, 303C, 303W, 304T, 304V, 304W, 325A, 331M, 332G, 332H, 333N/352N, 333N/390N/391N, 333N/390S/391N, 333N/391N, 334C, 334V, 335A, 335L, 336F, 336G, 336S, 336T, 338L, 339G, 339N, 339Q, 339V, 340H, 340I, 340K, 340M, 340P, 340W, 341F, 341M, 343L, 343R, 343S, 343W, 359F, 359L, 359R, 360H, 360V, 361T, 361V, 362H, 367A, 367D, 367L, 367M, 369D, 371G, 373L, 373S, 375L, 375Q, 377Q, 382I, 382I/398F, 385R, 387N/391N, 390S, and 398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D2S, G4L, L5M, L5V, D24S/C59A, D24S/C143S/D144N, D24S/C143S/D202N/G333N, D24S/C143S/D202N/F352N/M390N/Q391N, D24S/C143S/G333N/F352N/E387N/M390T/Q391N, D24S/C143S/M390T/Q391N, D24S/D202N, D24S/D202N/A271N, D24S/D202N/G333N/F352N, D24S/A271N/F352N, D24S/F352N/E387N/M390N/Q391N, D24S/E387N/Q391N, S31F, S31H, S31L, S31T, S31W, E40Q, C59A, C59A/C143S, C59A/C143S/A271N, C59A/D202N, C59T, C59T/C143S/D202N, C59T/C143S/G333N, C59T/D202N/G333N, C59V/C143S/D202N/A271N/G333N, C59V/A271N/E387N/M390T, G73A, Q76A, Q76F, Q76M, Q76S, Q80T, P83R, P83S, H84G, H84K, H84R, N91S/T215S/R361T, D122E, D122N, D122S, I123Q, I123R, I123S, I123T, C143S, C143S/D202N, C143S/A271N, C143S/A271N/F352N/M390N, C143S/G333N, C143S/G333N/E387N/M390T, C143S/E387N/Q391N, E147L, E147S, H155A, H155D, H155F, H155L, H155R, H155T, G164E, R165I, P179H, P179L, P179R, P179W, T186E, T186F, T186M, T186P, T186R, T186S, T186Y, D202N, D202N/G333N, S210I, T215S/N218Y, N218Y, N218Y/R361T, N218Y/R361T/L398F, N218Y/L398F, W246Y, A254T/L398F, A271N, A271N/G333N, A271N/G333N/M390N/Q391N, A271N/G333N/Q391N, A271N/F352N/Q391N, S273L, Q275A, Q275G, K277Q, K277V, A278N, A278R, A278S, L280G, Q281I, Q281M, K283L, K283P, K283T, K283V, D284A, D284E, D284G, D284L, D284M, D284R, D284S, A287R, L300F, G303A, G303C, G303W, D304T, D304V, D304W, R325A, P331M, R332G, R332H, G333N/F352N, G333N/M390N/Q391N, G333N/M390S/Q391N, G333N/Q391N, Y334C, Y334V, T335A, T335L, I336F, I336G, I336S, I336T, V338L, A339G, A339N, A339Q, A339V, S340H, S340I, S340K,

S340M, S340P, S340W, L341F, L341M, K343L, K343R, K343S, K343W, V359F, V359L, V359R, K360H, K360V, R361T, R361V, K362H, E367A, E367D, E367L, E367M, T369D, R371G, R373L, R373S, H375L, H375Q, N377Q, V382I, V382I/L398F, Q385R, E387N/Q391N, M390S, and L398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704.

[0014] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 39, 44, 47, 92, 166, 206, 217, 247, 261, 271, 302, 316, 322, 337, 368, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10A, 10C, 10D, 10E, 10F, 10G, 10H, 10I, 10K, 10L, 10M, 10N, 10Q, 10R, 10S, 10T, 10V, 10W, 10Y, 39A, 39C, 39D, 39F, 39G, 39H, 39I, 39K, 39L, 39M, 39N, 39P, 39Q, 39R, 39S, 39T, 39V, 39W, 39Y, 44A, 44C, 44D, 44E, 44F, 44G, 44H, 44I, 44K, 44L, 44N, 44P, 44Q, 44S, 44T, 44V, 44W, 44Y, 47A, 47C, 47D, 47E, 47F, 47G, 47H, 47I, 47K, 47L, 47M, 47N, 47P, 47Q, 47R, 47S, 47V, 47W, 47Y, 92A, 92C, 92D, 92E, 92F, 92G, 92I, 92K, 92L, 92M, 92N, 92P, 92Q, 92R, 92S, 92T, 92V, 92W, 92Y, 166A, 166C, 166D, 166E, 166F, 166G, 166H, 166I, 166K, 166L, 166M, 166N, 166Q, 166R, 166S, 166T, 166V, 166W, 166Y, 206C, 206D, 206E, 206F, 206G, 206H, 206I, 206K, 206L, 206M, 206N, 206P, 206Q, 206R, 206S, 206T, 206V, 206W, 206Y, 217A, 217C, 217D, 217E, 217F, 217G, 217H, 217I, 217K, 217L, 217M, 217N, 217P, 217Q, 217S, 217T, 217V, 217W, 217Y, 247A, 247C, 247E, 247F, 247G, 247H, 247I, 247K, 247L, 247M, 247N, 247P, 247Q, 247R, 247S, 247T, 247V, 247W, 247Y, 261A, 261C, 261D, 261E, 261F, 261H, 261I, 261K, 261L, 261M, 261N, 261P, 261Q, 261R, 261S, 261T, 261V, 261W, 261Y, 271C, 271D, 271E, 271F, 271G, 271H, 271I, 271K, 271L, 271M, 271N, 271P, 271Q, 271R, 271S, 271T, 271V, 271W, 271Y, 302A, 302C, 302D, 302E, 302F, 302G, 302H, 302I, 302L, 302M, 302N, 302P, 302Q, 302R, 302S, 302T, 302V, 302W, 302Y, 316A, 316C, 316E, 316F, 316G, 316H, 316I, 316K, 316L, 316M, 316N, 316P, 316Q, 316R, 316S, 316T, 316V, 316W, 316Y, 322A, 322C, 322D, 322E, 322F, 322G, 322H, 322K, 322L, 322M, 322N, 322P, 322Q, 322R, 322S, 322T, 322V, 322W, 322Y, 337A, 337C, 337D, 337E, 337F, 337G, 337H, 337I, 337K, 337L, 337M, 337N, 337Q, 337R, 337S, 337T, 337V, 337W, 337Y, 368C, 368D, 368E, 368F, 368G, 368H, 368I, 368K, 368L, 368M, 368N, 368P, 368Q, 368R, 368S, 368T, 368V, 368W, 368Y, 392A, 392C, 392D, 392E, 392F, 392G, 392H, 392I, 392K, 392L, 392M, 392N, 392P, 392Q, 392R, 392S, 392V, 392W, and 392Y, wherein the amino acid positions of said polypeptide sequence are

numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10A, P10C, P10D, P10E, P10F, P10G, P10H, P10I, P10K, P10L, P10M, P10N, P10Q, P10R, P10S, P10T, P10V, P10W, P10Y, E39A, E39C, E39D, E39F, E39G, E39H, E39I, E39K, E39L, E39M, E39N, E39P, E39Q, E39R, E39S, E39T, E39V, E39W, E39Y, R44A, R44C, R44D, R44E, R44F, R44G, R44H, R44I, R44K, R44L, R44N, R44P, R44Q, R44S, R44T, R44V, R44W, R44Y, T47A, T47C, T47D, T47E, T47F, T47G, T47H, T47I, T47K, T47L, T47M, T47N, T47P, T47Q, T47R, T47S, T47V, T47W, T47Y, H92A, H92C, H92D, H92E, H92F, H92G, H92I, H92K, H92L, H92M, H92N, H92P, H92Q, H92R, H92S, H92T, H92V, H92W, H92Y, P166A, P166C, P166D, P166E, P166F, P166G, P166H, P166I, P166K, P166L, P166M, P166N, P166Q, P166R, P166S, P166T, P166V, P166W, P166Y, A206C, A206D, A206E, A206F, A206G, A206H, A206I, A206K, A206L, A206M, A206N, A206P, A206Q, A206R, A206S, A206T, A206V, A206W, A206Y, R217A, R217C, R217D, R217E, R217F, R217G, R217H, R217I, R217K, R217L, R217M, R217N, R217P, R217Q, R217S, R217T, R217V, R217W, R217Y, D247A, D247C, D247E, D247F, D247G, D247H, D247I, D247K, D247L, D247M, D247N, D247P, D247Q, D247R, D247S, D247T, D247V, D247W, D247Y, G261A, G261C, G261D, G261E, G261F, G261H, G261I, G261K, G261L, G261M, G261N, G261P, G261Q, G261R, G261S, G261T, G261V, G261W, G261Y, A271C, A271D, A271E, A271F, A271G, A271H, A271I, A271K, A271L, A271M, A271N, A271P, A271Q, A271R, A271S, A271T, A271V, A271W, A271Y, K302A, K302C, K302D, K302E, K302F, K302G, K302H, K302I, K302L, K302M, K302N, K302P, K302Q, K302R, K302S, K302T, K302V, K302W, K302Y, D316A, D316C, D316E, D316F, D316G, D316H, D316I, D316K, D316L, D316M, D316N, D316P, D316Q, D316R, D316S, D316T, D316V, D316W, D316Y, I322A, I322C, I322D, I322E, I322F, I322G, I322H, I322K, I322L, I322M, I322N, I322P, I322Q, I322R, I322S, I322T, I322V, I322W, I322Y, P337A, P337C, P337D, P337E, P337F, P337G, P337H, P337I, P337K, P337L, P337M, P337N, P337Q, P337R, P337S, P337T, P337V, P337W, P337Y, A368C, A368D, A368E, A368F, A368G, A368H, A368I, A368K, A368L, A368M, A368N, A368P, A368Q, A368R, A368S, A368T, A368V, A368W, A368Y, T392A, T392C, T392D, T392E, T392F, T392G, T392H, T392I, T392K, T392L, T392M, T392N, T392P, T392Q, T392R, T392S, T392V, T392W, and T392Y, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0015] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/392, 31,

31/39/44/166/302, 31/47, 31/283/284, 39, 39/44, 39/44/47, 39/44/47/261/283/284, 39/44/283, 39/44/339, 39/47/261, 39/92, 39/206, 39/284, 44, 44/284/302, 84, 84/92, 84/284/302/392, 84/316, 84/368/392, 92, 92/206/217, 92/206/275, 92/206/284, 92/206/302/368, 92/271, 92/271/277, 92/275/284, 92/283, 92/283/392, 92/284, 92/302, 92/316, 92/368, 155, 155/217, 155/368, 166, 166/283/284, 166/302, 206, 206/217, 206/334, 261, 261/283, 271, 271/368, 275, 283, 283/284, 283/392, 284, 302, 316, 334, 339, 368, 368/392, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10G, P10G/T392D, S31T, S31T/E39V/R44V/P166D/K302Y, S31T/T47R, S31T/K283L/D284A, E39L, E39L/H92V, E39L/A206E, E39L/D284S, E39V/R44V, E39V/R44V/T47R, E39V/R44V/T47R/G261S/K283L/D284A, E39V/R44V/K283T, E39V/R44V/A339N, E39V/T47R/G261S, R44V, R44V/D284E/K302Y, H84K, H84K/H92V, H84K/D284S/K302L/T392A, H84K/D316H, H84K/A368E/T392A, H92Q, H92T, H92T/A206E/R217N, H92T/A206E/K302T/A368E, H92T/A271K, H92T/A271K/K277R, H92T/K283P, H92T/K283V/T392W, H92T/D284M, H92T/K302L, H92T/A368E, H92V, H92V/A206E/D284S, H92V/A206Y/Q275A, H92V/Q275A/D284S, H92V/D284S, H92V/K302L, H92V/D316H, H155F, H155F/R217I, H155F/A368E, P166D, P166D/K283L/D284A, P166D/K302Y, A206E, A206E/R217N, A206I, A206Q, A206T/Y334C, A206Y, G261S, G261S/K283L, A271K, A271K/A368E, Q275A, K283L, K283P/T392W, K283T, K283T/D284E, D284E, D284M, D284S, K302L, K302Y, D316H, Y334C, A339N, A368E, A368E/T392W, T392A, T392D, and T392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10G, 10G/392D, 31T, 31T/39V/44V/166D/302Y, 31T/47R, 31T/283L/284A, 39L, 39L/92V, 39L/206E, 39L/284S, 39V/44V, 39V/44V/47R, 39V/44V/47R/261S/283L/284A, 39V/44V/283T, 39V/44V/339N, 39V/47R/261S, 44V, 44V/284E/302Y, 84K, 84K/92V, 84K/284S/302L/392A, 84K/316H, 84K/368E/392A, 92Q, 92T, 92T/206E/217N, 92T/206E/302T/368E, 92T/271K, 92T/271K/277R, 92T/283P, 92T/283V/392W, 92T/284M, 92T/302L, 92T/368E, 92V, 92V/206E/284S, 92V/206Y/275A, 92V/275A/284S, 92V/284S, 92V/302L, 92V/316H, 155F, 155F/217I, 155F/368E, 166D, 166D/283L/284A, 166D/302Y, 206E, 206E/217N, 206I, 206Q, 206T/334C, 206Y, 261S, 261S/283L, 271K, 271K/368E, 275A, 283L, 283P/392W, 283T, 283T/284E, 284E, 284M, 284S, 302L, 302Y, 316H, 334C, 339N,

368E, 368E/392W, 392A, 392D, and 392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022.

[0016] In some embodiments, the alpha galactosidase A of the present invention comprises at least one mutation in at least one position as provided in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1, wherein the positions are numbered with reference to SEQ ID NO: 2 or another reference sequence, as indicated in the Tables. In some additional embodiments, the recombinant alpha galactosidase A is derived from a human alpha galactosidase A. In some further embodiments, the recombinant alpha galactosidase A comprises the polypeptide sequence of SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022.

[0017] In some embodiments, the recombinant alpha galactosidase A is more thermostable than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some additional embodiments, the recombinant alpha galactosidase A is more stable at pH 7 than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In yet some additional embodiments, the recombinant alpha galactosidase A is more stable at pH 4 than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In still some further embodiments, the recombinant alpha galactosidase A is more stable at pH 7 and more stable at pH 4 than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In still additional embodiments, the recombinant alpha galactosidase A is more stable to exposure to serum than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some further embodiments, the recombinant alpha galactosidase A is more lysosomally stable than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In yet some additional embodiments, the recombinant alpha galactosidase A is more readily taken up by cells than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some further embodiments, the recombinant alpha galactosidase A depletes more globotriaosylceramide from cells than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In yet some additional embodiments, the recombinant alpha galactosidase A exhibits improved uptake into cells, as compared to SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some further embodiments, the recombinant alpha galactosidase A is less immunogenic than the alpha galactosidase A of SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some further embodiments, the recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7; iii) increased tolerance to pH 4; iv) increased tolerance to serum; v) improved uptake into cells; vi) reduced immunogenicity; or vii) increased depletion of globotriaosylceramide from cells; or a combination of any of i), ii), iii), iv), v), vi) or vii), as compared to a reference sequence. In some embodiments, the reference sequence is SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022. In some further embodiments, the recombinant alpha galactosidase A is purified.

[0018] The present invention also provides recombinant polynucleotide sequences encoding at least one recombinant alpha galactosidase A as provided herein (e.g., in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1). In some embodiments, the polynucleotide sequence is selected from DNA, RNA, and mRNA. In some embodiments, the recombinant polynucleotide sequence is codon-optimized.

[0019] The present invention also provides expression vectors comprising the recombinant polynucleotide sequence encoding at least one recombinant alpha galactosidase A as provided herein (e.g., Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1). In some embodiments, the recombinant polynucleotide sequence is operably linked to a control sequence. In some additional embodiments, the control sequence is a promoter. In some further embodiments, the promoter is a heterologous promoter. In some embodiments, the expression vector further comprises a signal sequence, as provided herein.

[0020] The present invention also provides host cells comprising at least one expression vector as provided herein. In some embodiments, the host cell comprises an expression vector comprising the recombinant polynucleotide sequence encoding at least one recombinant alpha galactosidase A as provided herein (e.g., Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1). In some embodiments, the host cell is selected from eukaryotes and prokaryotes. In some embodiments, the host cell is eukaryotic. In some additional embodiments, the host cell is a mammalian cell.

[0021] The present invention also provides methods of producing an alpha galactosidase A variant, comprising culturing a host cell provided herein, under conditions that the alpha galactosidase A encoded by the recombinant polynucleotide is produced. In some embodiments, the methods further comprise the step of recovering alpha galactosidase A. In some further embodiments, the methods further comprise the step of purifying the alpha galactosidase A. The present invention also provides compositions comprising at least one recombinant alpha galactosidase A as provided herein (e.g., Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1). In some embodiments, the present invention provides pharmaceutical compositions. In some embodiments, the present invention provides pharmaceutical compositions comprising at least one recombinant polynucleotide provided herein. In some additional embodiments, the present invention provides pharmaceutical compositions for the treatment of Fabry disease, comprising an enzyme composition provided herein. In some embodiments, the pharmaceutical compositions, further comprise a pharmaceutically acceptable carrier and/or excipient. In some additional embodiments, the pharmaceutical composition is suitable for parenteral injection or infusion to a human.

[0022] The present invention also provides methods for treating and/or preventing the symptoms of Fabry disease in a subject, comprising providing a subject having Fabry disease, and providing at least one pharmaceutical composition comprising at least one recombinant alpha galactosidase A as provided herein (e.g., Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1), and administering the pharmaceutical composition to the subject. In some embodiments, the

symptoms of Fabry disease are ameliorated in the subject. In some additional embodiments, the subject to whom the pharmaceutical composition of the present invention has been administered is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease. In some embodiments, the subject is an infant or child, while in some alternative embodiments, the subject is an adult or young adult.

[0023] The present invention also provides for the use of the compositions provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 provides a graph showing the relative activity of GLA variants after incubation for 1 hour at temperatures 30-50 °C.

[0025] Figure 2 provides a graph showing the relative activity of GLA variants after challenge at 37°C for 0-24 hours with human serum.

[0026] Figure 3 provides a graph showing the relative activity of GLA variants after challenge at 37°C for 0-24 hours with human lysosomal extract.

[0027] Figure 4 provides a graph showing the cellular uptake of different purified GLA variants, expressed as relative activity compared to wild type after 4 hours incubation at 37 °C with cultured Fabry patient fibroblasts.

[0028] Figure 5 provides a graph showing the activity of GLA variants in the heart of the Fabry mice compared to SEQ ID NO: 2 at 1, 2, and 4 weeks post-administration.

[0029] Figure 6 provides a graph showing residual Gb₃ in the heart of Fabry mice treated with GLA variants at 1 and 2 weeks post-administration.

[0030] Figure 7 provides a graph showing the residual activity of GLA variants after a challenge with human serum for 0-24 hrs.

[0031] Figure 8 provides a graph showing the cellular uptake of purified GLA variants in cultured Fabry patient fibroblasts after 4 hours incubation and 3 day washout at 37°C.

[0032] Figure 9 provides a graph showing *in vivo* enzyme activity in the heart in the Fabry mouse model, 7 days after the last treatment.

[0033] Figure 10 provides a graph showing *in vivo* enzyme activity in the kidney in the Fabry mouse model, 7 days after the last treatment.

[0034] Figure 11 provides a graph showing Gb₃ degradation in heart tissue.

[0035] Figure 12 provides a graph showing Gb₃ degradation in kidney tissue.

[0036] Figure 13 provides a graph showing lyso-Gb₃ degradation in heart tissue.

[0037] Figure 14 provides a graph showing lyso-Gb₃ degradation in kidney tissue.

DESCRIPTION OF THE INVENTION

[0038] The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized

to provide improved thermostability, serum stability, improved cellular uptake, and stability under both acidic (pH <4) and basic (pH >7) conditions, reduced immunogenicity, and improved globotriaosylceramide clearance from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes. In some embodiments, the engineered human alpha-galactosidase polypeptides have been optimized to provide improved cellular uptake while maintaining stability. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

[0039] In some cases, enzyme replacement therapy for treatment of Fabry disease (e.g., FABRAZYME[®] agalsidase beta; Genzyme) is considered for eligible individuals. Currently used enzyme replacement therapies are recombinantly expressed forms of the wild-type human GLA. It is known that intravenously administered GLA circulates, is taken into cells via receptor-mediated endocytosis, primarily mannose 6-phosphate receptors (M6PR), and travels to the endosomes/lysosomes of target organs, where it clears accumulated Gb3. These drugs do not completely relieve patient symptoms, as neuropathic pain and transient ischemic attacks continue to occur at reduced rates. In addition, the uptake of GLA by most target organs is poor in comparison to the highly vascularized and M6PR-rich liver, and the enzyme is unstable at the pH of blood and lysosomes. Thus, issues remain with available treatments. In addition, patients may develop an immune response (IgG and IgE antibodies targeting the administered drug), and suffer severe allergic (anaphylactic) reactions, severe infusion reactions, and even death. The present invention is intended to provide more stable and efficacious enzymes suitable for treatment of Fabry disease, yet with reduced side effects and improved outcomes, as compared to currently available treatments. Indeed, the present invention is intended to provide recombinant GLA enzymes that have increased stability in blood (pH 7.4), which the enzyme encounters upon introduction into the bloodstream. In addition, the enzyme has increased stability at the pH of the lysosome (pH 4.3), the location where the enzyme is active during therapy. Thus, directed evolution of recombinantly expressed human GLA in human HEK293T cells, employing high throughput screening of diverse enzyme variant libraries, was used to provide novel GLA variants with maintained stability properties, improved globotriaosylceramide clearance, and cellular uptake. In some embodiments, the GLA variants exhibit reduced immunogenicity.

Abbreviations and Definitions:

[0040] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein and the laboratory procedures of cell culture, molecular genetics, microbiology, biochemistry, organic chemistry, analytical chemistry and nucleic acid chemistry described below are those well-known and commonly employed in the art. Such

techniques are well-known and described in numerous texts and reference works well known to those of skill in the art. Standard techniques, or modifications thereof, are used for chemical syntheses and chemical analyses. All patents, patent applications, articles and publications mentioned herein, both *supra* and *infra*, are hereby expressly incorporated herein by reference.

[0041] Although any suitable methods and materials similar or equivalent to those described herein find use in the practice of the present invention, some methods and materials are described herein. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context they are used by those of skill in the art. Accordingly, the terms defined immediately below are more fully described by reference to the application as a whole. All patents, patent applications, articles and publications mentioned herein, both *supra* and *infra*, are hereby expressly incorporated herein by reference.

[0042] Also, as used herein, the singular "a", "an," and "the" include the plural references, unless the context clearly indicates otherwise.

[0043] Numeric ranges are inclusive of the numbers defining the range. Thus, every numerical range disclosed herein is intended to encompass every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. It is also intended that every maximum (or minimum) numerical limitation disclosed herein includes every lower (or higher) numerical limitation, as if such lower (or higher) numerical limitations were expressly written herein.

[0044] The term "about" means an acceptable error for a particular value. In some instances, "about" means within 0.05%, 0.5%, 1.0%, or 2.0%, of a given value range. In some instances, "about" means within 1, 2, 3, or 4 standard deviations of a given value.

[0045] Furthermore, the headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the application as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the application as a whole. Nonetheless, in order to facilitate understanding of the invention, a number of terms are defined below.

[0046] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0047] As used herein, the term "comprising" and its cognates are used in their inclusive sense (*i.e.*, equivalent to the term "including" and its corresponding cognates).

[0048] As used herein, the "EC" number refers to the Enzyme Nomenclature of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). The IUBMB biochemical classification is a numerical classification system for enzymes based on the chemical reactions they catalyze.

[0049] As used herein, "ATCC" refers to the American Type Culture Collection whose biorepository collection includes genes and strains.

[0050] As used herein, “NCBI” refers to National Center for Biological Information and the sequence databases provided therein.

[0051] “Protein,” “polypeptide,” and “peptide” are used interchangeably herein to denote a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).

[0052] “Amino acids” are referred to herein by either their commonly known three-letter symbols or by the one-letter symbols recommended by IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single letter codes. The abbreviations used for the genetically encoded amino acids are conventional and are as follows: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartate (Asp or D), cysteine (Cys or C), glutamate (Glu or E), glutamine (Gln or Q), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V). When the three-letter abbreviations are used, unless specifically preceded by an “L” or a “D” or clear from the context in which the abbreviation is used, the amino acid may be in either the L- or D-configuration about α -carbon (C_{α}). For example, whereas “Ala” designates alanine without specifying the configuration about the α -carbon, “D-Ala” and “L-Ala” designate D-alanine and L-alanine, respectively. When polypeptide sequences are presented as a string of one-letter or three-letter abbreviations (or mixtures thereof), the sequences are presented in the amino (N) to carboxy (C) direction in accordance with common convention.

[0053] The abbreviations used for the genetically encoding nucleosides are conventional and are as follows: adenosine (A); guanosine (G); cytidine (C); thymidine (T); and uridine (U). Unless specifically delineated, the abbreviated nucleosides may be either ribonucleosides or 2'-deoxyribonucleosides. The nucleosides may be specified as being either ribonucleosides or 2'-deoxyribonucleosides on an individual basis or on an aggregate basis. When nucleic acid sequences are presented as a string of one-letter abbreviations, the sequences are presented in the 5' to 3' direction in accordance with common convention, and the phosphates are not indicated.

[0054] The terms “engineered,” “recombinant,” “non-naturally occurring,” and “variant,” when used with reference to a cell, a polynucleotide or a polypeptide refers to a material or a material corresponding to the natural or native form of the material that has been modified in a manner that would not otherwise exist in nature or is identical thereto but produced or derived from synthetic materials and/or by manipulation using recombinant techniques.

[0055] As used herein, “UTR” refers to untranslated regions of an mRNA polynucleotide. In some embodiments, a “5' untranslated region” or “5'UTR” is referred to as a “leader sequence” or “leader RNA.” This mRNA region is directly upstream from the initiation codon. In some embodiments, a “3' untranslated region” or “3'UTR” is an mRNA region directly downstream from the stop codon.

In various organisms (e.g., prokaryotes, eukaryotes, and viruses), both of these regions are important for translation regulation and intracellular trafficking.

[0056] As used herein, “wild-type,” “WT,” and “naturally-occurring” refer to the form found in nature. For example, a wild-type polypeptide or polynucleotide sequence is a sequence present in an organism that can be isolated from a source in nature and which has not been intentionally modified by human manipulation.

[0057] As used herein, “coding sequence” refers to that part of a nucleic acid (e.g., a gene) that encodes an amino acid sequence of a protein.

[0058] The term “percent (%) sequence identity” is used herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence for optimal alignment of the two sequences. The percentage may be calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Alternatively, the percentage may be calculated by determining the number of positions at which either the identical nucleic acid base or amino acid residue occurs in both sequences or a nucleic acid base or amino acid residue is aligned with a gap to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Those of skill in the art appreciate that there are many established algorithms available to align two sequences. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (Smith and Waterman, *Adv. Appl. Math.*, 2:482 [1981]), by the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch, *J. Mol. Biol.*, 48:443 [1970]), by the search for similarity method of Pearson and Lipman (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 [1988]), by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Software Package), or by visual inspection, as known in the art. Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include, but are not limited to the BLAST and BLAST 2.0 algorithms, which are described by Altschul et al. (See, Altschul et al., *J. Mol. Biol.*, 215: 403-410 [1990]; and Altschul et al., 1977, *Nucleic Acids Res.*, 3389-3402 [1977], respectively). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as, the neighborhood word score threshold (See, Altschul et

al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (See, Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 [1989]). Exemplary determination of sequence alignment and % sequence identity can employ the BESTFIT or GAP programs in the GCG Wisconsin Software package (Accelrys, Madison WI), using default parameters provided.

[0059] As used herein, “reference sequence” refers to a defined sequence used as a basis for a sequence comparison. A reference sequence may be a subset of a larger sequence, for example, a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotide or amino acid residues in length, at least 25 residues in length, at least 50 residues in length, at least 100 residues in length or the full length of the nucleic acid or polypeptide. Since two polynucleotides or polypeptides may each (1) comprise a sequence (*i.e.*, a portion of the complete sequence) that is similar between the two sequences, and (2) may further comprise a sequence that is divergent between the two sequences, sequence comparisons between two (or more) polynucleotides or polypeptide are typically performed by comparing sequences of the two polynucleotides or polypeptides over a “comparison window” to identify and compare local regions of sequence similarity. In some embodiments, a “reference sequence” can be based on a primary amino acid sequence, where the reference sequence is a sequence that can have one or more changes in the primary sequence. “Comparison window” refers to a conceptual segment of at least about 20 contiguous nucleotide positions or amino acids residues wherein a sequence may be compared to a reference sequence of at least 20 contiguous nucleotides or amino acids and wherein the portion of the sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The comparison window can be longer than 20 contiguous residues, and includes, optionally 30, 40, 50, 100, or longer windows.

[0060] “Corresponding to”, “reference to” and “relative to” when used in the context of the numbering of a given amino acid or polynucleotide sequence refers to the numbering of the residues

of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. In other words, the residue number or residue position of a given polymer is designated with respect to the reference sequence rather than by the actual numerical position of the residue within the given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as that of an engineered GLA, can be aligned to a reference sequence by introducing gaps to optimize residue matches between the two sequences. In these cases, although the gaps are present, the numbering of the residue in the given amino acid or polynucleotide sequence is made with respect to the reference sequence to which it has been aligned.

[0061] As used herein, “amino acid difference” and “residue difference” refer to a difference in the amino acid residue at a position of a polypeptide sequence relative to the amino acid residue at a corresponding position in a reference sequence. The positions of amino acid differences generally are referred to herein as “X_n,” where n refers to the corresponding position in the reference sequence upon which the residue difference is based. For example, a “residue difference at position X₄₄ as compared to SEQ ID NO: 8” refers to a difference of the amino acid residue at the polypeptide position corresponding to position 44 of SEQ ID NO: 8. Thus, if the reference polypeptide of SEQ ID NO: 8 has an arginine at position 44, then a “residue difference at position X₄₄ as compared to SEQ ID NO: 8” an amino acid substitution of any residue other than arginine at the position of the polypeptide corresponding to position 44 of SEQ ID NO: 8. In most instances herein, the specific amino acid residue difference at a position is indicated as “X_nY” where “X_n” specified the corresponding position as described above, and “Y” is the single letter identifier of the amino acid found in the engineered polypeptide (i.e., the different residue than in the reference polypeptide). In some instances (e.g., as shown in in Tables 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and 13-1), the present disclosure also provides specific amino acid differences denoted by the conventional notation “A_nB”, where A is the single letter identifier of the residue in the reference sequence, “n” is the number of the residue position in the reference sequence, and B is the single letter identifier of the residue substitution in the sequence of the engineered polypeptide. In some instances, a polypeptide of the present disclosure can include one or more amino acid residue differences relative to a reference sequence, which is indicated by a list of the specified positions where residue differences are present relative to the reference sequence. In some embodiments, where more than one amino acid can be used in a specific residue position of a polypeptide, the various amino acid residues that can be used are separated by a “/” (e.g., X₂₄₇D/X₂₄₇N or X₂₄₇D/N). In some embodiments, the enzyme variants comprise more than one substitution. These substitutions are separated by a slash for ease in reading (e.g., D₂₄S/D₂₀₂N). The present application includes engineered polypeptide sequences comprising one or more amino acid differences that include either/or both conservative and non-conservative amino acid substitutions.

[0062] As used herein, “mutation” refers to substitutions, insertions, deletions, and other modifications of polypeptide and polynucleotide sequences. It is not intended that the present invention be limited to any specific type of mutation(s).

[0063] “Conservative amino acid substitution” refers to a substitution of a residue with a different residue having a similar side chain, and thus typically involves substitution of the amino acid in the polypeptide with amino acids within the same or similar defined class of amino acids. By way of example and not limitation, an amino acid with an aliphatic side chain may be substituted with another aliphatic amino acid (e.g., alanine, valine, leucine, and isoleucine); an amino acid with hydroxyl side chain is substituted with another amino acid with a hydroxyl side chain (e.g., serine and threonine); an amino acids having aromatic side chains is substituted with another amino acid having an aromatic side chain (e.g., phenylalanine, tyrosine, tryptophan, and histidine); an amino acid with a basic side chain is substituted with another amino acid with a basis side chain (e.g., lysine and arginine); an amino acid with an acidic side chain is substituted with another amino acid with an acidic side chain (e.g., aspartic acid or glutamic acid); and/or a hydrophobic or hydrophilic amino acid is replaced with another hydrophobic or hydrophilic amino acid, respectively.

[0064] “Non-conservative substitution” refers to substitution of an amino acid in the polypeptide with an amino acid with significantly differing side chain properties. Non-conservative substitutions may use amino acids between, rather than within, the defined groups and affects (a) the structure of the peptide backbone in the area of the substitution (e.g., proline for glycine) (b) the charge or hydrophobicity, or (c) the bulk of the side chain. By way of example and not limitation, an exemplary non-conservative substitution can be an acidic amino acid substituted with a basic or aliphatic amino acid; an aromatic amino acid substituted with a small amino acid; and a hydrophilic amino acid substituted with a hydrophobic amino acid.

[0065] As used herein, “deletion” refers to modification to the polypeptide by removal of one or more amino acids from the reference polypeptide. Deletions can comprise removal of 1 or more amino acids, 2 or more amino acids, 5 or more amino acids, 10 or more amino acids, 15 or more amino acids, or 20 or more amino acids, up to 10% of the total number of amino acids, or up to 20% of the total number of amino acids making up the reference enzyme while retaining enzymatic activity and/or retaining the improved properties of an engineered enzyme. Deletions can be directed to the internal portions and/or terminal portions of the polypeptide. In various embodiments, the deletion can comprise a continuous segment or can be discontinuous.

[0066] As used herein, “insertion” refers to modification to the polypeptide by addition of one or more amino acids from the reference polypeptide. Insertions can be in the internal portions of the polypeptide, or to the carboxy or amino terminus. Insertions as used herein include fusion proteins as is known in the art. The insertion can be a contiguous segment of amino acids or separated by one or more of the amino acids in the naturally occurring polypeptide.

[0067] A “functional fragment” and “biologically active fragment” are used interchangeably herein to refer to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion(s) and/or internal deletions, but where the remaining amino acid sequence is identical to the corresponding positions in the sequence to which it is being compared (e.g., a full-length engineered GLA of the present invention) and that retains substantially all of the activity of the full-length polypeptide.

[0068] As used herein, “isolated polypeptide” refers to a polypeptide which is substantially separated from other contaminants that naturally accompany it (e.g., protein, lipids, and polynucleotides). The term embraces polypeptides which have been removed or purified from their naturally-occurring environment or expression system (e.g., host cell or *in vitro* synthesis). The recombinant GLA polypeptides may be present within a cell, present in the cellular medium, or prepared in various forms, such as lysates or isolated preparations. As such, in some embodiments, the recombinant GLA polypeptides can be an isolated polypeptide.

[0069] As used herein, “substantially pure polypeptide” refers to a composition in which the polypeptide species is the predominant species present (i.e., on a molar or weight basis it is more abundant than any other individual macromolecular species in the composition), and is generally a substantially purified composition when the object species comprises at least about 50 percent of the macromolecular species present by mole or % weight. Generally, a substantially pure GLA composition comprises about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, and about 98% or more of all macromolecular species by mole or % weight present in the composition. In some embodiments, the object species is purified to essential homogeneity (i.e., contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species. Solvent species, small molecules (<500 Daltons), and elemental ion species are not considered macromolecular species. In some embodiments, the isolated recombinant GLA polypeptides are substantially pure polypeptide compositions.

[0070] As used herein, “improved enzyme property” refers to an engineered GLA polypeptide that exhibits an improvement in any enzyme property as compared to a reference GLA polypeptide and/or as a wild-type GLA polypeptide or another engineered GLA polypeptide. Improved properties include, but are not limited to such properties as increased gene expression, increased protein production, increased thermoactivity, increased thermostability, increased activity at various pH levels, increased stability, increased enzymatic activity, increased substrate specificity or affinity, increased specific activity, increased resistance to substrate and/or product inhibition, increased chemical stability, improved chemoselectivity, improved solvent stability, increased tolerance to acidic, neutral, or basic pH, increased tolerance to proteolytic activity (i.e., reduced sensitivity to proteolysis), reduced aggregation, increased solubility, reduced immunogenicity, improved post-translational modification (e.g., glycosylation), altered temperature profile, increased cellular uptake,

increased lysosomal stability, increased ability to deplete cells of Gb3, increased secretion from GLA producing cells, etc.

[0071] As used herein, “increased enzymatic activity” and “enhanced catalytic activity” refer to an improved property of the engineered GLA polypeptides, which can be represented by an increase in specific activity (e.g., product produced/time/weight protein) or an increase in percent conversion of the substrate to the product (e.g., percent conversion of starting amount of substrate to product in a specified time period using a specified amount of GLA) as compared to the reference GLA enzyme.

[0072] Exemplary methods to determine enzyme activity are provided in the Examples. Any property relating to enzyme activity may be affected, including the classical enzyme properties of K_m , V_{max} or k_{cat} , changes of which can lead to increased enzymatic activity. Improvements in enzyme activity can be from about 1.1 fold the enzymatic activity of the corresponding wild-type enzyme, to as much as 2-fold, 5-fold, 10-fold, 20-fold, 25-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold or more enzymatic activity than the naturally occurring GLA or another engineered GLA from which the GLA polypeptides were derived.

[0073] In some embodiments, the engineered GLA polypeptides have a k_{cat} of at least 0.1/sec, at least 0.5/sec, at least 1.0/sec, at least 5.0/sec, at least 10.0/sec and in some preferred embodiments greater than 10.0/sec. In some embodiments, the K_m is in the range of about 1 μ M to about 5 mM; in the range of about 5 μ M to about 2 mM; in the range of about 10 μ M to about 2 mM; or in the range of about 10 μ M to about 1 mM. In some specific embodiments, the engineered GLA enzyme exhibits improved enzymatic activity after exposure to certain conditions in the range of 1.5 to 10 fold, 1.5 to 25 fold, 1.5 to 50 fold, 1.5 to 100 fold or greater than that of a reference GLA enzyme (e.g., a wild-type GLA or any other reference GLA, such as SEQ ID NO: 8). GLA activity can be measured by any suitable method known in the art (e.g., standard assays, such as monitoring changes in spectrophotometric properties of reactants or products). In some embodiments, the amount of product produced can be measured by High-Performance Liquid Chromatography (HPLC) separation combined with UV absorbance or fluorescent detection directly or following o-phthalaldehyde (OPA) derivatization. In some embodiments, the amount of product produced can be measured by monitoring fluorescence (Ex. 355 nm, Em. 460 nm) after hydrolysis of a 4-methylumbelliferyl- α -D-galactopyranoside (4-MUGal) molecule. Comparisons of enzyme activities are made using a defined preparation of enzyme, a defined assay under a set condition, and one or more defined substrates, as further described in detail herein. Generally, when lysates are compared, the numbers of cells and the amount of protein assayed are determined as well as use of identical expression systems and identical host cells to minimize variations in amount of enzyme produced by the host cells and present in the lysates.

[0074] As used herein, the term “improved tolerance to acidic pH” means that a recombinant GLA according to the invention will have increased stability (higher retained activity at about pH 4.8 after

exposure to acidic pH for a specified period of time (1 hour, up to 24 hours)) as compared to a reference GLA or another enzyme.

[0075] As used herein, the term “improved cellular uptake” means that a recombinant GLA provided herein exhibits increased endocytosis into cells, as compared to a reference GLA (including wild-type GLA) or another enzyme. In some embodiments, the cells are cultured Fabry patient fibroblasts (higher retained intracellular activity after incubation with cultured cells over a specified period of time, as compared to a reference GLA or another enzyme). In some additional embodiments, the recombinant GLA provided herein exhibits greater retained intracellular activity with cultured cells over a specific period of time as compared to a reference GLA (including wild-type GLA) or another enzyme. In some additional embodiments, the time period is about 4 hours, while in some other embodiments, the time period is less than 4 hours (e.g., 1, 2, or 3 hours), and in some alternative embodiments, the time period is more than 4 hours (e.g., 5, 6, 7, 8, or more hours).

[0076] “Physiological pH” as used herein means the pH range generally found in a subject’s (e.g., human) blood.

[0077] The term “basic pH” (e.g., used with reference to improved stability to basic pH conditions or increased tolerance to basic pH) means a pH range of about 7 to 11.

[0078] The term “acidic pH” (e.g., used with reference to improved stability to acidic pH conditions or increased tolerance to acidic pH) means a pH range of about 1.5 to 4.5.

[0079] As used herein, “conversion” refers to the enzymatic conversion (or biotransformation) of a substrate(s) to the corresponding product(s). “Percent conversion” refers to the percent of the substrate that is converted to the product within a period of time under specified conditions. Thus, the “enzymatic activity” or “activity” of a GLA polypeptide can be expressed as “percent conversion” of the substrate to the product in a specific period of time.

[0080] As used herein, “hybridization stringency” relates to hybridization conditions, such as washing conditions, in the hybridization of nucleic acids. Generally, hybridization reactions are performed under conditions of lower stringency, followed by washes of varying but higher stringency. The term “moderately stringent hybridization” refers to conditions that permit target-DNA to bind a complementary nucleic acid that has about 60% identity, preferably about 75% identity, about 85% identity to the target DNA, with greater than about 90% identity to target-polynucleotide. Exemplary moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5× Denhart’s solution, 5×SSPE, 0.2% SDS at 42°C, followed by washing in 0.2×SSPE, 0.2% SDS, at 42°C. “High stringency hybridization” refers generally to conditions that are about 10°C or less from the thermal melting temperature T_m as determined under the solution condition for a defined polynucleotide sequence. In some embodiments, a high stringency condition refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C (*i.e.*, if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions, as contemplated herein). High stringency conditions can be provided, for example, by

hybridization in conditions equivalent to 50% formamide, 5× Denhart's solution, 5×SSPE, 0.2% SDS at 42°C, followed by washing in 0.1×SSPE, and 0.1% SDS at 65°C. Another high stringency condition is hybridizing in conditions equivalent to hybridizing in 5X SSC containing 0.1% (w:v) SDS at 65°C and washing in 0.1x SSC containing 0.1% SDS at 65°C. Other high stringency hybridization conditions, as well as moderately stringent conditions, are described in the references cited above.

[0081] As used herein, “codon optimized” refers to changes in the codons of the polynucleotide encoding a protein such that the encoded protein is more efficiently expressed in the organism and/or cells of interest. Although the genetic code is degenerate in that most amino acids are represented by several codons, called “synonyms” or “synonymous” codons, it is well known that codon usage by particular organisms is nonrandom and biased towards particular codon triplets. This codon usage bias may be higher in reference to a given gene, genes of common function or ancestral origin, highly expressed proteins versus low copy number proteins, and the aggregate protein coding regions of an organism's genome. In some embodiments, the polynucleotides encoding the GLA enzymes may be codon optimized for optimal production from the host organism(s) and/or cell type(s) selected for expression accounting for GC content, cryptic splice sites, transcription termination signals, motifs that may affect RNA stability, and nucleic acid secondary structures, as well as any other factors of interest.

[0082] As used herein, “control sequence” refers to include all components, which are necessary or advantageous for the expression of a polynucleotide and/or polypeptide of the present application. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter sequence, signal peptide sequence, initiation sequence and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

[0083] As used herein, “operably linked” refers to a configuration in which a control sequence is appropriately placed (i.e., in a functional relationship) at a position relative to a polynucleotide of interest such that the control sequence directs or regulates the expression of the polynucleotide and/or polypeptide of interest.

[0084] As used herein, “promoter sequence” refers to a nucleic acid sequence that is recognized by a host cell for expression of a polynucleotide of interest, such as a coding sequence. The promoter sequence contains transcriptional control sequences, which mediate the expression of a polynucleotide of interest. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from

genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

[0085] As used herein, “suitable reaction conditions” refers to those conditions in the enzymatic conversion reaction solution (e.g., ranges of enzyme loading, temperature, pH, buffers, co-solvents, etc.) under which a GLA polypeptide of the present application is capable of converting a substrate to the desired product compound. Exemplary “suitable reaction conditions” are provided in the present application and illustrated by the Examples. “Enzyme loading” refers to the concentration or amount of a component in a reaction mixture at the start of the reaction. “Substrate” in the context of an enzymatic conversion reaction process refers to the compound or molecule acted on by the GLA polypeptide. “Product” in the context of an enzymatic conversion process refers to the compound or molecule resulting from the action of the GLA polypeptide on a substrate.

[0086] As used herein the term “culturing” refers to the growing of a population of microbial, mammalian, or other suitable cells under any suitable conditions (e.g., using a liquid, gel or solid medium).

[0087] Recombinant polypeptides can be produced using any suitable methods known the art. Genes encoding the wild-type polypeptide of interest can be cloned in vectors, such as plasmids, and expressed in desired hosts, such as *E. coli*, *S. cerevisiae*, or mammalian cell lines (e.g., HEK, or CHO cells), etc. Variants of recombinant polypeptides can be generated by various methods known in the art. Indeed, there is a wide variety of different mutagenesis techniques well known to those skilled in the art. In addition, mutagenesis kits are also available from many commercial molecular biology suppliers. Methods are available to make specific substitutions at defined amino acids (site-directed), specific or random mutations in a localized region of the gene (regio-specific), or random mutagenesis over the entire gene (e.g., saturation mutagenesis). Numerous suitable methods are known to those in the art to generate enzyme variants, including but not limited to site-directed mutagenesis of single-stranded DNA or double-stranded DNA using PCR, cassette mutagenesis, gene synthesis, error-prone PCR, shuffling, and chemical saturation mutagenesis, or any other suitable method known in the art. Non-limiting examples of methods used for DNA and protein engineering are provided in the following patents: US Pat. No. 6,117,679; US Pat. No. 6,420,175; US Pat. No. 6,376,246; US Pat. No. 6,586,182; US Pat. No. 7,747,391; US Pat. No. 7,747,393; US Pat. No. 7,783,428; and US Pat. No. 8,383,346. After the variants are produced, they can be screened for any desired property (e.g., high or increased activity, or low or reduced activity, increased thermal activity, increased thermal stability, and/or acidic pH stability, etc.). In some embodiments, “recombinant GLA polypeptides” (also referred to herein as “engineered GLA polypeptides,” “variant GLA enzymes,” and “GLA variants”) find use.

[0088] As used herein, a “vector” is a DNA construct for introducing a DNA sequence into a cell. In some embodiments, the vector is an expression vector that is operably linked to a suitable control sequence capable of effecting the expression in a suitable host of the polypeptide encoded in the DNA

sequence. In some embodiments, an "expression vector" has a promoter sequence operably linked to the DNA sequence (*e.g.*, transgene) to drive expression in a host cell, and in some embodiments, also comprises a transcription terminator sequence.

[0089] As used herein, the term "gene therapy vector" refers to vehicles or carriers suitable for delivery of polynucleotide sequences to cells. In some embodiments, the vectors encapsulate genes (*e.g.*, therapeutic genes) or polynucleotide sequences for delivery to cells or tissues, including but not limited to adenovirus (AV), adeno-associated virus (AAV), lentivirus (LV), and non-viral vectors, such as liposomes. It is not intended that the present invention be limited to any specific gene therapy vector, as any vehicle suitable for a given setting finds use. The gene therapy vector may be designed to deliver genes to a specific species or host, or may find more general applicability.

[0090] As used herein, the term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses secretion of the polypeptide from a cell.

[0091] As used herein, the term "produces" refers to the production of proteins and/or other compounds by cells. It is intended that the term encompass any step involved in the production of polypeptides including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses secretion of the polypeptide from a cell.

[0092] As used herein, an amino acid or nucleotide sequence (*e.g.*, a promoter sequence, signal peptide, terminator sequence, etc.) is "recombinant" or "heterologous" to another sequence with which it is operably linked if the two sequences are not associated in nature.

[0093] As used herein, the terms "host cell" and "host strain" refer to suitable hosts for expression vectors comprising DNA provided herein (*e.g.*, the polynucleotides encoding the GLA variants). In some embodiments, the host cells are prokaryotic or eukaryotic cells that have been transformed or transfected with vectors constructed using recombinant DNA techniques as known in the art.

[0094] The term "analogue" means a polypeptide having more than 70% sequence identity but less than 100% sequence identity (*e.g.*, more than 75%, 78%, 80%, 83%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity) with a reference polypeptide. In some embodiments, "analogues" means polypeptides that contain one or more non-naturally occurring amino acid residues including, but not limited, to homoarginine, ornithine and norvaline, as well as naturally occurring amino acids. In some embodiments, analogues also include one or more D-amino acid residues and non-peptide linkages between two or more amino acid residues.

[0095] As used herein, the term "therapeutic" refers to a compound administered to a subject who shows signs or symptoms of pathology having beneficial or desirable medical effects.

[0096] As used herein, the term “pharmaceutical composition” refers to a composition suitable for pharmaceutical use in a mammalian subject (e.g., human) comprising a pharmaceutically effective amount of an engineered GLA polypeptide encompassed by the invention and an acceptable carrier.

[0097] As used herein, the term “gene therapy” refers to the delivery of a gene, polydeoxyribonucleotide, or polynucleotide sequence(s) with a gene therapy vector to cells or tissues for the modification of those cells or tissues for the treatment or prevention of a disease. Gene therapy may include replacing a mutated gene that causes disease with a healthy copy of the gene, or inactivating, or “knocking out,” a mutated gene that is functioning improperly. In some embodiments, gene therapy is used in the treatment of disease in patients.

[0098] As used herein, the term “mRNA therapy” refers to the delivery of an mRNA polyribonucleotide sequence to cells or tissues for the modification of those cells or tissues for the treatment or prevention of a disease. In some embodiments, the mRNA polynucleotide sequences for delivery to cells or tissue, are formulated, for instance, but not limited to, in liposomes. In some embodiments, mRNA therapy is used in the treatment of disease in patients.

[0099] As used herein, the term “cell therapy” refers to the delivery of living cells that have been modified exogenously to patients to provide a missing gene for the treatment or prevention of a disease. The modified cells are then reintroduced into the body.

[0100] As used herein, the term “effective amount” means an amount sufficient to produce the desired result. One of general skill in the art may determine what the effective amount by using routine experimentation.

[0101] The terms “isolated” and “purified” are used herein to refer to a molecule (e.g., an isolated nucleic acid, polypeptide, etc.) or other component that is removed from at least one other component with which it is naturally associated. The term “purified” does not require absolute purity, rather it is intended as a relative definition.

[0102] As used herein, the term “subject” encompasses mammals such as humans, non-human primates, livestock, companion animals, and laboratory animals (e.g., rodents and lagamorphs). It is intended that the term encompass females as well as males.

[0103] As used herein, the term “patient” means any subject that is being assessed for, treated for, or is experiencing disease.

[0104] The term “infant” refers to a child in the period of the first month after birth to approximately one (1) year of age. As used herein, the term “newborn” refers to child in the period from birth to the 28th day of life. The term “premature infant” refers to an infant born after the twentieth completed week of gestation, yet before full term, generally weighing ~500 to ~2499 grams at birth. A “very low birth weight infant” is an infant weighing less than 1500 g at birth.

[0105] As used herein, the term “child” refers to a person who has not attained the legal age for consent to treatment or research procedures. In some embodiments, the term refers to a person between the time of birth and adolescence.

[0106] As used herein, the term “adult” refers to a person who has attained legal age for the relevant jurisdiction (e.g., 18 years of age in the United States). In some embodiments, the term refers to any fully grown, mature organism. In some embodiments, the term “young adult” refers to a person less than 18 years of age, but who has reached sexual maturity.

[0107] As used herein, “composition” and “formulation” encompass products comprising at least one engineered GLA of the present invention, intended for any suitable use (e.g., pharmaceutical compositions, dietary/nutritional supplements, feed, etc.).

[0108] As used herein, the terms “administration” and “administering” a composition mean providing a composition of the present invention to a subject (e.g., to a person suffering from the effects of Fabry disease).

[0109] As used herein, the term “carrier” when used in reference to a pharmaceutical composition means any of the standard pharmaceutical carrier, buffers, and excipients, such as stabilizers, preservatives, and adjuvants.

[0110] As used herein, the term “pharmaceutically acceptable” means a material that can be administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the components in which it is contained and that possesses the desired biological activity.

[0111] As used herein, the term “excipient” refers to any pharmaceutically acceptable additive, carrier, diluent, adjuvant, or other ingredient, other than the active pharmaceutical ingredient (API; e.g., the engineered GLA polypeptides of the present invention). Excipients are typically included for formulation and/or administration purposes.

[0112] As used herein, the term “therapeutically effective amount” when used in reference to symptoms of disease/condition refers to the amount and/or concentration of a compound (e.g., engineered GLA polypeptides) that ameliorates, attenuates, or eliminates one or more symptom of a disease/condition or prevents or delays the onset of symptom(s).

[0113] As used herein, the term “therapeutically effective amount” when used in reference to a disease/condition refers to the amount and/or concentration of a composition (e.g., engineered GLA polypeptides) that ameliorates, attenuates, or eliminates the disease/condition. In some embodiments, the term is used in reference to the amount of a composition that elicits the biological (e.g., medical) response by a tissue, system, or animal subject that is sought by the researcher, physician, veterinarian, or other clinician.

[0114] It is intended that the terms “treating,” “treat” and “treatment” encompass preventative (e.g., prophylactic), as well as palliative treatment.

Engineered GLA Expression and Activity:

[0115] Secreted expression of a yeast codon-optimized mature human GLA was achieved using a synthetic mouse IG signal peptide. Clones were expressed from a pCDNA3.1(+) vector in HEK293T

cells. This approach provided supernatants with measurable activity on the fluorogenic substrate 4-methylumbelliferyl α -D-galactopyranoside (4-MuGal).

[0116] In some embodiments, to identify mutational diversity with similar stability and improved cellular uptake compared to SEQ ID NO: 8, a combinatorial library was constructed generating GLA variants derived from SEQ ID NO:8. Equivalent volumes of supernatant were screened in an unchallenged condition (no incubation, pH 4.6) or following a one-hour incubation in a low pH (3.9-4.2), a neutral pH (7.0-7.6) or human serum (physiological pH 7.1- 8.2) environment. GLA variants with activity due to increased GLA expression or GLA specific activity were identified based on their fold improvement over the parent GLA. GLA variants with increased stability were identified by dividing the fold-improvement observed under challenged conditions by the fold-improvement observed under unchallenged conditions. This approach reduces the bias towards selecting variants based on increased expression but without changes in specific activity at pH extremes. Composite activity scores (the product of fold-improvements for all three conditions) and stability (the product of stability scores) were used to rank mutations in improved variants for inclusion in subsequent GLA libraries. In additional embodiments, the additional methods and sequences described in the Examples were used.

Engineered GLA:

[0117] In some embodiments the engineered GLA which exhibits an improved property has at least about 85%, at least about 88%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at about 100% amino acid sequence identity with SEQ ID NO: 2, 8, 48, 158, 372, 374, 704, and/or 1022, and an amino acid residue difference as compared to SEQ ID NO: 2, 8, 48, 158, 372, 374, 704, and/or 1022, at one or more amino acid positions (such as at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 20 or more amino acid positions compared to SEQ ID NO: 2, 8, 48, 158, 372, 374, 704, and/or 1022, or a sequence having at least 85%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or greater amino acid sequence identity with SEQ ID NO: 2, 8, 48, 158, 372, 374, 704, and/or 1022). In some embodiment the residue difference as compared to SEQ ID NO:5, at one or more positions include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more conservative amino acid substitutions. In some embodiments, the engineered GLA polypeptide is a polypeptide listed in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1. In some embodiments, the engineered GLA polypeptide comprises SEQ ID NO: 2, 8, 48, 158, 372, 374, 704, and/or 1022.

[0118] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one

substitution or substitution set at one or more positions selected from 44, 44/217, 44/217/316, 44/217/322, 44/217/322/337, 44/247, 44/247/302, 44/247/302/322, 44/247/322, 44/247/337, 44/247/362, 44/302, 44/337, 44/373, 217/322, 217/373, 247/322, 247/362, 302/322/362/373, 302/337, 316, 316/337, 322, 322/337, 362/373, and 373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 44L, 44L/217F, 44L/217F/316L, 44L/217F/322M, 44L/217F/322M/337A, 44L/247N, 44L/247N/302Q, 44L/247N/302Q/322M, 44L/247N/322M, 44L/247N/337A, 44L/247N/362K, 44L/302Q, 44L/337A, 44L/373R, 217F/322M, 217F/373R, 247N/322M, 247N/362K, 302Q/322M/362K/373R, 302Q/337A, 316L, 316L/337A, 322M, 322M/337A, 362K/373R, and 373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from R44L, R44L/R217F, R44L/R217F/D316L, R44L/R217F/I322M, R44L/R217F/I322M/P337A, R44L/D247N, R44L/D247N/K302Q, R44L/D247N/K302Q/I322M, R44L/D247N/I322M, R44L/D247N/P337A, R44L/D247N/Q362K, R44L/K302Q, R44L/P337A, R44L/K373R, R217F/I322M, R217F/K373R, D247N/I322M, D247N/Q362K, K302Q/I322M/Q362K/K373R, K302Q/P337A, D316L, D316L/P337A, I322M, I322M/P337A, Q362K/K373R, and K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0119] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10/39/44/47/92/166/206/217/247/261/271/302/316/322/337/362/368/373/392, 44/217/316, 44/217/322/337, 166/362, 217/373, and 362/373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10T/39M/44L/47S/92Y/166S/206K/217F/247N/261A/271H/302Q/316L/322M/337A/362K/368W/37

3R/392M, 44L/217F/316L, 44L/217F/322M/337A, 166A/362K, 217F/373R, and 362K/373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from

P10T/E39M/R44L/T47S/H92Y/P166S/A206K/R217F/D247N/G261A/A271H/K302Q/D316L/I322M/P337A/Q362K/A368W/K373R/T392M, R44L/R217F/D316L, R44L/R217F/I322M/P337A, P166A/Q362K, R217F/K373R, and Q362K/K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0120] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7, 7/48/68, 7/48/68/120/282/299, 7/48/130/282, 7/48/180, 7/68/130/282/365, 7/68/180, 7/88/120/305/365, 7/120, 7/130, 7/282, 7/305, 7/305/365, 7/365, 39, 47, 47/87/95/96/158/162, 47/95, 47/273, 47/343, 48, 48/68, 48/180/282, 48/282, 48/282/305, 67/180, 68, 68/299/300, 71, 87/91/95/96/158/162, 87/91/95/96/206/343, 87/96/155/273/343, 88, 91/95, 91/95/96, 92, 93, 96, 96/273, 96/312/343, 120, 120/299/305, 151, 158, 158/162/273, 162, 162/273, 162/343, 166, 178, 180, 181, 206, 217, 271, 273, 273/343, 282, 282/365, 293/391, 299/300, 299/300/305/365, 300, 301, 305, 305/365, 314, 333, 336, 337, 343, 345, 363, 365, 370, 389, 393, 394, 396/398, 397, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7L, 7L/48D/68E, 7L/48D/68E/120H/282N/299R, 7L/48D/130E/282N, 7L/48D/180G, 7L/68E/130E/282N/365V, 7L/68E/180G, 7L/88A/120H/305G/365V, 7L/120H, 7L/130E, 7L/282N, 7L/305G, 7L/305G/365V, 7L/365V, 39V, 47D, 47D/87K/95E/96L/158R/162H, 47D/95E, 47D/273P, 47D/343G, 47V, 48D, 48D/68E, 48D/180G/282N, 48D/282N, 48D/282N/305G, 67T/180G, 68E, 68E/299R/300I, 71P, 87K/91Q/95E/96L/158A/162K, 87K/91Q/95E/96L/206S/343G, 87K/96I/155N/273P/343G, 88A, 91Q/95E, 91Q/95E/96L, 92F, 92T, 93I, 96L, 96L/273P, 96L/312Q/343G, 120H, 120H/299R/305G, 151L, 158A, 158A/162K/273G, 158R, 162H/343D, 162K, 162K/273P, 162S, 166K, 178G, 178S, 180G, 180L, 180T, 180V, 181A, 206K, 206S, 217K, 271R, 273P, 273P/343G, 282N, 282N/365V, 293P/391A, 299R/300I, 299R/300I/305G/365V, 300I, 301M,

305G, 305G/365V, 314A, 333F, 333G, 336V, 337R, 343D, 343G, 345A, 345Q, 363Q, 365A, 365Q, 365V, 370G, 389K, 393V, 394K, 396G/398T, 397A, 398A, 398P, 398S, and 398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58.

[0121] In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from R7L, R7L/E48D/Q68E, R7L/E48D/Q68E/Y120H/D282N/Q299R, R7L/E48D/D130E/D282N, R7L/E48D/F180G, R7L/Q68E/D130E/D282N/F365V, R7L/Q68E/F180G, R7L/Q88A/Y120H/N305G/F365V, R7L/Y120H, R7L/D130E, R7L/D282N, R7L/N305G, R7L/N305G/F365V, R7L/F365V, E39V, T47D, T47D/R87K/S95E/K96L/L158R/R162H, T47D/S95E, T47D/S273P, T47D/K343G, T47V, E48D, E48D/Q68E, E48D/F180G/D282N, E48D/D282N, E48D/D282N/N305G, P67T/F180G, Q68E, Q68E/Q299R/L300I, S71P, R87K/N91Q/S95E/K96L/L158A/R162K, R87K/N91Q/S95E/K96L/A206S/K343G, R87K/K96I/H155N/S273P/K343G, Q88A, N91Q/S95E, N91Q/S95E/K96L, H92F, H92T, V93I, K96L, K96L/S273P, K96L/P312Q/K343G, Y120H, Y120H/Q299R/N305G, D151L, L158A, L158A/R162K/S273G, L158R, R162H/K343D, R162K, R162K/S273P, R162S, P166K, W178G, W178S, F180G, F180L, F180T, F180V, Q181A, A206K, A206S, R217K, A271R, S273P, S273P/K343G, D282N, D282N/F365V, L293P/Q391A, Q299R/L300I, Q299R/L300I/N305G/F365V, L300I, R301M, N305G, N305G/F365V, S314A, S333F, S333G, I336V, P337R, K343D, K343G, V345A, V345Q, L363Q, F365A, F365Q, F365V, S370G, T389K, S393V, L394K, D396G/L398T, L397A, L398A, L398P, L398S, and L398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58.

[0122] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24/202, 39/47, 39/47/217, 39/151, 39/282/337/398, 39/337/343/398, 39/393/398, 47/130, 47/151, 47/343/345/393, 48, 48/68, 48/68/217/333/391/393, 48/68/333, 48/217, 48/333, 48/345/393, 48/393, 59/143, 68, 68/345, 130, 130/158, 130/158/393, 130/345/393, 143/271, 143/333, 143/387, 151, 151/158/217/343/345/393, 151/206/282/337/343/345/398, 151/282/393, 151/345/393/398, 151/393, 158, 158/393, 202, 206, 206/217, 217, 217/333, 217/337/345/398, 271, 282/393, 333, 333/345, 337/343/345/398, 343, 343/345/393/398, 393, and 393/398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%,

91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24S/202N, 39V/47D, 39V/47V/217K, 39V/151L, 39V/282N/337R/398A, 39V/337R/343G/398A, 39V/393V/398A, 47V/130E, 47V/151L, 47V/343D/345Q/393V, 48D, 48D/68E, 48D/68E/217K/333F/391A/393V, 48D/68E/333F, 48D/217K, 48D/333F, 48D/333G, 48D/345Q/393V, 48D/393V, 59A/143S, 68E, 68E/345Q, 130E, 130E/158R, 130E/158R/393V, 130E/345Q/393V, 143S/271N, 143S/333N, 143S/387N, 151L, 151L/158R/217K/343G/345Q/393V, 151L/206S/282N/337R/343D/345Q/398A, 151L/282N/393V, 151L/345Q/393V/398A, 151L/393V, 158R, 158R/393V, 202N, 206S, 206S/217K, 217K, 217K/333F, 217K/333G, 217K/337R/345Q/398A, 271N, 282N/393V, 333F/345Q, 333G, 333N, 337R/343G/345Q/398A, 343D, 343D/345Q/393V/398A, 393V, and 393V/398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D24S/D202N, E39V/T47D, E39V/T47V/R217K, E39V/D151L, E39V/D282N/P337R/L398A, E39V/P337R/K343G/L398A, E39V/S393V/L398A, T47V/D130E, T47V/D151L, T47V/K343D/V345Q/S393V, E48D, E48D/Q68E, E48D/Q68E/R217K/S333F/Q391A/S393V, E48D/Q68E/S333F, E48D/R217K, E48D/S333F, E48D/S333G, E48D/V345Q/S393V, E48D/S393V, C59A/C143S, Q68E, Q68E/V345Q, D130E, D130E/L158R, D130E/L158R/S393V, D130E/V345Q/S393V, C143S/A271N, C143S/S333N, C143S/E387N, D151L, D151L/L158R/R217K/K343G/V345Q/S393V, D151L/A206S/D282N/P337R/K343D/V345Q/L398A, D151L/D282N/S393V, D151L/V345Q/S393V/L398A, D151L/S393V, L158R, L158R/S393V, D202N, A206S, A206S/R217K, R217K, R217K/S333F, R217K/S333G, R217K/P337R/V345Q/L398A, A271N, D282N/S393V, S333F/V345Q, S333G, S333N, P337R/K343G/V345Q/L398A, K343D, K343D/V345Q/S393V/L398A, S393V, and S393V/L398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158.

[0123] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/39/44/322, 10/39/92/206/217/271, 10/39/92/247, 10/39/92/247/271/316, 10/44, 10/44/47/92/247, 10/44/47/261/302/322/368, 10/44/92/316/322, 10/44/261/302/316, 10/44/302/337/368, 10/47/217/247/316/392, 10/47/217/322, 10/47/271, 10/92, 10/92/206/217/247,

10/92/206/247/316/322/392, 10/92/206/247/322/368, 10/92/217/261/302/337, 10/206/217/271, 10/206/247, 10/206/261/271/316, 10/261, 10/271/302, 10/302, 10/302/316, 10/302/322/337, 10/316/322, 10/337/392, 10/368, 39/44/92/162/247/302/316/322, 39/44/92/217/322, 39/44/92/247/271/302, 39/47/92/247/302/316/322, 39/47/217/247/368, 39/47/247, 39/92/247/302/316/337/368, 39/92/316/322, 39/247/271, 39/247/271/316, 39/322, 44/47/92/206/217/316/322, 44/47/92/247/261/271/316/337/368, 44/47/206/217/247/271/322, 44/47/247/322/368, 44/47/302/316/322, 44/92/206/247/368, 44/206/337, 44/247/261/302/316, 44/247/261/302/316/322, 47/92/247/271, 47/217/302, 47/247, 47/247/271, 89/217/247/261/302/316, 92/217/271, 92/247, 92/247/271/322, 92/247/302/322/337, 92/271/337, 92/302, 92/316, 206/217/271/392, 217/247/316/322/337/368, 247, 247/271, 247/302, 271, 271/302/322, 271/316/322, 302/322/368, and 368, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10P, 10P/39E/44R/322I, 10P/39E/92H/206A/217R/271A, 10P/39E/92H/247D, 10P/39E/92H/247D/271A/316D, 10P/44R, 10P/44R/47T/92H/247D, 10P/44R/47T/261G/302K/322I/368A, 10P/44R/92H/316D/322I, 10P/44R/261G/302K/316D, 10P/44R/302K/337P/368A, 10P/47T/217R/247D/316D/392T, 10P/47T/217R/322I, 10P/47T/271A, 10P/92H, 10P/92H/206A/217R/247D, 10P/92H/206A/247D/316D/322I/392T, 10P/92H/206A/247D/322I/368A, 10P/92H/217R/261G/302K/337P, 10P/206A/217R/271A, 10P/206A/247D, 10P/206A/261G/271A/316D, 10P/261G, 10P/271A/302K, 10P/302K, 10P/302K/316D, 10P/302K/322I/337P, 10P/316D/322I, 10P/337P/392T, 10P/368A, 39E/44R/92H/162M/247D/302K/316D/322I, 39E/44R/92H/217R/322I, 39E/44R/92H/247D/271A/302K, 39E/47T/92H/247D/302K/316D/322I, 39E/47T/217R/247D/368A, 39E/47T/247D, 39E/92H/247D/302K/316D/337P/368A, 39E/92H/316D/322I, 39E/247D/271A, 39E/247D/271A/316D, 39E/322I, 44R/47T/92H/206A/217R/316D/322I, 44R/47T/92H/247D/261G/271A/316D/337P/368A, 44R/47T/206A/217R/247D/271A/322I, 44R/47T/247D/322I/368A, 44R/47T/302K/316D/322I, 44R/92H/206A/247D/368A, 44R/206A/337P, 44R/247D/261G/302K/316D, 44R/247D/261G/302K/316D/322I, 47T/92H/247D/271A, 47T/217R/302K, 47T/247D, 47T/247D/271A, 89I/217R/247D/261G/302K/316D, 92H/217R/271A, 92H/247D, 92H/247D/271A/322I, 92H/247D/302K/322I/337P, 92H/271A/337P, 92H/302K, 92H/316D, 206A/217R/271A/392T, 217R/247D/316D/322I/337P/368A, 247D, 247D/271A, 247D/302K, 271A, 271A/302K/322I, 271A/316D/322I, 302K/322I/368A, and 368A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence

having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from T10P, T10P/M39E/L44R/M322I, T10P/M39E/Y92H/K206A/F217R/H271A, T10P/M39E/Y92H/N247D, T10P/M39E/Y92H/N247D/H271A/L316D, T10P/L44R, T10P/L44R/S47T/Y92H/N247D, T10P/L44R/S47T/A261G/Q302K/M322I/W368A, T10P/L44R/Y92H/L316D/M322I, T10P/L44R/A261G/Q302K/L316D, T10P/L44R/Q302K/A337P/W368A, T10P/S47T/F217R/N247D/L316D/M392T, T10P/S47T/F217R/M322I, T10P/S47T/H271A, T10P/Y92H, T10P/Y92H/K206A/F217R/N247D, T10P/Y92H/K206A/N247D/L316D/M322I/M392T, T10P/Y92H/K206A/N247D/M322I/W368A, T10P/Y92H/F217R/A261G/Q302K/A337P, T10P/K206A/F217R/H271A, T10P/K206A/N247D, T10P/K206A/A261G/H271A/L316D, T10P/A261G, T10P/H271A/Q302K, T10P/Q302K, T10P/Q302K/L316D, T10P/Q302K/M322I/A337P, T10P/L316D/M322I, T10P/A337P/M392T, T10P/W368A, M39E/L44R/Y92H/R162M/N247D/Q302K/L316D/M322I, M39E/L44R/Y92H/F217R/M322I, M39E/L44R/Y92H/N247D/H271A/Q302K, M39E/S47T/Y92H/N247D/Q302K/L316D/M322I, M39E/S47T/F217R/N247D/W368A, M39E/S47T/N247D, M39E/Y92H/N247D/Q302K/L316D/A337P/W368A, M39E/Y92H/L316D/M322I, M39E/N247D/H271A, M39E/N247D/H271A/L316D, M39E/M322I, L44R/S47T/Y92H/K206A/F217R/L316D/M322I, L44R/S47T/Y92H/N247D/A261G/H271A/L316D/A337P/W368A, L44R/S47T/K206A/F217R/N247D/H271A/M322I, L44R/S47T/N247D/M322I/W368A, L44R/S47T/Q302K/L316D/M322I, L44R/Y92H/K206A/N247D/W368A, L44R/K206A/A337P, L44R/N247D/A261G/Q302K/L316D, L44R/N247D/A261G/Q302K/L316D/M322I, S47T/Y92H/N247D/H271A, S47T/F217R/Q302K, S47T/N247D, S47T/N247D/H271A, L89I/F217R/N247D/A261G/Q302K/L316D, Y92H/F217R/H271A, Y92H/N247D, Y92H/N247D/H271A/M322I, Y92H/N247D/Q302K/M322I/A337P, Y92H/H271A/A337P, Y92H/Q302K, Y92H/L316D, K206A/F217R/H271A/M392T, F217R/N247D/L316D/M322I/A337P/W368A, N247D, N247D/H271A, N247D/Q302K, H271A, H271A/Q302K/M322I, H271A/L316D/M322I, Q302K/M322I/W368A, and W368A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372.

[0124] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10/36/92/166/247/261/316/392, 10/39, 10/39/44/47/92/206/217, 10/39/44/47/316, 10/39/44/47/337, 10/39/44/92/166/261/316/322,

10/39/44/92/166/302/322, 10/39/44/92/166/392, 10/39/44/92/217/302/322, 10/39/44/92/302/322, 10/39/44/166/261/271/316/322, 10/39/44/392, 10/39/47/92/337, 10/39/92/131/166/271/316/322, 10/39/92/166/217/247/271, 10/39/92/217/316, 10/44/47/166/261/271, 10/44/47/166/271/322/368, 10/44/47/217/271/316/322, 10/44/92, 10/44/92/217/247/271/302/316/392, 10/44/166/302, 10/44/206/316/322, 10/47/92/166/271/316/337, 10/47/92/271/302, 10/47/92/316/322/392, 10/47/166/271, 10/47/166/316, 10/92/166, 10/92/166/217/247/261/271, 10/92/166/261/271/392, 10/92/166/261/316/322/337, 10/92/166/337/368, 10/92/302/337, 10/92/316/322, 10/206, 10/206/247/261, 10/217/322, 10/261, 10/261/337/392, 10/316/392, 10/368, 39/44/47/92/166/206/392, 39/44/47/92/206/247/261, 39/44/47/92/206/392, 39/44/47/206/337/368/392, 39/44/92/166/247/261/302/337, 39/44/166/271, 39/44/166/271/337/368/392, 39/47/92/316/322, 39/47/92/392, 39/47/166/217/261/392, 39/47/217/247/368, 39/47/247, 39/92/166/217/392, 39/92/261/302, 39/166/217/261/316/368, 39/322, 39/392, 44/47, 44/47/92/217/271, 44/47/92/217/316/322/392, 44/47/92/392, 44/47/166, 44/47/166/271, 44/47/247/271/392, 44/316/322/392, 44/337, 47/166/206/217/247/337, 47/166/217/271/337, 47/206, 47/217/247/261, 47/271, 52/217/302/316, 92/166/206/271/316, 92/166/217/261/271/392, 92/166/217/316/337/392, 92/166/247, 92/166/316, 92/206/322, 92/217, 92/217/271/337, 92/261/271, 92/271, 166/217/316/322/337, 166/247/271/316, 166/316/322/337, 206/217, 217/392, 247/316, 316/322/368, and 316/337/392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10T/36M/92Y/166S/247N/261A/316L/392M, 10T/39M, 10T/39M/44L/47S/92Y/206K/217F, 10T/39M/44L/47S/316L, 10T/39M/44L/47S/337A, 10T/39M/44L/92Y/166S/261A/316L/322M, 10T/39M/44L/92Y/166S/302Q/322M, 10T/39M/44L/92Y/166S/392M, 10T/39M/44L/92Y/217F/302Q/322M, 10T/39M/44L/92Y/302Q/322M, 10T/39M/44L/166S/261A/271H/316L/322M, 10T/39M/44L/392M, 10T/39M/47S/92Y/337A, 10T/39M/92Y/131G/166S/271H/316L/322M, 10T/39M/92Y/166S/217F/247N/271H, 10T/39M/92Y/217F/316L, 10T/44L/47S/166S/261A/271H, 10T/44L/47S/166S/271H/322M/368W, 10T/44L/47S/217F/271H/316L/322M, 10T/44L/92Y, 10T/44L/92Y/217F/247N/271H/302Q/316L/392M, 10T/44L/166S/302Q, 10T/44L/206K/316L/322M, 10T/47S/92Y/166S/271H/316L/337A, 10T/47S/92Y/271H/302Q, 10T/47S/92Y/316L/322M/392M, 10T/47S/166S/271H, 10T/47S/166S/316L, 10T/92Y/166S, 10T/92Y/166S/217F/247N/261A/271H, 10T/92Y/166S/261A/271H/392M, 10T/92Y/166S/261A/316L/322M/337A, 10T/92Y/166S/337A/368W, 10T/92Y/302Q/337A, 10T/92Y/316L/322M, 10T/206K, 10T/206K/247N/261A, 10T/217F/322M, 10T/261A, 10T/261A/337A/392M, 10T/316L/392M,

10T/368W, 39M/44L/47S/92Y/166S/206K/392M, 39M/44L/47S/92Y/206K/247N/261A, 39M/44L/47S/92Y/206K/392M, 39M/44L/47S/206K/337A/368W/392M, 39M/44L/92Y/166S/247N/261A/302Q/337A, 39M/44L/166S/271H, 39M/44L/166S/271H/337A/368W/392M, 39M/47S/92Y/316L/322M, 39M/47S/92Y/392M, 39M/47S/166S/217F/261A/392M, 39M/47S/217F/247N/368W, 39M/47S/247N, 39M/92Y/166S/217F/392M, 39M/92Y/261A/302Q, 39M/166S/217F/261A/316L/368W, 39M/322M, 39M/392M, 44L/47S, 44L/47S/92Y/217F/271H, 44L/47S/92Y/217F/316L/322M/392M, 44L/47S/92Y/392M, 44L/47S/166S, 44L/47S/166S/271H, 44L/47S/247N/271H/392M, 44L/316L/322M/392M, 44L/337A, 47S/166S/206K/217F/247N/337A, 47S/166S/217F/271H/337A, 47S/206K, 47S/217F/247N/261A, 47S/271H, 52N/217F/302Q/316L, 92Y/166S/206K/271H/316L, 92Y/166S/217F/261A/271H/392M, 92Y/166S/217F/316L/337A/392M, 92Y/166S/247N, 92Y/166S/316L, 92Y/206K/322M, 92Y/217F, 92Y/217F/271H/337A, 92Y/261A/271H, 92Y/271H, 166S/217F/316L/322M/337A, 166S/247N/271H/316L, 166S/316L/322M/337A, 206K/217F, 217F/392M, 247N/316L, 316L/322M/368W, and 316L/337A/392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10T/K36M/H92Y/P166S/D247N/G261A/D316L/T392M, P10T/E39M, P10T/E39M/R44L/T47S/H92Y/A206K/R217F, P10T/E39M/R44L/T47S/D316L, P10T/E39M/R44L/T47S/P337A, P10T/E39M/R44L/H92Y/P166S/G261A/D316L/I322M, P10T/E39M/R44L/H92Y/P166S/K302Q/I322M, P10T/E39M/R44L/H92Y/P166S/T392M, P10T/E39M/R44L/H92Y/R217F/K302Q/I322M, P10T/E39M/R44L/H92Y/K302Q/I322M, P10T/E39M/R44L/P166S/G261A/A271H/D316L/I322M, P10T/E39M/R44L/T392M, P10T/E39M/T47S/H92Y/P337A, P10T/E39M/H92Y/W131G/P166S/A271H/D316L/I322M, P10T/E39M/H92Y/P166S/R217F/D247N/A271H, P10T/E39M/H92Y/R217F/D316L, P10T/R44L/T47S/P166S/G261A/A271H, P10T/R44L/T47S/P166S/A271H/I322M/A368W, P10T/R44L/T47S/R217F/A271H/D316L/I322M, P10T/R44L/H92Y, P10T/R44L/H92Y/R217F/D247N/A271H/K302Q/D316L/T392M, P10T/R44L/P166S/K302Q, P10T/R44L/A206K/D316L/I322M, P10T/T47S/H92Y/P166S/A271H/D316L/P337A, P10T/T47S/H92Y/A271H/K302Q, P10T/T47S/H92Y/D316L/I322M/T392M, P10T/T47S/P166S/A271H, P10T/T47S/P166S/D316L, P10T/H92Y/P166S, P10T/H92Y/P166S/R217F/D247N/G261A/A271H, P10T/H92Y/P166S/G261A/A271H/T392M, P10T/H92Y/P166S/G261A/D316L/I322M/P337A, P10T/H92Y/P166S/P337A/A368W, P10T/H92Y/K302Q/P337A, P10T/H92Y/D316L/I322M, P10T/A206K, P10T/A206K/D247N/G261A, P10T/R217F/I322M, P10T/G261A, P10T/G261A/P337A/T392M,

P10T/D316L/T392M, P10T/A368W, E39M/R44L/T47S/H92Y/P166S/A206K/T392M, E39M/R44L/T47S/H92Y/A206K/D247N/G261A, E39M/R44L/T47S/H92Y/A206K/T392M, E39M/R44L/T47S/A206K/P337A/A368W/T392M, E39M/R44L/H92Y/P166S/D247N/G261A/K302Q/P337A, E39M/R44L/P166S/A271H, E39M/R44L/P166S/A271H/P337A/A368W/T392M, E39M/T47S/H92Y/D316L/I322M, E39M/T47S/H92Y/T392M, E39M/T47S/P166S/R217F/G261A/T392M, E39M/T47S/R217F/D247N/A368W, E39M/T47S/D247N, E39M/H92Y/P166S/R217F/T392M, E39M/H92Y/G261A/K302Q, E39M/P166S/R217F/G261A/D316L/A368W, E39M/I322M, E39M/T392M, R44L/T47S, R44L/T47S/H92Y/R217F/A271H, R44L/T47S/H92Y/R217F/D316L/I322M/T392M, R44L/T47S/H92Y/T392M, R44L/T47S/P166S, R44L/T47S/P166S/A271H, R44L/T47S/D247N/A271H/T392M, R44L/D316L/I322M/T392M, R44L/P337A, T47S/P166S/A206K/R217F/D247N/P337A, T47S/P166S/R217F/A271H/P337A, T47S/A206K, T47S/R217F/D247N/G261A, T47S/A271H, D52N/R217F/K302Q/D316L, H92Y/P166S/A206K/A271H/D316L, H92Y/P166S/R217F/G261A/A271H/T392M, H92Y/P166S/R217F/D316L/P337A/T392M, H92Y/P166S/D247N, H92Y/P166S/D316L, H92Y/A206K/I322M, H92Y/R217F, H92Y/R217F/A271H/P337A, H92Y/G261A/A271H, H92Y/A271H, P166S/R217F/D316L/I322M/P337A, P166S/D247N/A271H/D316L, P166S/D316L/I322M/P337A, A206K/R217F, R217F/T392M, D247N/D316L, D316L/I322M/A368W, and D316L/P337A/T392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0125] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2, 4, 5, 24/59, 24/143/144, 24/143/202/333, 24/143/202/352/390/391, 24/143/333/352/387/390/391, 24/143/390/391, 24/202, 24/202/271, 24/202/333/352, 24/271/352, 24/352/387/390/391, 24/387/391, 31, 40, 59, 59/143, 59/143/202, 59/143/202/271/333, 59/143/271, 59/143/333, 59/202, 59/202/333, 59/271/387/390, 73, 76, 80, 83, 84, 91/215/361, 122, 123, 143, 143/202, 143/271, 143/271/352/390, 143/333, 143/333/387/390, 143/387/391, 147, 155, 164, 165, 179, 186, 202, 202/333, 210, 215/218, 218, 218/361, 218/361/398, 218/398, 246, 254/398, 271, 271/333, 271/333/390/391, 271/333/391, 271/352/391, 273, 275, 277, 278, 280, 281, 283, 284, 287, 300, 303, 304, 325, 331, 332, 333/352, 333/390/391, 333/391, 334, 335, 336, 338, 339, 340, 341, 343, 359, 360, 361, 362, 367, 369, 371, 373, 375, 377, 382, 382/398, 385, 387/391, 390, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to

SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2S, 4L, 5M, 5V, 24S/59A, 24S/143S/144N, 24S/143S/202N/333N, 24S/143S/202N/352N/390N/391N, 24S/143S/333N/352N/387N/390T/391N, 24S/143S/390T/391N, 24S/202N, 24S/202N/271N, 24S/202N/333N/352N, 24S/271N/352N, 24S/352N/387N/390N/391N, 24S/387N/391N, 31F, 31H, 31L, 31T, 31W, 40Q, 59A, 59A/143S, 59A/143S/271N, 59A/202N, 59T, 59T/143S/202N, 59T/143S/333N, 59T/202N/333N, 59V/143S/202N/271N/333N, 59V/271N/387N/390T, 73A, 76A, 76F, 76M, 76S, 80T, 83R, 83S, 84G, 84K, 84R, 91S/215S/361T, 122E, 122N, 122S, 123Q, 123R, 123S, 123T, 143S, 143S/202N, 143S/271N, 143S/271N/352N/390N, 143S/333N, 143S/333N/387N/390T, 143S/387N/391N, 147L, 147S, 155A, 155D, 155F, 155L, 155R, 155T, 164E, 165I, 179H, 179L, 179R, 179W, 186E, 186F, 186M, 186P, 186R, 186S, 186Y, 202N, 202N/333N, 210I, 215S/218Y, 218Y, 218Y/361T, 218Y/361T/398F, 218Y/398F, 246Y, 254T/398F, 271N, 271N/333N, 271N/333N/390N/391N, 271N/333N/391N, 271N/352N/391N, 273L, 275A, 275G, 277Q, 277V, 278N, 278R, 278S, 280G, 281I, 281M, 283L, 283P, 283T, 283V, 284A, 284E, 284G, 284L, 284M, 284R, 284S, 287R, 300F, 303A, 303C, 303W, 304T, 304V, 304W, 325A, 331M, 332G, 332H, 333N/352N, 333N/390N/391N, 333N/390S/391N, 333N/391N, 334C, 334V, 335A, 335L, 336F, 336G, 336S, 336T, 338L, 339G, 339N, 339Q, 339V, 340H, 340I, 340K, 340M, 340P, 340W, 341F, 341M, 343L, 343R, 343S, 343W, 359F, 359L, 359R, 360H, 360V, 361T, 361V, 362H, 367A, 367D, 367L, 367M, 369D, 371G, 373L, 373S, 375L, 375Q, 377Q, 382I, 382I/398F, 385R, 387N/391N, 390S, and 398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D2S, G4L, L5M, L5V, D24S/C59A, D24S/C143S/D144N, D24S/C143S/D202N/G333N, D24S/C143S/D202N/F352N/M390N/Q391N, D24S/C143S/G333N/F352N/E387N/M390T/Q391N, D24S/C143S/M390T/Q391N, D24S/D202N, D24S/D202N/A271N, D24S/D202N/G333N/F352N, D24S/A271N/F352N, D24S/F352N/E387N/M390N/Q391N, D24S/E387N/Q391N, S31F, S31H, S31L, S31T, S31W, E40Q, C59A, C59A/C143S, C59A/C143S/A271N, C59A/D202N, C59T, C59T/C143S/D202N, C59T/C143S/G333N, C59T/D202N/G333N, C59V/C143S/D202N/A271N/G333N, C59V/A271N/E387N/M390T, G73A, Q76A, Q76F, Q76M, Q76S, Q80T, P83R, P83S, H84G, H84K, H84R, N91S/T215S/R361T, D122E, D122N, D122S, I123Q, I123R, I123S, I123T, C143S, C143S/D202N, C143S/A271N, C143S/A271N/F352N/M390N, C143S/G333N, C143S/G333N/E387N/M390T, C143S/E387N/Q391N, E147L, E147S, H155A, H155D, H155F, H155L, H155R, H155T, G164E, R165I, P179H, P179L, P179R, P179W, T186E, T186F, T186M, T186P, T186R, T186S, T186Y, D202N, D202N/G333N, S210I, T215S/N218Y,

N218Y, N218Y/R361T, N218Y/R361T/L398F, N218Y/L398F, W246Y, A254T/L398F, A271N, A271N/G333N, A271N/G333N/M390N/Q391N, A271N/G333N/Q391N, A271N/F352N/Q391N, S273L, Q275A, Q275G, K277Q, K277V, A278N, A278R, A278S, L280G, Q281I, Q281M, K283L, K283P, K283T, K283V, D284A, D284E, D284G, D284L, D284M, D284R, D284S, A287R, L300F, G303A, G303C, G303W, D304T, D304V, D304W, R325A, P331M, R332G, R332H, G333N/F352N, G333N/M390N/Q391N, G333N/M390S/Q391N, G333N/Q391N, Y334C, Y334V, T335A, T335L, I336F, I336G, I336S, I336T, V338L, A339G, A339N, A339Q, A339V, S340H, S340I, S340K, S340M, S340P, S340W, L341F, L341M, K343L, K343R, K343S, K343W, V359F, V359L, V359R, K360H, K360V, R361T, R361V, K362H, E367A, E367D, E367L, E367M, T369D, R371G, R373L, R373S, H375L, H375Q, N377Q, V382I, V382I/L398F, Q385R, E387N/Q391N, M390S, and L398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704.

[0126] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 39, 44, 47, 92, 166, 206, 217, 247, 261, 271, 302, 316, 322, 337, 368, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10A, 10C, 10D, 10E, 10F, 10G, 10H, 10I, 10K, 10L, 10M, 10N, 10Q, 10R, 10S, 10T, 10V, 10W, 10Y, 39A, 39C, 39D, 39F, 39G, 39H, 39I, 39K, 39L, 39M, 39N, 39P, 39Q, 39R, 39S, 39T, 39V, 39W, 39Y, 44A, 44C, 44D, 44E, 44F, 44G, 44H, 44I, 44K, 44L, 44N, 44P, 44Q, 44S, 44T, 44V, 44W, 44Y, 47A, 47C, 47D, 47E, 47F, 47G, 47H, 47I, 47K, 47L, 47M, 47N, 47P, 47Q, 47R, 47S, 47V, 47W, 47Y, 92A, 92C, 92D, 92E, 92F, 92G, 92I, 92K, 92L, 92M, 92N, 92P, 92Q, 92R, 92S, 92T, 92V, 92W, 92Y, 166A, 166C, 166D, 166E, 166F, 166G, 166H, 166I, 166K, 166L, 166M, 166N, 166Q, 166R, 166S, 166T, 166V, 166W, 166Y, 206C, 206D, 206E, 206F, 206G, 206H, 206I, 206K, 206L, 206M, 206N, 206P, 206Q, 206R, 206S, 206T, 206V, 206W, 206Y, 217A, 217C, 217D, 217E, 217F, 217G, 217H, 217I, 217K, 217L, 217M, 217N, 217P, 217Q, 217S, 217T, 217V, 217W, 217Y, 247A, 247C, 247E, 247F, 247G, 247H, 247I, 247K, 247L, 247M, 247N, 247P, 247Q, 247R, 247S, 247T, 247V, 247W, 247Y, 261A, 261C, 261D, 261E, 261F, 261H, 261I, 261K, 261L, 261M, 261N, 261P, 261Q, 261R, 261S, 261T, 261V, 261W, 261Y, 271C, 271D, 271E, 271F, 271G, 271H, 271I, 271K, 271L, 271M, 271N, 271P, 271Q, 271R, 271S, 271T, 271V, 271W, 271Y, 302A, 302C, 302D, 302E, 302F, 302G, 302H, 302I, 302L, 302M, 302N, 302P, 302Q, 302R, 302S, 302T, 302V, 302W, 302Y, 316A,

316C, 316E, 316F, 316G, 316H, 316I, 316K, 316L, 316M, 316N, 316P, 316Q, 316R, 316S, 316T, 316V, 316W, 316Y, 322A, 322C, 322D, 322E, 322F, 322G, 322H, 322K, 322L, 322M, 322N, 322P, 322Q, 322R, 322S, 322T, 322V, 322W, 322Y, 337A, 337C, 337D, 337E, 337F, 337G, 337H, 337I, 337K, 337L, 337M, 337N, 337Q, 337R, 337S, 337T, 337V, 337W, 337Y, 368C, 368D, 368E, 368F, 368G, 368H, 368I, 368K, 368L, 368M, 368N, 368P, 368Q, 368R, 368S, 368T, 368V, 368W, 368Y, 392A, 392C, 392D, 392E, 392F, 392G, 392H, 392I, 392K, 392L, 392M, 392N, 392P, 392Q, 392R, 392S, 392V, 392W, and 392Y, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10A, P10C, P10D, P10E, P10F, P10G, P10H, P10I, P10K, P10L, P10M, P10N, P10Q, P10R, P10S, P10T, P10V, P10W, P10Y, E39A, E39C, E39D, E39F, E39G, E39H, E39I, E39K, E39L, E39M, E39N, E39P, E39Q, E39R, E39S, E39T, E39V, E39W, E39Y, R44A, R44C, R44D, R44E, R44F, R44G, R44H, R44I, R44K, R44L, R44N, R44P, R44Q, R44S, R44T, R44V, R44W, R44Y, T47A, T47C, T47D, T47E, T47F, T47G, T47H, T47I, T47K, T47L, T47M, T47N, T47P, T47Q, T47R, T47S, T47V, T47W, T47Y, H92A, H92C, H92D, H92E, H92F, H92G, H92I, H92K, H92L, H92M, H92N, H92P, H92Q, H92R, H92S, H92T, H92V, H92W, H92Y, P166A, P166C, P166D, P166E, P166F, P166G, P166H, P166I, P166K, P166L, P166M, P166N, P166Q, P166R, P166S, P166T, P166V, P166W, P166Y, A206C, A206D, A206E, A206F, A206G, A206H, A206I, A206K, A206L, A206M, A206N, A206P, A206Q, A206R, A206S, A206T, A206V, A206W, A206Y, R217A, R217C, R217D, R217E, R217F, R217G, R217H, R217I, R217K, R217L, R217M, R217N, R217P, R217Q, R217S, R217T, R217V, R217W, R217Y, D247A, D247C, D247E, D247F, D247G, D247H, D247I, D247K, D247L, D247M, D247N, D247P, D247Q, D247R, D247S, D247T, D247V, D247W, D247Y, G261A, G261C, G261D, G261E, G261F, G261H, G261I, G261K, G261L, G261M, G261N, G261P, G261Q, G261R, G261S, G261T, G261V, G261W, G261Y, A271C, A271D, A271E, A271F, A271G, A271H, A271I, A271K, A271L, A271M, A271N, A271P, A271Q, A271R, A271S, A271T, A271V, A271W, A271Y, K302A, K302C, K302D, K302E, K302F, K302G, K302H, K302I, K302L, K302M, K302N, K302P, K302Q, K302R, K302S, K302T, K302V, K302W, K302Y, D316A, D316C, D316E, D316F, D316G, D316H, D316I, D316K, D316L, D316M, D316N, D316P, D316Q, D316R, D316S, D316T, D316V, D316W, D316Y, I322A, I322C, I322D, I322E, I322F, I322G, I322H, I322K, I322L, I322M, I322N, I322P, I322Q, I322R, I322S, I322T, I322V, I322W, I322Y, P337A, P337C, P337D, P337E, P337F, P337G, P337H, P337I, P337K, P337L, P337M, P337N, P337Q, P337R, P337S, P337T, P337V, P337W, P337Y, A368C, A368D, A368E, A368F, A368G, A368H, A368I, A368K, A368L, A368M, A368N, A368P, A368Q, A368R, A368S, A368T, A368V, A368W, A368Y, T392A, T392C, T392D, T392E, T392F, T392G, T392H, T392I, T392K, T392L, T392M, T392N, T392P, T392Q, T392R, T392S, T392V,

T392W, and T392Y, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0127] The present invention also provides recombinant alpha galactosidase A wherein said comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/392, 31, 31/39/44/166/302, 31/47, 31/283/284, 39, 39/44, 39/44/47, 39/44/47/261/283/284, 39/44/283, 39/44/339, 39/47/261, 39/92, 39/206, 39/284, 44, 44/284/302, 84, 84/92, 84/284/302/392, 84/316, 84/368/392, 92, 92/206/217, 92/206/275, 92/206/284, 92/206/302/368, 92/271, 92/271/277, 92/275/284, 92/283, 92/283/392, 92/284, 92/302, 92/316, 92/368, 155, 155/217, 155/368, 166, 166/283/284, 166/302, 206, 206/217, 206/334, 261, 261/283, 271, 271/368, 275, 283, 283/284, 283/392, 284, 302, 316, 334, 339, 368, 368/392, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10G, P10G/T392D, S31T, S31T/E39V/R44V/P166D/K302Y, S31T/T47R, S31T/K283L/D284A, E39L, E39L/H92V, E39L/A206E, E39L/D284S, E39V/R44V, E39V/R44V/T47R, E39V/R44V/T47R/G261S/K283L/D284A, E39V/R44V/K283T, E39V/R44V/A339N, E39V/T47R/G261S, R44V, R44V/D284E/K302Y, H84K, H84K/H92V, H84K/D284S/K302L/T392A, H84K/D316H, H84K/A368E/T392A, H92Q, H92T, H92T/A206E/R217N, H92T/A206E/K302T/A368E, H92T/A271K, H92T/A271K/K277R, H92T/K283P, H92T/K283V/T392W, H92T/D284M, H92T/K302L, H92T/A368E, H92V, H92V/A206E/D284S, H92V/A206Y/Q275A, H92V/Q275A/D284S, H92V/D284S, H92V/K302L, H92V/D316H, H155F, H155F/R217I, H155F/A368E, P166D, P166D/K283L/D284A, P166D/K302Y, A206E, A206E/R217N, A206I, A206Q, A206T/Y334C, A206Y, G261S, G261S/K283L, A271K, A271K/A368E, Q275A, K283L, K283P/T392W, K283T, K283T/D284E, D284E, D284M, D284S, K302L, K302Y, D316H, Y334C, A339N, A368E, A368E/T392W, T392A, T392D, and T392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10G, 10G/392D, 31T, 31T/39V/44V/166D/302Y, 31T/47R, 31T/283L/284A, 39L, 39L/92V, 39L/206E, 39L/284S, 39V/44V, 39V/44V/47R,

39V/44V/47R/261S/283L/284A, 39V/44V/283T, 39V/44V/339N, 39V/47R/261S, 44V, 44V/284E/302Y, 84K, 84K/92V, 84K/284S/302L/392A, 84K/316H, 84K/368E/392A, 92Q, 92T, 92T/206E/217N, 92T/206E/302T/368E, 92T/271K, 92T/271K/277R, 92T/283P, 92T/283V/392W, 92T/284M, 92T/302L, 92T/368E, 92V, 92V/206E/284S, 92V/206Y/275A, 92V/275A/284S, 92V/284S, 92V/302L, 92V/316H, 155F, 155F/217I, 155F/368E, 166D, 166D/283L/284A, 166D/302Y, 206E, 206E/217N, 206I, 206Q, 206T/334C, 206Y, 261S, 261S/283L, 271K, 271K/368E, 275A, 283L, 283P/392W, 283T, 283T/284E, 284E, 284M, 284S, 302L, 302Y, 316H, 334C, 339N, 368E, 368E/392W, 392A, 392D, and 392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022.

[0128] In some embodiments, the recombinant alpha galactosidase A polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the even-numbered sequences of SEQ ID NOS: 4-1864.

[0129] In some embodiments, the engineered GLA polypeptide comprises a functional fragment of an engineered GLA polypeptide encompassed by the invention. Functional fragments have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the activity of the engineered GLA polypeptide from which it was derived (i.e., the parent engineered GLA). A functional fragment comprises at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and even 99% of the parent sequence of the engineered GLA. In some embodiments the functional fragment is truncated by less than 5, less than 10, less than 15, less than 20, less than 25, less than 30, less than 35, less than 40, less than 45, and less than 50 amino acids.

Polynucleotides Encoding Engineered Polypeptides, Expression Vectors and Host Cells:

[0130] The present invention provides polynucleotides encoding the engineered GLA polypeptides described herein. In some embodiments, the polynucleotides are operatively linked to one or more heterologous or homologous regulatory sequences that control gene expression to create a recombinant polynucleotide capable of expressing the polypeptide. Expression constructs containing a heterologous polynucleotide encoding the engineered GLA polypeptides can be introduced into appropriate host cells to express the corresponding GLA polypeptide.

[0131] As will be apparent to the skilled artisan, availability of a protein sequence and the knowledge of the codons corresponding to the various amino acids provide a description of all the polynucleotides capable of encoding the subject polypeptides. The degeneracy of the genetic code, where the same amino acids are encoded by alternative or synonymous codons, allows an extremely large number of nucleic acids to be made, all of which encode the engineered GLA polypeptide. Thus, having knowledge of a particular amino acid sequence, those skilled in the art could make any number of different nucleic acids by simply modifying the sequence of one or more codons in a way which does not change the amino acid sequence of the protein. In this regard, the present invention

specifically contemplates each and every possible variation of polynucleotides that could be made encoding the polypeptides described herein by selecting combinations based on the possible codon choices, and all such variations are to be considered specifically disclosed for any polypeptide described herein, including the variants provided in Tables 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1.

[0132] In various embodiments, the codons are preferably selected to fit the host cell in which the protein is being produced. For example, preferred codons used in bacteria are used for expression in bacteria. Consequently, codon optimized polynucleotides encoding the engineered GLA polypeptides contain preferred codons at about 40%, 50%, 60%, 70%, 80%, or greater than 90% of codon positions of the full length coding region. In some embodiments, the present invention provides recombinant polynucleotide sequences in which the codons are optimized for expression in human cells or tissues.

[0133] In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 1. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 7. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 7. In some embodiments, the recombinant polynucleotide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the odd-numbered sequences of SEQ ID NOS: 3-1863.

[0134] In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 44, 44/217, 44/217/316, 44/217/322, 44/217/322/337, 44/247, 44/247/302, 44/247/302/322, 44/247/322, 44/247/337, 44/247/362, 44/302, 44/337, 44/373, 217/322, 217/373, 247/322, 247/362, 302/322/362/373, 302/337, 316, 316/337, 322, 322/337, 362/373, and 373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence

identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 44L, 44L/217F, 44L/217F/316L, 44L/217F/322M, 44L/217F/322M/337A, 44L/247N, 44L/247N/302Q, 44L/247N/302Q/322M, 44L/247N/322M, 44L/247N/337A, 44L/247N/362K, 44L/302Q, 44L/337A, 44L/373R, 217F/322M, 217F/373R, 247N/322M, 247N/362K, 302Q/322M/362K/373R, 302Q/337A, 316L, 316L/337A, 322M, 322M/337A, 362K/373R, and 373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from R44L, R44L/R217F, R44L/R217F/D316L, R44L/R217F/I322M, R44L/R217F/I322M/P337A, R44L/D247N, R44L/D247N/K302Q, R44L/D247N/K302Q/I322M, R44L/D247N/I322M, R44L/D247N/P337A, R44L/D247N/Q362K, R44L/K302Q, R44L/P337A, R44L/K373R, R217F/I322M, R217F/K373R, D247N/I322M, D247N/Q362K, K302Q/I322M/Q362K/K373R, K302Q/P337A, D316L, D316L/P337A, I322M, I322M/P337A, Q362K/K373R, and K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0135] In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10/39/44/47/92/166/206/217/247/261/271/302/316/322/337/362/368/373/392, 44/217/316, 44/217/322/337, 166/362, 217/373, and 362/373, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from

10T/39M/44L/47S/92Y/166S/206K/217F/247N/261A/271H/302Q/316L/322M/337A/362K/368W/373R/392M, 44L/217F/316L, 44L/217F/322M/337A, 166A/362K, 217F/373R, and 362K/373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional

fragment thereof, wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from

P10T/E39M/R44L/T47S/H92Y/P166S/A206K/R217F/D247N/G261A/A271H/K302Q/D316L/I322M/P337A/Q362K/A368W/K373R/T392M, R44L/R217F/D316L, R44L/R217F/I322M/P337A, P166A/Q362K, R217F/K373R, and Q362K/K373R, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 8.

[0136] In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 57. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 57. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A, wherein said recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7, 7/48/68, 7/48/68/120/282/299, 7/48/130/282, 7/48/180, 7/68/130/282/365, 7/68/180, 7/88/120/305/365, 7/120, 7/130, 7/282, 7/305, 7/305/365, 7/365, 39, 47, 47/87/95/96/158/162, 47/95, 47/273, 47/343, 48, 48/68, 48/180/282, 48/282, 48/282/305, 67/180, 68, 68/299/300, 71, 87/91/95/96/158/162, 87/91/95/96/206/343, 87/96/155/273/343, 88, 91/95, 91/95/96, 92, 93, 96, 96/273, 96/312/343, 120, 120/299/305, 151, 158, 158/162/273, 162, 162/273, 162/343, 166, 178, 180, 181, 206, 217, 271, 273, 273/343, 282, 282/365, 293/391, 299/300, 299/300/305/365, 300, 301, 305, 305/365, 314, 333, 336, 337, 343, 345, 363, 365, 370, 389, 393, 394, 396/398, 397, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 7L, 7L/48D/68E, 7L/48D/68E/120H/282N/299R, 7L/48D/130E/282N, 7L/48D/180G, 7L/68E/130E/282N/365V, 7L/68E/180G, 7L/88A/120H/305G/365V, 7L/120H, 7L/130E, 7L/282N, 7L/305G, 7L/305G/365V, 7L/365V, 39V, 47D, 47D/87K/95E/96L/158R/162H, 47D/95E, 47D/273P, 47D/343G, 47V, 48D, 48D/68E, 48D/180G/282N, 48D/282N, 48D/282N/305G, 67T/180G, 68E, 68E/299R/300I, 71P, 87K/91Q/95E/96L/158A/162K, 87K/91Q/95E/96L/206S/343G, 87K/96I/155N/273P/343G, 88A, 91Q/95E, 91Q/95E/96L, 92F, 92T, 93I, 96L, 96L/273P, 96L/312Q/343G, 120H, 120H/299R/305G, 151L, 158A, 158A/162K/273G, 158R, 162H/343D, 162K, 162K/273P, 162S, 166K, 178G, 178S, 180G, 180L, 180T, 180V, 181A, 206K, 206S, 217K, 271R,

273P, 273P/343G, 282N, 282N/365V, 293P/391A, 299R/300I, 299R/300I/305G/365V, 300I, 301M, 305G, 305G/365V, 314A, 333F, 333G, 336V, 337R, 343D, 343G, 345A, 345Q, 363Q, 365A, 365Q, 365V, 370G, 389K, 393V, 394K, 396G/398T, 397A, 398A, 398P, 398S, and 398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from R7L, R7L/E48D/Q68E, R7L/E48D/Q68E/Y120H/D282N/Q299R, R7L/E48D/D130E/D282N, R7L/E48D/F180G, R7L/Q68E/D130E/D282N/F365V, R7L/Q68E/F180G, R7L/Q88A/Y120H/N305G/F365V, R7L/Y120H, R7L/D130E, R7L/D282N, R7L/N305G, R7L/N305G/F365V, R7L/F365V, E39V, T47D, T47D/R87K/S95E/K96L/L158R/R162H, T47D/S95E, T47D/S273P, T47D/K343G, T47V, E48D, E48D/Q68E, E48D/F180G/D282N, E48D/D282N, E48D/D282N/N305G, P67T/F180G, Q68E, Q68E/Q299R/L300I, S71P, R87K/N91Q/S95E/K96L/L158A/R162K, R87K/N91Q/S95E/K96L/A206S/K343G, R87K/K96I/H155N/S273P/K343G, Q88A, N91Q/S95E, N91Q/S95E/K96L, H92F, H92T, V93I, K96L, K96L/S273P, K96L/P312Q/K343G, Y120H, Y120H/Q299R/N305G, D151L, L158A, L158A/R162K/S273G, L158R, R162H/K343D, R162K, R162K/S273P, R162S, P166K, W178G, W178S, F180G, F180L, F180T, F180V, Q181A, A206K, A206S, R217K, A271R, S273P, S273P/K343G, D282N, D282N/F365V, L293P/Q391A, Q299R/L300I, Q299R/L300I/N305G/F365V, L300I, R301M, N305G, N305G/F365V, S314A, S333F, S333G, I336V, P337R, K343D, K343G, V345A, V345Q, L363Q, F365A, F365Q, F365V, S370G, T389K, S393V, L394K, D396G/L398T, L397A, L398A, L398P, L398S, and L398V, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 58.

[0137] In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 157. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 157. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A, wherein said recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24/202, 39/47, 39/47/217, 39/151, 39/282/337/398, 39/337/343/398, 39/393/398, 47/130, 47/151,

47/343/345/393, 48, 48/68, 48/68/217/333/391/393, 48/68/333, 48/217, 48/333, 48/345/393, 48/393, 59/143, 68, 68/345, 130, 130/158, 130/158/393, 130/345/393, 143/271, 143/333, 143/387, 151, 151/158/217/343/345/393, 151/206/282/337/343/345/398, 151/282/393, 151/345/393/398, 151/393, 158, 158/393, 202, 206, 206/217, 217, 217/333, 217/337/345/398, 271, 282/393, 333, 333/345, 337/343/345/398, 343, 343/345/393/398, 393, and 393/398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 158, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 24S/202N, 39V/47D, 39V/47V/217K, 39V/151L, 39V/282N/337R/398A, 39V/337R/343G/398A, 39V/393V/398A, 47V/130E, 47V/151L, 47V/343D/345Q/393V, 48D, 48D/68E, 48D/68E/217K/333F/391A/393V, 48D/68E/333F, 48D/217K, 48D/333F, 48D/333G, 48D/345Q/393V, 48D/393V, 59A/143S, 68E, 68E/345Q, 130E, 130E/158R, 130E/158R/393V, 130E/345Q/393V, 143S/271N, 143S/333N, 143S/387N, 151L, 151L/158R/217K/343G/345Q/393V, 151L/206S/282N/337R/343D/345Q/398A, 151L/282N/393V, 151L/345Q/393V/398A, 151L/393V, 158R, 158R/393V, 202N, 206S, 206S/217K, 217K, 217K/333F, 217K/333G, 217K/337R/345Q/398A, 271N, 282N/393V, 333F/345Q, 333G, 333N, 337R/343G/345Q/398A, 343D, 343D/345Q/393V/398A, 393V, and 393V/398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D24S/D202N, E39V/T47D, E39V/T47V/R217K, E39V/D151L, E39V/D282N/P337R/L398A, E39V/P337R/K343G/L398A, E39V/S393V/L398A, T47V/D130E, T47V/D151L, T47V/K343D/V345Q/S393V, E48D, E48D/Q68E, E48D/Q68E/R217K/S333F/Q391A/S393V, E48D/Q68E/S333F, E48D/R217K, E48D/S333F, E48D/S333G, E48D/V345Q/S393V, E48D/S393V, C59A/C143S, Q68E, Q68E/V345Q, D130E, D130E/L158R, D130E/L158R/S393V, D130E/V345Q/S393V, C143S/A271N, C143S/S333N, C143S/E387N, D151L, D151L/L158R/R217K/K343G/V345Q/S393V, D151L/A206S/D282N/P337R/K343D/V345Q/L398A, D151L/D282N/S393V, D151L/V345Q/S393V/L398A, D151L/S393V, L158R, L158R/S393V, D202N, A206S, A206S/R217K, R217K, R217K/S333F, R217K/S333G, R217K/P337R/V345Q/L398A, A271N, D282N/S393V, S333F/V345Q, S333G, S333N, P337R/K343G/V345Q/L398A, K343D, K343D/V345Q/S393V/L398A, S393V, and S393V/L398A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 158.

[0138] In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 371. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 371. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A, wherein said recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/39/44/322, 10/39/92/206/217/271, 10/39/92/247, 10/39/92/247/271/316, 10/44, 10/44/47/92/247, 10/44/47/261/302/322/368, 10/44/92/316/322, 10/44/261/302/316, 10/44/302/337/368, 10/47/217/247/316/392, 10/47/217/322, 10/47/271, 10/92, 10/92/206/217/247, 10/92/206/247/316/322/392, 10/92/206/247/322/368, 10/92/217/261/302/337, 10/206/217/271, 10/206/247, 10/206/261/271/316, 10/261, 10/271/302, 10/302, 10/302/316, 10/302/322/337, 10/316/322, 10/337/392, 10/368, 39/44/92/162/247/302/316/322, 39/44/92/217/322, 39/44/92/247/271/302, 39/47/92/247/302/316/322, 39/47/217/247/368, 39/47/247, 39/92/247/302/316/337/368, 39/92/316/322, 39/247/271, 39/247/271/316, 39/322, 44/47/92/206/217/316/322, 44/47/92/247/261/271/316/337/368, 44/47/206/217/247/271/322, 44/47/247/322/368, 44/47/302/316/322, 44/92/206/247/368, 44/206/337, 44/247/261/302/316, 44/247/261/302/316/322, 47/92/247/271, 47/217/302, 47/247, 47/247/271, 89/217/247/261/302/316, 92/217/271, 92/247, 92/247/271/322, 92/247/302/322/337, 92/271/337, 92/302, 92/316, 206/217/271/392, 217/247/316/322/337/368, 247, 247/271, 247/302, 271, 271/302/322, 271/316/322, 302/322/368, and 368, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10P, 10P/39E/44R/322I, 10P/39E/92H/206A/217R/271A, 10P/39E/92H/247D, 10P/39E/92H/247D/271A/316D, 10P/44R, 10P/44R/47T/92H/247D, 10P/44R/47T/261G/302K/322I/368A, 10P/44R/92H/316D/322I, 10P/44R/261G/302K/316D, 10P/44R/302K/337P/368A, 10P/47T/217R/247D/316D/392T, 10P/47T/217R/322I, 10P/47T/271A, 10P/92H, 10P/92H/206A/217R/247D, 10P/92H/206A/247D/316D/322I/392T, 10P/92H/206A/247D/322I/368A, 10P/92H/217R/261G/302K/337P, 10P/206A/217R/271A, 10P/206A/247D, 10P/206A/261G/271A/316D, 10P/261G, 10P/271A/302K, 10P/302K, 10P/302K/316D,

10P/302K/322I/337P, 10P/316D/322I, 10P/337P/392T, 10P/368A, 39E/44R/92H/162M/247D/302K/316D/322I, 39E/44R/92H/217R/322I, 39E/44R/92H/247D/271A/302K, 39E/47T/92H/247D/302K/316D/322I, 39E/47T/217R/247D/368A, 39E/47T/247D, 39E/92H/247D/302K/316D/337P/368A, 39E/92H/316D/322I, 39E/247D/271A, 39E/247D/271A/316D, 39E/322I, 44R/47T/92H/206A/217R/316D/322I, 44R/47T/92H/247D/261G/271A/316D/337P/368A, 44R/47T/206A/217R/247D/271A/322I, 44R/47T/247D/322I/368A, 44R/47T/302K/316D/322I, 44R/92H/206A/247D/368A, 44R/206A/337P, 44R/247D/261G/302K/316D, 44R/247D/261G/302K/316D/322I, 47T/92H/247D/271A, 47T/217R/302K, 47T/247D, 47T/247D/271A, 89I/217R/247D/261G/302K/316D, 92H/217R/271A, 92H/247D, 92H/247D/271A/322I, 92H/247D/302K/322I/337P, 92H/271A/337P, 92H/302K, 92H/316D, 206A/217R/271A/392T, 217R/247D/316D/322I/337P/368A, 247D, 247D/271A, 247D/302K, 271A, 271A/302K/322I, 271A/316D/322I, 302K/322I/368A, and 368A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 372, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from T10P, T10P/M39E/L44R/M322I, T10P/M39E/Y92H/K206A/F217R/H271A, T10P/M39E/Y92H/N247D, T10P/M39E/Y92H/N247D/H271A/L316D, T10P/L44R, T10P/L44R/S47T/Y92H/N247D, T10P/L44R/S47T/A261G/Q302K/M322I/W368A, T10P/L44R/Y92H/L316D/M322I, T10P/L44R/A261G/Q302K/L316D, T10P/L44R/Q302K/A337P/W368A, T10P/S47T/F217R/N247D/L316D/M392T, T10P/S47T/F217R/M322I, T10P/S47T/H271A, T10P/Y92H, T10P/Y92H/K206A/F217R/N247D, T10P/Y92H/K206A/N247D/L316D/M322I/M392T, T10P/Y92H/K206A/N247D/M322I/W368A, T10P/Y92H/F217R/A261G/Q302K/A337P, T10P/K206A/F217R/H271A, T10P/K206A/N247D, T10P/K206A/A261G/H271A/L316D, T10P/A261G, T10P/H271A/Q302K, T10P/Q302K, T10P/Q302K/L316D, T10P/Q302K/M322I/A337P, T10P/L316D/M322I, T10P/A337P/M392T, T10P/W368A, M39E/L44R/Y92H/R162M/N247D/Q302K/L316D/M322I, M39E/L44R/Y92H/F217R/M322I, M39E/L44R/Y92H/N247D/H271A/Q302K, M39E/S47T/Y92H/N247D/Q302K/L316D/M322I, M39E/S47T/F217R/N247D/W368A, M39E/S47T/N247D, M39E/Y92H/N247D/Q302K/L316D/A337P/W368A, M39E/Y92H/L316D/M322I, M39E/N247D/H271A, M39E/N247D/H271A/L316D, M39E/M322I, L44R/S47T/Y92H/K206A/F217R/L316D/M322I, L44R/S47T/Y92H/N247D/A261G/H271A/L316D/A337P/W368A, L44R/S47T/K206A/F217R/N247D/H271A/M322I, L44R/S47T/N247D/M322I/W368A, L44R/S47T/Q302K/L316D/M322I, L44R/Y92H/K206A/N247D/W368A, L44R/K206A/A337P,

L44R/N247D/A261G/Q302K/L316D, L44R/N247D/A261G/Q302K/L316D/M322I, S47T/Y92H/N247D/H271A, S47T/F217R/Q302K, S47T/N247D, S47T/N247D/H271A, L89I/F217R/N247D/A261G/Q302K/L316D, Y92H/F217R/H271A, Y92H/N247D, Y92H/N247D/H271A/M322I, Y92H/N247D/Q302K/M322I/A337P, Y92H/H271A/A337P, Y92H/Q302K, Y92H/L316D, K206A/F217R/H271A/M392T, F217R/N247D/L316D/M322I/A337P/W368A, N247D, N247D/H271A, N247D/Q302K, H271A, H271A/Q302K/M322I, H271A/L316D/M322I, Q302K/M322I/W368A, and W368A, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 372.

[0139] In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity to SEQ ID NO: 373. In some embodiments, the present invention provides a recombinant polynucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 373. In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A, wherein said recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10/36/92/166/247/261/316/392, 10/39, 10/39/44/47/92/206/217, 10/39/44/47/316, 10/39/44/47/337, 10/39/44/92/166/261/316/322, 10/39/44/92/166/302/322, 10/39/44/92/166/392, 10/39/44/92/217/302/322, 10/39/44/92/302/322, 10/39/44/166/261/271/316/322, 10/39/44/392, 10/39/47/92/337, 10/39/92/131/166/271/316/322, 10/39/92/166/217/247/271, 10/39/92/217/316, 10/44/47/166/261/271, 10/44/47/166/271/322/368, 10/44/47/217/271/316/322, 10/44/92, 10/44/92/217/247/271/302/316/392, 10/44/166/302, 10/44/206/316/322, 10/47/92/166/271/316/337, 10/47/92/271/302, 10/47/92/316/322/392, 10/47/166/271, 10/47/166/316, 10/92/166, 10/92/166/217/247/261/271, 10/92/166/261/271/392, 10/92/166/261/316/322/337, 10/92/166/337/368, 10/92/302/337, 10/92/316/322, 10/206, 10/206/247/261, 10/217/322, 10/261, 10/261/337/392, 10/316/392, 10/368, 39/44/47/92/166/206/392, 39/44/47/92/206/247/261, 39/44/47/92/206/392, 39/44/47/206/337/368/392, 39/44/92/166/247/261/302/337, 39/44/166/271, 39/44/166/271/337/368/392, 39/47/92/316/322, 39/47/92/392, 39/47/166/217/261/392, 39/47/217/247/368, 39/47/247, 39/92/166/217/392, 39/92/261/302, 39/166/217/261/316/368, 39/322, 39/392, 44/47, 44/47/92/217/271, 44/47/92/217/316/322/392, 44/47/92/392, 44/47/166, 44/47/166/271, 44/47/247/271/392, 44/316/322/392, 44/337, 47/166/206/217/247/337, 47/166/217/271/337, 47/206, 47/217/247/261, 47/271, 52/217/302/316, 92/166/206/271/316, 92/166/217/261/271/392, 92/166/217/316/337/392, 92/166/247, 92/166/316, 92/206/322, 92/217, 92/217/271/337, 92/261/271, 92/271, 166/217/316/322/337, 166/247/271/316, 166/316/322/337,

206/217, 217/392, 247/316, 316/322/368, and 316/337/392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10T/36M/92Y/166S/247N/261A/316L/392M, 10T/39M, 10T/39M/44L/47S/92Y/206K/217F, 10T/39M/44L/47S/316L, 10T/39M/44L/47S/337A, 10T/39M/44L/92Y/166S/261A/316L/322M, 10T/39M/44L/92Y/166S/302Q/322M, 10T/39M/44L/92Y/166S/392M, 10T/39M/44L/92Y/217F/302Q/322M, 10T/39M/44L/92Y/302Q/322M, 10T/39M/44L/166S/261A/271H/316L/322M, 10T/39M/44L/392M, 10T/39M/47S/92Y/337A, 10T/39M/92Y/131G/166S/271H/316L/322M, 10T/39M/92Y/166S/217F/247N/271H, 10T/39M/92Y/217F/316L, 10T/44L/47S/166S/261A/271H, 10T/44L/47S/166S/271H/322M/368W, 10T/44L/47S/217F/271H/316L/322M, 10T/44L/92Y, 10T/44L/92Y/217F/247N/271H/302Q/316L/392M, 10T/44L/166S/302Q, 10T/44L/206K/316L/322M, 10T/47S/92Y/166S/271H/316L/337A, 10T/47S/92Y/271H/302Q, 10T/47S/92Y/316L/322M/392M, 10T/47S/166S/271H, 10T/47S/166S/316L, 10T/92Y/166S, 10T/92Y/166S/217F/247N/261A/271H, 10T/92Y/166S/261A/271H/392M, 10T/92Y/166S/261A/316L/322M/337A, 10T/92Y/166S/337A/368W, 10T/92Y/302Q/337A, 10T/92Y/316L/322M, 10T/206K, 10T/206K/247N/261A, 10T/217F/322M, 10T/261A, 10T/261A/337A/392M, 10T/316L/392M, 10T/368W, 39M/44L/47S/92Y/166S/206K/392M, 39M/44L/47S/92Y/206K/247N/261A, 39M/44L/47S/92Y/206K/392M, 39M/44L/47S/206K/337A/368W/392M, 39M/44L/92Y/166S/247N/261A/302Q/337A, 39M/44L/166S/271H, 39M/44L/166S/271H/337A/368W/392M, 39M/47S/92Y/316L/322M, 39M/47S/92Y/392M, 39M/47S/166S/217F/261A/392M, 39M/47S/217F/247N/368W, 39M/47S/247N, 39M/92Y/166S/217F/392M, 39M/92Y/261A/302Q, 39M/166S/217F/261A/316L/368W, 39M/322M, 39M/392M, 44L/47S, 44L/47S/92Y/217F/271H, 44L/47S/92Y/217F/316L/322M/392M, 44L/47S/92Y/392M, 44L/47S/166S, 44L/47S/166S/271H, 44L/47S/247N/271H/392M, 44L/316L/322M/392M, 44L/337A, 47S/166S/206K/217F/247N/337A, 47S/166S/217F/271H/337A, 47S/206K, 47S/217F/247N/261A, 47S/271H, 52N/217F/302Q/316L, 92Y/166S/206K/271H/316L, 92Y/166S/217F/261A/271H/392M, 92Y/166S/217F/316L/337A/392M, 92Y/166S/247N, 92Y/166S/316L, 92Y/206K/322M, 92Y/217F, 92Y/217F/271H/337A, 92Y/261A/271H, 92Y/271H, 166S/217F/316L/322M/337A, 166S/247N/271H/316L, 166S/316L/322M/337A, 206K/217F, 217F/392M, 247N/316L, 316L/322M/368W, and 316L/337A/392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more

sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10T/K36M/H92Y/P166S/D247N/G261A/D316L/T392M, P10T/E39M, P10T/E39M/R44L/T47S/H92Y/A206K/R217F, P10T/E39M/R44L/T47S/D316L, P10T/E39M/R44L/T47S/P337A, P10T/E39M/R44L/H92Y/P166S/G261A/D316L/I322M, P10T/E39M/R44L/H92Y/P166S/K302Q/I322M, P10T/E39M/R44L/H92Y/P166S/T392M, P10T/E39M/R44L/H92Y/R217F/K302Q/I322M, P10T/E39M/R44L/H92Y/K302Q/I322M, P10T/E39M/R44L/P166S/G261A/A271H/D316L/I322M, P10T/E39M/R44L/T392M, P10T/E39M/T47S/H92Y/P337A, P10T/E39M/H92Y/W131G/P166S/A271H/D316L/I322M, P10T/E39M/H92Y/P166S/R217F/D247N/A271H, P10T/E39M/H92Y/R217F/D316L, P10T/R44L/T47S/P166S/G261A/A271H, P10T/R44L/T47S/P166S/A271H/I322M/A368W, P10T/R44L/T47S/R217F/A271H/D316L/I322M, P10T/R44L/H92Y, P10T/R44L/H92Y/R217F/D247N/A271H/K302Q/D316L/T392M, P10T/R44L/P166S/K302Q, P10T/R44L/A206K/D316L/I322M, P10T/T47S/H92Y/P166S/A271H/D316L/P337A, P10T/T47S/H92Y/A271H/K302Q, P10T/T47S/H92Y/D316L/I322M/T392M, P10T/T47S/P166S/A271H, P10T/T47S/P166S/D316L, P10T/H92Y/P166S, P10T/H92Y/P166S/R217F/D247N/G261A/A271H, P10T/H92Y/P166S/G261A/A271H/T392M, P10T/H92Y/P166S/G261A/D316L/I322M/P337A, P10T/H92Y/P166S/P337A/A368W, P10T/H92Y/K302Q/P337A, P10T/H92Y/D316L/I322M, P10T/A206K, P10T/A206K/D247N/G261A, P10T/R217F/I322M, P10T/G261A, P10T/G261A/P337A/T392M, P10T/D316L/T392M, P10T/A368W, E39M/R44L/T47S/H92Y/P166S/A206K/T392M, E39M/R44L/T47S/H92Y/A206K/D247N/G261A, E39M/R44L/T47S/H92Y/A206K/T392M, E39M/R44L/T47S/A206K/P337A/A368W/T392M, E39M/R44L/H92Y/P166S/D247N/G261A/K302Q/P337A, E39M/R44L/P166S/A271H, E39M/R44L/P166S/A271H/P337A/A368W/T392M, E39M/T47S/H92Y/D316L/I322M, E39M/T47S/H92Y/T392M, E39M/T47S/P166S/R217F/G261A/T392M, E39M/T47S/R217F/D247N/A368W, E39M/T47S/D247N, E39M/H92Y/P166S/R217F/T392M, E39M/H92Y/G261A/K302Q, E39M/P166S/R217F/G261A/D316L/A368W, E39M/I322M, E39M/T392M, R44L/T47S, R44L/T47S/H92Y/R217F/A271H, R44L/T47S/H92Y/R217F/D316L/I322M/T392M, R44L/T47S/H92Y/T392M, R44L/T47S/P166S, R44L/T47S/P166S/A271H, R44L/T47S/D247N/A271H/T392M, R44L/D316L/I322M/T392M, R44L/P337A, T47S/P166S/A206K/R217F/D247N/P337A, T47S/P166S/R217F/A271H/P337A, T47S/A206K, T47S/R217F/D247N/G261A, T47S/A271H, D52N/R217F/K302Q/D316L, H92Y/P166S/A206K/A271H/D316L, H92Y/P166S/R217F/G261A/A271H/T392M, H92Y/P166S/R217F/D316L/P337A/T392M, H92Y/P166S/D247N, H92Y/P166S/D316L, H92Y/A206K/I322M, H92Y/R217F, H92Y/R217F/A271H/P337A, H92Y/G261A/A271H, H92Y/A271H, P166S/R217F/D316L/I322M/P337A, P166S/D247N/A271H/D316L,

P166S/D316L/I322M/P337A, A206K/R217F, R217F/T392M, D247N/D316L, D316L/I322M/A368W, and D316L/P337A/T392M, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0140] In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2, 4, 5, 24/59, 24/143/144, 24/143/202/333, 24/143/202/352/390/391, 24/143/333/352/387/390/391, 24/143/390/391, 24/202, 24/202/271, 24/202/333/352, 24/271/352, 24/352/387/390/391, 24/387/391, 31, 40, 59, 59/143, 59/143/202, 59/143/202/271/333, 59/143/271, 59/143/333, 59/202, 59/202/333, 59/271/387/390, 73, 76, 80, 83, 84, 91/215/361, 122, 123, 143, 143/202, 143/271, 143/271/352/390, 143/333, 143/333/387/390, 143/387/391, 147, 155, 164, 165, 179, 186, 202, 202/333, 210, 215/218, 218, 218/361, 218/361/398, 218/398, 246, 254/398, 271, 271/333, 271/333/390/391, 271/333/391, 271/352/391, 273, 275, 277, 278, 280, 281, 283, 284, 287, 300, 303, 304, 325, 331, 332, 333/352, 333/390/391, 333/391, 334, 335, 336, 338, 339, 340, 341, 343, 359, 360, 361, 362, 367, 369, 371, 373, 375, 377, 382, 382/398, 385, 387/391, 390, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2S, 4L, 5M, 5V, 24S/59A, 24S/143S/144N, 24S/143S/202N/333N, 24S/143S/202N/352N/390N/391N, 24S/143S/333N/352N/387N/390T/391N, 24S/143S/390T/391N, 24S/202N, 24S/202N/271N, 24S/202N/333N/352N, 24S/271N/352N, 24S/352N/387N/390N/391N, 24S/387N/391N, 31F, 31H, 31L, 31T, 31W, 40Q, 59A, 59A/143S, 59A/143S/271N, 59A/202N, 59T, 59T/143S/202N, 59T/143S/333N, 59T/202N/333N, 59V/143S/202N/271N/333N, 59V/271N/387N/390T, 73A, 76A, 76F, 76M, 76S, 80T, 83R, 83S, 84G, 84K, 84R, 91S/215S/361T, 122E, 122N, 122S, 123Q, 123R, 123S, 123T, 143S, 143S/202N, 143S/271N, 143S/271N/352N/390N, 143S/333N, 143S/333N/387N/390T, 143S/387N/391N, 147L, 147S, 155A, 155D, 155F, 155L, 155R, 155T, 164E, 165I, 179H, 179L, 179R, 179W, 186E, 186F, 186M, 186P, 186R, 186S, 186Y, 202N, 202N/333N, 210I, 215S/218Y, 218Y, 218Y/361T, 218Y/361T/398F, 218Y/398F, 246Y, 254T/398F, 271N, 271N/333N, 271N/333N/390N/391N, 271N/333N/391N, 271N/352N/391N, 273L, 275A, 275G, 277Q, 277V, 278N, 278R, 278S, 280G, 281I, 281M, 283L, 283P, 283T, 283V, 284A, 284E, 284G, 284L, 284M, 284R, 284S, 287R, 300F, 303A, 303C, 303W, 304T, 304V, 304W, 325A, 331M, 332G, 332H, 333N/352N, 333N/390N/391N, 333N/390S/391N, 333N/391N, 334C, 334V, 335A, 335L, 336F, 336G, 336S, 336T, 338L, 339G, 339N, 339Q, 339V, 340H, 340I, 340K, 340M, 340P, 340W,

341F, 341M, 343L, 343R, 343S, 343W, 359F, 359L, 359R, 360H, 360V, 361T, 361V, 362H, 367A, 367D, 367L, 367M, 369D, 371G, 373L, 373S, 375L, 375Q, 377Q, 382I, 382I/398F, 385R, 387N/391N, 390S, and 398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 704, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from D2S, G4L, L5M, L5V, D24S/C59A, D24S/C143S/D144N, D24S/C143S/D202N/G333N, D24S/C143S/D202N/F352N/M390N/Q391N, D24S/C143S/G333N/F352N/E387N/M390T/Q391N, D24S/C143S/M390T/Q391N, D24S/D202N, D24S/D202N/A271N, D24S/D202N/G333N/F352N, D24S/A271N/F352N, D24S/F352N/E387N/M390N/Q391N, D24S/E387N/Q391N, S31F, S31H, S31L, S31T, S31W, E40Q, C59A, C59A/C143S, C59A/C143S/A271N, C59A/D202N, C59T, C59T/C143S/D202N, C59T/C143S/G333N, C59T/D202N/G333N, C59V/C143S/D202N/A271N/G333N, C59V/A271N/E387N/M390T, G73A, Q76A, Q76F, Q76M, Q76S, Q80T, P83R, P83S, H84G, H84K, H84R, N91S/T215S/R361T, D122E, D122N, D122S, I123Q, I123R, I123S, I123T, C143S, C143S/D202N, C143S/A271N, C143S/A271N/F352N/M390N, C143S/G333N, C143S/G333N/E387N/M390T, C143S/E387N/Q391N, E147L, E147S, H155A, H155D, H155F, H155L, H155R, H155T, G164E, R165I, P179H, P179L, P179R, P179W, T186E, T186F, T186M, T186P, T186R, T186S, T186Y, D202N, D202N/G333N, S210I, T215S/N218Y, N218Y, N218Y/R361T, N218Y/R361T/L398F, N218Y/L398F, W246Y, A254T/L398F, A271N, A271N/G333N, A271N/G333N/M390N/Q391N, A271N/G333N/Q391N, A271N/F352N/Q391N, S273L, Q275A, Q275G, K277Q, K277V, A278N, A278R, A278S, L280G, Q281I, Q281M, K283L, K283P, K283T, K283V, D284A, D284E, D284G, D284L, D284M, D284R, D284S, A287R, L300F, G303A, G303C, G303W, D304T, D304V, D304W, R325A, P331M, R332G, R332H, G333N/F352N, G333N/M390N/Q391N, G333N/M390S/Q391N, G333N/Q391N, Y334C, Y334V, T335A, T335L, I336F, I336G, I336S, I336T, V338L, A339G, A339N, A339Q, A339V, S340H, S340I, S340K, S340M, S340P, S340W, L341F, L341M, K343L, K343R, K343S, K343W, V359F, V359L, V359R, K360H, K360V, R361T, R361V, K362H, E367A, E367D, E367L, E367M, T369D, R371G, R373L, R373S, H375L, H375Q, N377Q, V382I, V382I/L398F, Q385R, E387N/Q391N, M390S, and L398F, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704.

[0141] In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 39, 44, 47, 92, 166, 206,

217, 247, 261, 271, 302, 316, 322, 337, 368, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10A, 10C, 10D, 10E, 10F, 10G, 10H, 10I, 10K, 10L, 10M, 10N, 10Q, 10R, 10S, 10T, 10V, 10W, 10Y, 39A, 39C, 39D, 39F, 39G, 39H, 39I, 39K, 39L, 39M, 39N, 39P, 39Q, 39R, 39S, 39T, 39V, 39W, 39Y, 44A, 44C, 44D, 44E, 44F, 44G, 44H, 44I, 44K, 44L, 44N, 44P, 44Q, 44S, 44T, 44V, 44W, 44Y, 47A, 47C, 47D, 47E, 47F, 47G, 47H, 47I, 47K, 47L, 47M, 47N, 47P, 47Q, 47R, 47S, 47V, 47W, 47Y, 92A, 92C, 92D, 92E, 92F, 92G, 92I, 92K, 92L, 92M, 92N, 92P, 92Q, 92R, 92S, 92T, 92V, 92W, 92Y, 166A, 166C, 166D, 166E, 166F, 166G, 166H, 166I, 166K, 166L, 166M, 166N, 166Q, 166R, 166S, 166T, 166V, 166W, 166Y, 206C, 206D, 206E, 206F, 206G, 206H, 206I, 206K, 206L, 206M, 206N, 206P, 206Q, 206R, 206S, 206T, 206V, 206W, 206Y, 217A, 217C, 217D, 217E, 217F, 217G, 217H, 217I, 217K, 217L, 217M, 217N, 217P, 217Q, 217S, 217T, 217V, 217W, 217Y, 247A, 247C, 247E, 247F, 247G, 247H, 247I, 247K, 247L, 247M, 247N, 247P, 247Q, 247R, 247S, 247T, 247V, 247W, 247Y, 261A, 261C, 261D, 261E, 261F, 261H, 261I, 261K, 261L, 261M, 261N, 261P, 261Q, 261R, 261S, 261T, 261V, 261W, 261Y, 271C, 271D, 271E, 271F, 271G, 271H, 271I, 271K, 271L, 271M, 271N, 271P, 271Q, 271R, 271S, 271T, 271V, 271W, 271Y, 302A, 302C, 302D, 302E, 302F, 302G, 302H, 302I, 302L, 302M, 302N, 302P, 302Q, 302R, 302S, 302T, 302V, 302W, 302Y, 316A, 316C, 316E, 316F, 316G, 316H, 316I, 316K, 316L, 316M, 316N, 316P, 316Q, 316R, 316S, 316T, 316V, 316W, 316Y, 322A, 322C, 322D, 322E, 322F, 322G, 322H, 322K, 322L, 322M, 322N, 322P, 322Q, 322R, 322S, 322T, 322V, 322W, 322Y, 337A, 337C, 337D, 337E, 337F, 337G, 337H, 337I, 337K, 337L, 337M, 337N, 337Q, 337R, 337S, 337T, 337V, 337W, 337Y, 368C, 368D, 368E, 368F, 368G, 368H, 368I, 368K, 368L, 368M, 368N, 368P, 368Q, 368R, 368S, 368T, 368V, 368W, 368Y, 392A, 392C, 392D, 392E, 392F, 392G, 392H, 392I, 392K, 392L, 392M, 392N, 392P, 392Q, 392R, 392S, 392V, 392W, and 392Y, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 374, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10A, P10C, P10D, P10E, P10F, P10G, P10H, P10I, P10K, P10L, P10M, P10N, P10Q, P10R, P10S, P10T, P10V, P10W, P10Y, E39A, E39C, E39D, E39F, E39G, E39H, E39I, E39K, E39L, E39M, E39N, E39P, E39Q, E39R, E39S, E39T, E39V, E39W, E39Y, R44A, R44C, R44D, R44E, R44F, R44G, R44H, R44I, R44K, R44L, R44N, R44P, R44Q, R44S, R44T, R44V, R44W, R44Y, T47A, T47C, T47D, T47E, T47F, T47G, T47H, T47I, T47K, T47L, T47M, T47N, T47P, T47Q, T47R, T47S, T47V, T47W, T47Y,

H92A, H92C, H92D, H92E, H92F, H92G, H92I, H92K, H92L, H92M, H92N, H92P, H92Q, H92R, H92S, H92T, H92V, H92W, H92Y, P166A, P166C, P166D, P166E, P166F, P166G, P166H, P166I, P166K, P166L, P166M, P166N, P166Q, P166R, P166S, P166T, P166V, P166W, P166Y, A206C, A206D, A206E, A206F, A206G, A206H, A206I, A206K, A206L, A206M, A206N, A206P, A206Q, A206R, A206S, A206T, A206V, A206W, A206Y, R217A, R217C, R217D, R217E, R217F, R217G, R217H, R217I, R217K, R217L, R217M, R217N, R217P, R217Q, R217S, R217T, R217V, R217W, R217Y, D247A, D247C, D247E, D247F, D247G, D247H, D247I, D247K, D247L, D247M, D247N, D247P, D247Q, D247R, D247S, D247T, D247V, D247W, D247Y, G261A, G261C, G261D, G261E, G261F, G261H, G261I, G261K, G261L, G261M, G261N, G261P, G261Q, G261R, G261S, G261T, G261V, G261W, G261Y, A271C, A271D, A271E, A271F, A271G, A271H, A271I, A271K, A271L, A271M, A271N, A271P, A271Q, A271R, A271S, A271T, A271V, A271W, A271Y, K302A, K302C, K302D, K302E, K302F, K302G, K302H, K302I, K302L, K302M, K302N, K302P, K302Q, K302R, K302S, K302T, K302V, K302W, K302Y, D316A, D316C, D316E, D316F, D316G, D316H, D316I, D316K, D316L, D316M, D316N, D316P, D316Q, D316R, D316S, D316T, D316V, D316W, D316Y, I322A, I322C, I322D, I322E, I322F, I322G, I322H, I322K, I322L, I322M, I322N, I322P, I322Q, I322R, I322S, I322T, I322V, I322W, I322Y, P337A, P337C, P337D, P337E, P337F, P337G, P337H, P337I, P337K, P337L, P337M, P337N, P337Q, P337R, P337S, P337T, P337V, P337W, P337Y, A368C, A368D, A368E, A368F, A368G, A368H, A368I, A368K, A368L, A368M, A368N, A368P, A368Q, A368R, A368S, A368T, A368V, A368W, A368Y, T392A, T392C, T392D, T392E, T392F, T392G, T392H, T392I, T392K, T392L, T392M, T392N, T392P, T392Q, T392R, T392S, T392V, T392W, and T392Y, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.

[0142] In some embodiments, the polynucleotide encodes a recombinant alpha galactosidase A comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/392, 31, 31/39/44/166/302, 31/47, 31/283/284, 39, 39/44, 39/44/47, 39/44/47/261/283/284, 39/44/283, 39/44/339, 39/47/261, 39/92, 39/206, 39/284, 44, 44/284/302, 84, 84/92, 84/284/302/392, 84/316, 84/368/392, 92, 92/206/217, 92/206/275, 92/206/284, 92/206/302/368, 92/271, 92/271/277, 92/275/284, 92/283, 92/283/392, 92/284, 92/302, 92/316, 92/368, 155, 155/217, 155/368, 166, 166/283/284, 166/302, 206, 206/217, 206/334, 261, 261/283, 271, 271/368, 275, 283, 283/284, 283/392, 284, 302, 316, 334, 339, 368, 368/392, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha

galactosidase A comprises at least one substitution or substitution set at one or more positions selected from P10G, P10G/T392D, S31T, S31T/E39V/R44V/P166D/K302Y, S31T/T47R, S31T/K283L/D284A, E39L, E39L/H92V, E39L/A206E, E39L/D284S, E39V/R44V, E39V/R44V/T47R, E39V/R44V/T47R/G261S/K283L/D284A, E39V/R44V/K283T, E39V/R44V/A339N, E39V/T47R/G261S, R44V, R44V/D284E/K302Y, H84K, H84K/H92V, H84K/D284S/K302L/T392A, H84K/D316H, H84K/A368E/T392A, H92Q, H92T, H92T/A206E/R217N, H92T/A206E/K302T/A368E, H92T/A271K, H92T/A271K/K277R, H92T/K283P, H92T/K283V/T392W, H92T/D284M, H92T/K302L, H92T/A368E, H92V, H92V/A206E/D284S, H92V/A206Y/Q275A, H92V/Q275A/D284S, H92V/D284S, H92V/K302L, H92V/D316H, H155F, H155F/R217I, H155F/A368E, P166D, P166D/K283L/D284A, P166D/K302Y, A206E, A206E/R217N, A206I, A206Q, A206T/Y334C, A206Y, G261S, G261S/K283L, A271K, A271K/A368E, Q275A, K283L, K283P/T392W, K283T, K283T/D284E, D284E, D284M, D284S, K302L, K302Y, D316H, Y334C, A339N, A368E, A368E/T392W, T392A, T392D, and T392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022. In some embodiments, the recombinant alpha galactosidase A comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 1022, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10G, 10G/392D, 31T, 31T/39V/44V/166D/302Y, 31T/47R, 31T/283L/284A, 39L, 39L/92V, 39L/206E, 39L/284S, 39V/44V, 39V/44V/47R, 39V/44V/47R/261S/283L/284A, 39V/44V/283T, 39V/44V/339N, 39V/47R/261S, 44V, 44V/284E/302Y, 84K, 84K/92V, 84K/284S/302L/392A, 84K/316H, 84K/368E/392A, 92Q, 92T, 92T/206E/217N, 92T/206E/302T/368E, 92T/271K, 92T/271K/277R, 92T/283P, 92T/283V/392W, 92T/284M, 92T/302L, 92T/368E, 92V, 92V/206E/284S, 92V/206Y/275A, 92V/275A/284S, 92V/284S, 92V/302L, 92V/316H, 155F, 155F/217I, 155F/368E, 166D, 166D/283L/284A, 166D/302Y, 206E, 206E/217N, 206I, 206Q, 206T/334C, 206Y, 261S, 261S/283L, 271K, 271K/368E, 275A, 283L, 283P/392W, 283T, 283T/284E, 284E, 284M, 284S, 302L, 302Y, 316H, 334C, 339N, 368E, 368E/392W, 392A, 392D, and 392W, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022.

[0143] In some embodiments, as described above, the polynucleotide encodes an engineered polypeptide having GLA activity with the properties disclosed herein, wherein the polypeptide comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to a reference sequence (e.g., SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and 1022), or the amino acid sequence of any variant as disclosed in any of the Tables herein, and one or more residue differences as compared to the reference polypeptide of SEQ ID NO: 8, or the amino acid sequence of any variant as disclosed in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1 (for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or

more amino acid residue positions). In some embodiments, the polynucleotide encodes an engineered polypeptide having GLA activity with the properties disclosed herein, wherein the polypeptide comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to reference sequence SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022, and one or more residue differences as compared to SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022, at residue positions selected from those provided in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1 when optimally aligned with the polypeptide of SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022.

[0144] In some embodiments, the polynucleotide encoding the engineered GLA polypeptides comprises the polynucleotide sequence of SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022. In some embodiments, the polynucleotides are capable of hybridizing under highly stringent conditions to a reference polynucleotide sequence. In some embodiments, the reference sequence is selected from SEQ ID NOS: 1, 7, 57, 157, 275, 371, 373, and/or 1019, or a complement thereof, or a polynucleotide sequence encoding any of the variant GLA polypeptides provided herein. In some embodiments, the polynucleotide capable of hybridizing under highly stringent conditions encodes a GLA polypeptide comprising an amino acid sequence that has one or more residue differences as compared to SEQ ID NO: 2, 8, 58, 158, 372, 374, 704, and/or 1022, at residue positions selected from any positions as set forth in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1.

[0145] In some embodiments, an isolated polynucleotide encoding any of the engineered GLA polypeptides provided herein is manipulated in a variety of ways to provide for expression of the polypeptide. In some embodiments, the polynucleotides encoding the polypeptides are provided as expression vectors where one or more control sequences is present to regulate the expression of the polynucleotides and/or polypeptides. Manipulation of the isolated polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides and nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

[0146] In some embodiments, the control sequences include among other sequences, promoters, Kozak sequence, leader sequences, polyadenylation sequences, propeptide sequences, signal peptide sequences, DNA based regulatory elements for gene therapy retention and transcription terminators. As known in the art, suitable promoters can be selected based on the host cells used. Exemplary promoters for filamentous fungal host cells, include promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (glaA), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, and *Fusarium oxysporum* trypsin-like protease (See e.g., WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose

phosphate isomerase), and mutant, truncated, and hybrid promoters thereof. Exemplary yeast cell promoters can be from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are known in the art (See e.g., Romanos et al., Yeast 8:423-488 [1992]). Exemplary promoters for use in mammalian cells include, but are not limited to those from cytomegalovirus (CMV), chicken β -actin promoter fused with the CMV enhancer, Simian vacuolating virus 40 (SV40), from *Homo sapiens* phosphoglycerate kinase, beta actin, elongation factor-1a or glyceraldehyde-3-phosphate dehydrogenase, or from *Gallus gallus* β -actin.

[0147] In some embodiments, the control sequence is a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice finds use in the present invention. For example, exemplary transcription terminators for filamentous fungal host cells can be obtained from the genes for *Aspergillus oryzae* TKA amylose, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease. Exemplary terminators for yeast host cells can be obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are known in the art (See e.g., Romanos et al., *supra*). Exemplary terminators for mammalian cells include, but are not limited to those from cytomegalovirus (CMV), Simian vacuolating virus 40 (SV40), from *Homo sapiens* growth hormone hGH, from bovine growth hormone BGH, and from human or rabbit beta globulin.

[0148] In some embodiments, the control sequence is a suitable leader sequence, 5'-cap modification, 5' UTR, etc. In some embodiments, these regulatory sequence elements mediate binding to molecules involved in mRNA trafficking and translation, inhibit 5'-exonucleolytic degradation and confer resistance to de-capping. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used. Exemplary leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TKA amylose and *Aspergillus nidulans* triose phosphate isomerase. Suitable leaders for yeast host cells include, but are not limited to those obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP). Suitable leaders for mammalian host cells include but are not limited to the 5'-UTR element present in orthopoxvirus mRNA.

[0149] In some embodiments, the control sequence comprises a 3' untranslated nucleic acid region and polyadenylation tail nucleic acid sequence, sequences operably linked to the 3' terminus of the protein coding nucleic acid sequence which mediate binding to proteins involved in mRNA trafficking and translation and mRNA half-life. Any polyadenylation sequence and 3' UTR which is functional in the host cell of choice may be used in the present invention. Exemplary polyadenylation sequences for filamentous fungal host cells include, but are not limited to those from the genes for *Aspergillus oryzae* TKA amylose, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-like protease, and *Aspergillus niger* alpha-glucosidase. Useful polyadenylation sequences for yeast host cells are also known in the art (See e.g., Guo and Sherman, Mol. Cell. Biol., 15:5983-5990 [1995]). Useful polyadenylation and 3' UTR sequences for mammalian host cells include, but are not limited to the 3'-UTRs of α - and β -globin mRNAs that harbor several sequence elements that increase the stability and translation of mRNA.

[0150] In some embodiments, the control sequence is a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence. Any signal peptide coding region that directs the expressed polypeptide into the secretory pathway of a host cell of choice finds use for expression of the engineered GLA polypeptides provided herein. Effective signal peptide coding regions for filamentous fungal host cells include, but are not limited to the signal peptide coding regions obtained from the genes for *Aspergillus oryzae* TKA amylose, *Aspergillus niger* neutral amylose, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* cellulase, and *Humicola lanuginosa* lipase. Useful signal peptides for yeast host cells include, but are not limited to those from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Useful signal peptides for mammalian host cells include but are not limited to those from the genes for immunoglobulin gamma (IgG).

[0151] In some embodiments, the control sequence is a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is referred to as a "proenzyme," "propeptide," or "zymogen," in some cases). A propeptide can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propeptide.

[0152] In another aspect, the present invention also provides a recombinant expression vector comprising a polynucleotide encoding an engineered GLA polypeptide, and one or more expression regulating regions such as a promoter and a terminator, a replication origin, etc., depending on the type of hosts into which they are to be introduced. In some embodiments, the various nucleic acid and

control sequences described above are joined together to produce a recombinant expression vector which includes one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the variant GLA polypeptide at such sites. Alternatively, the polynucleotide sequence(s) of the present invention are expressed by inserting the polynucleotide sequence or a nucleic acid construct comprising the polynucleotide sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

[0153] The recombinant expression vector may be any vector (e.g., a plasmid or virus including but not limited to adenovirus (AV), adeno-associated virus (AAV), lentivirus (LV), and non-viral vectors, such as liposomes), that can be conveniently subjected to recombinant DNA procedures and can result in the expression of the variant GLA polynucleotide sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

[0154] In some embodiments, the expression vector is an autonomously replicating vector (i.e., a vector that exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication, such as a plasmid, an extra-chromosomal element, a minichromosome, or an artificial chromosome). The vector may contain any means for assuring self-replication. In some alternative embodiments, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

[0155] In some embodiments, the expression vector preferably contains one or more selectable markers, which permit easy selection of transformed cells. A “selectable marker” is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Suitable markers for yeast host cells include, but are not limited to ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferases), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenylyltransferase), and trpC (anthranilate synthase), as well as equivalents thereof. In another aspect, the present invention provides a host cell comprising a polynucleotide encoding at least one engineered GLA polypeptide of the present application, the polynucleotide being operatively linked to one or more control sequences for expression of the engineered GLA enzyme(s) in the host cell. Host cells for use in expressing the polypeptides encoded by the expression vectors of the present invention are well known in the art and include but are not limited to, fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* and *Pichia pastoris* [e.g., ATCC Accession No. 201178]); insect cells (e.g., *Drosophila* S2 and *Spodoptera Sf9* cells), plant cells, animal cells (e.g., CHO, CHO-K1, COS, and

BHK), and human cells (e.g., HEK293T, human fibroblast, THP-1, Jurkat and Bowes melanoma cell lines).

[0156] Accordingly, in another aspect, the present invention provides methods for producing the engineered GLA polypeptides, where the methods comprise culturing a host cell capable of expressing a polynucleotide encoding the engineered GLA polypeptide under conditions suitable for expression of the polypeptide. In some embodiments, the methods further comprise the steps of isolating and/or purifying the GLA polypeptides, as described herein.

[0157] Appropriate culture media and growth conditions for the above-described host cells are well known in the art. Polynucleotides for expression of the GLA polypeptides may be introduced into cells by various methods known in the art. Techniques include, among others, electroporation, biolistic particle bombardment, liposome mediated transfection, calcium chloride transfection, and protoplast fusion.

[0158] The engineered GLA with the properties disclosed herein can be obtained by subjecting the polynucleotide encoding the naturally occurring or engineered GLA polypeptide to mutagenesis and/or directed evolution methods known in the art, and as described herein. An exemplary directed evolution technique is mutagenesis and/or DNA shuffling (See e.g., Stemmer, Proc. Natl. Acad. Sci. USA 91:10747-10751 [1994]; WO 95/22625; WO 97/0078; WO 97/35966; WO 98/27230; WO 00/42651; WO 01/75767 and U.S. Pat. 6,537,746). Other directed evolution procedures that can be used include, among others, staggered extension process (StEP), in vitro recombination (See e.g., Zhao et al., Nat. Biotechnol., 16:258-261 [1998]), mutagenic PCR (See e.g., Caldwell et al., PCR Methods Appl., 3:S136-S140 [1994]), and cassette mutagenesis (See e.g., Black et al., Proc. Natl. Acad. Sci. USA 93:3525-3529 [1996]).

[0159] For example, mutagenesis and directed evolution methods can be readily applied to polynucleotides to generate variant libraries that can be expressed, screened, and assayed.

Mutagenesis and directed evolution methods are well known in the art (See e.g., US Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, 5,837,458, 5,928,905, 6,096,548, 6,117,679, 6,132,970, 6,165,793, 6,180,406, 6,251,674, 6,277,638, 6,287,861, 6,287,862, 6,291,242, 6,297,053, 6,303,344, 6,309,883, 6,319,713, 6,319,714, 6,323,030, 6,326,204, 6,335,160, 6,335,198, 6,344,356, 6,352,859, 6,355,484, 6,358,740, 6,358,742, 6,365,377, 6,365,408, 6,368,861, 6,372,497, 6,376,246, 6,379,964, 6,387,702, 6,391,552, 6,391,640, 6,395,547, 6,406,855, 6,406,910, 6,413,745, 6,413,774, 6,420,175, 6,423,542, 6,426,224, 6,436,675, 6,444,468, 6,455,253, 6,479,652, 6,482,647, 6,489,146, 6,506,602, 6,506,603, 6,519,065, 6,521,453, 6,528,311, 6,537,746, 6,573,098, 6,576,467, 6,579,678, 6,586,182, 6,602,986, 6,613,514, 6,653,072, 6,716,631, 6,946,296, 6,961,664, 6,995,017, 7,024,312, 7,058,515, 7,105,297, 7,148,054, 7,288,375, 7,421,347, 7,430,477, 7,534,564, 7,620,500, 7,620,502, 7,629,170, 7,702,464, 7,747,391, 7,747,393, 7,751,986, 7,776,598, 7,783,428, 7,795,030, 7,853,410, 7,868,138, 7,873,499, 7,904,249, 7,957,912, 8,383,346, 8,504,498, 8,849,575, 8,876,066, 8,768,871, 9,593,326, and all related non-US counterparts; Ling *et al.*, Anal. Biochem., 254(2):157-78 [1997]; Dale *et al.*,

Meth. Mol. Biol., 57:369-74 [1996]; Smith, Ann. Rev. Genet., 19:423-462 [1985]; Botstein *et al.*, Science, 229:1193-1201 [1985]; Carter, Biochem. J., 237:1-7 [1986]; Kramer *et al.*, Cell, 38:879-887 [1984]; Wells *et al.*, Gene, 34:315-323 [1985]; Minshull *et al.*, Curr. Op. Chem. Biol., 3:284-290 [1999]; Christians *et al.*, Nat. Biotechnol., 17:259-264 [1999]; Cramer *et al.*, Nature, 391:288-291 [1998]; Cramer *et al.*, Nat. Biotechnol., 15:436-438 [1997]; Zhang *et al.*, Proc. Nat. Acad. Sci. U.S.A., 94:4504-4509 [1997]; Cramer *et al.*, Nat. Biotechnol., 14:315-319 [1996]; Stemmer, Nature, 370:389-391 [1994]; Stemmer, Proc. Nat. Acad. Sci. USA, 91:10747-10751 [1994]; US Pat. Appln. Publ. Nos. 2008/0220990, US 2009/0312196, US2014/0005057, US2014/0214391, US2014/0221216; US2015/0050658, US2015/0133307, US2015/0134315 and all related non-US counterparts; WO 95/22625, WO 97/0078, WO 97/35966, WO 98/27230, WO 00/42651, WO 01/75767, and WO 2009/152336; all of which are incorporated herein by reference).

[0160] In some embodiments, the enzyme variants obtained following mutagenesis treatment are screened by subjecting the enzyme variants to a defined temperature (or other assay conditions) and measuring the amount of enzyme activity remaining after heat treatments or other assay conditions. DNA containing the polynucleotide encoding the GLA polypeptide is then isolated from the host cell, sequenced to identify the nucleotide sequence changes (if any), and used to express the enzyme in a different or the same host cell. Measuring enzyme activity from the expression libraries can be performed using any suitable method known in the art (e.g., standard biochemistry techniques, such as HPLC analysis).

[0161] For engineered polypeptides of known sequence, the polynucleotides encoding the enzyme can be prepared by standard solid-phase methods, according to known synthetic methods. In some embodiments, fragments of up to about 100 bases can be individually synthesized, then joined (e.g., by enzymatic or chemical ligation methods, or polymerase mediated methods) to form any desired continuous sequence. For example, polynucleotides and oligonucleotides disclosed herein can be prepared by chemical synthesis using the classical phosphoramidite method (See e.g., Beaucage *et al.*, Tetra. Lett., 22:1859-69 [1981]; and Matthes *et al.*, EMBO J., 3:801-05 [1984]), as it is typically practiced in automated synthetic methods. According to the phosphoramidite method, oligonucleotides are synthesized (e.g., in an automatic DNA synthesizer), purified, annealed, ligated and cloned in appropriate vectors.

[0162] Accordingly, in some embodiments, a method for preparing the engineered GLA polypeptide can comprise: (a) synthesizing a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the amino acid sequence of any variant provided in Table 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and/or 13-1, as well as SEQ ID NOS: 8, 58, 158, 372, 374, 704, and/or 1022, and (b) expressing the GLA polypeptide encoded by the polynucleotide. In some embodiments of the method, the amino acid sequence encoded by the polynucleotide can optionally have one or several (e.g., up to 3, 4, 5, or up to 10) amino acid residue mutations (e.g., deletions, insertions and/or substitutions). In some embodiments, the amino acid sequence has optionally 1-2, 1-3, 1-4, 1-5, 1-6,

1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-30, 1-35, 1-40, 1-45, or 1-50 amino acid residue mutations (e.g., deletions, insertions and/or substitutions). In some embodiments, the amino acid sequence has optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50 amino acid residue mutations (e.g., deletions, insertions and/or substitutions). In some embodiments, the amino acid sequence has optionally 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21, 22, 23, 24, or 25 amino acid residue mutations (e.g., deletions, insertions and/or substitutions). In some embodiments, the substitutions can be conservative or non-conservative substitutions.

[0163] The expressed engineered GLA polypeptide can be assessed for any desired improved property (e.g., activity, selectivity, stability, acid tolerance, protease sensitivity, etc.), using any suitable assay known in the art, including but not limited to the assays and conditions described herein.

[0164] In some embodiments, any of the engineered GLA polypeptides expressed in a host cell are recovered from the cells and/or the culture medium using any one or more of the well-known techniques for protein purification, including, among others, lysozyme treatment, sonication, filtration, salting-out, ultra-centrifugation, and chromatography.

[0165] Chromatographic techniques for isolation of the GLA polypeptides include, among others, reverse phase chromatography high performance liquid chromatography, ion exchange chromatography, hydrophobic interaction chromatography, gel electrophoresis, and affinity chromatography. Conditions for purifying a particular enzyme depends, in part, on factors such as net charge, hydrophobicity, hydrophilicity, molecular weight, molecular shape, etc., and will be apparent to those having skill in the art. In some embodiments, affinity techniques may be used to isolate the improved variant GLA enzymes. In some embodiments utilizing affinity chromatography purification, any antibody which specifically binds the variant GLA polypeptide finds use. In some embodiments utilizing affinity chromatography purification, proteins that bind to the glycans covalently attached to GLA find use. In still other embodiments utilizing affinity-chromatography purifications, any small molecule that binds to the GLA active site finds use. For the production of antibodies, various host animals, including but not limited to rabbits, mice, rats, etc., are immunized by injection with a GLA polypeptide (e.g., a GLA variant), or a fragment thereof. In some embodiments, the GLA polypeptide or fragment is attached to a suitable carrier, such as BSA, by means of a side chain functional group or linkers attached to a side chain functional group.

[0166] In some embodiments, the engineered GLA polypeptide is produced in a host cell by a method comprising culturing a host cell (e.g., *S. cerevisiae*, *Daucus carota*, *Nicotiana tabacum*, *H. sapiens* (e.g., HEK293T), or *Cricetulus griseus* (e.g., CHO)) comprising a polynucleotide sequence encoding an engineered GLA polypeptide as described herein under conditions conducive to the production of the engineered GLA polypeptide and recovering the engineered GLA polypeptide from the cells and/or culture medium.

[0167] In some embodiments, the invention encompasses a method of producing an engineered GLA polypeptide comprising culturing a recombinant eukaryotic cell comprising a polynucleotide sequence encoding an engineered GLA polypeptide having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a reference sequence (e.g., SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022), and one or more amino acid residue differences as compared to SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022, selected from those provided in Tables 2-1, 5-1, 6-1, 7-1, 8-1, 9-1, 11-1, 12-1, and 13-1, and/or combinations thereof when optimally aligned with the amino acid sequence of SEQ ID NO: 8, 58, 158, 372, 374, 704, and/or 1022, under suitable culture conditions to allow the production of the engineered GLA polypeptide and optionally recovering the engineered GLA polypeptide from the culture and/or cultured cells.

[0168] In some embodiments, once the engineered GLA polypeptides are recovered from the recombinant host cells or cell culture medium, they are further purified by any suitable method(s) known in the art. In some additional embodiments, the purified GLA polypeptides are combined with other ingredients and compounds to provide compositions and formulations comprising the engineered GLA polypeptide as appropriate for different applications and uses (e.g., pharmaceutical compositions). In some additional embodiments, the purified engineered GLA polypeptides, or the formulated engineered GLA polypeptides are lyophilized. In some embodiments, the engineered GLA polypeptides are directly produced within a body (i.e., cells within a body, such as a human or another animal) and are not purified. However, in some alternative embodiments, the engineered GLA polypeptides are produced within a body (i.e., cells within a body, such as a human or another animal) and are collected from the body using methods known in the art. In some additional embodiments, these collected engineered GLA polypeptides are purified. In yet some further embodiments, these collected and/or purified engineered polypeptides are introduced into another animal (e.g., human or another animal) or reintroduced into the body that originally produced the collected and/or purified engineered GLA polypeptides.

Compositions:

[0169] The present invention provides various compositions and formats, including but not limited to those described below. In some embodiments, the present invention provides engineered GLA polypeptides suitable for use in pharmaceutical and other compositions, such as dietary/nutritional supplements.

[0170] Depending on the mode of administration, these compositions comprising a therapeutically effective amount of an engineered GLA according to the invention are in the form of a solid, semi-solid, or liquid. In some embodiments, the compositions include other pharmaceutically acceptable components such as diluents, buffers, excipients, salts, emulsifiers, preservatives, stabilizers, fillers, and other ingredients. Details on techniques for formulation and administration are well known in the

art and described in the literature. In some embodiments, these compositions are produced directly in the human body after introduction as gene therapy.

[0171] In some embodiments, the engineered GLA polypeptides are formulated for use in pharmaceutical compositions. Any suitable format for use in delivering the engineered GLA polypeptides find use in the present invention, including but not limited to pills, tablets, gel tabs, capsules, lozenges, dragees, powders, soft gels, sol-gels, gels, emulsions, implants, patches, sprays, ointments, liniments, creams, pastes, jellies, paints, aerosols, chewing gums, demulcents, sticks, solutions, suspensions (including but not limited to oil-based suspensions, oil-in water emulsions, etc.), slurries, syrups, controlled release formulations, suppositories, etc. In some embodiments, the engineered GLA polypeptides are provided in a format suitable for injection or infusion (i.e., in an injectable formulation). In some embodiments, the polynucleotide sequences for the engineered GLA polypeptide is provided in a format suitable for injection. In some embodiments, the engineered GLA polypeptides are provided in biocompatible matrices such as sol-gels, including silica-based (e.g., oxysilane) sol-gels. In some embodiments, the engineered GLA polypeptides are encapsulated. In some alternative embodiments, the engineered GLA polypeptides are encapsulated in nanostructures (e.g., nanotubes, nanotubules, nanocapsules, or microcapsules, microspheres, liposomes, etc.). Indeed, it is not intended that the present invention be limited to any particular delivery formulation and/or means of delivery. It is intended that the engineered GLA polypeptides be administered by any suitable means known in the art, including but not limited to parenteral, oral, topical, transdermal, intranasal, intraocular, intrathecal, via implants, etc.

[0172] In some embodiments, the engineered GLA polypeptides are chemically modified by glycosylation, chemical crosslinking reagents, pegylation (i.e., modified with polyethylene glycol [PEG] or activated PEG, etc.) or other compounds (See e.g., Ikeda, *Amino Acids* 29:283-287 [2005]; US Pat. Nos. 7,531,341, 7,534,595, 7,560,263, and 7,53,653; US Pat. Appln. Publ. Nos. 2013/0039898, 2012/0177722, etc.). Indeed, it is not intended that the present invention be limited to any particular delivery method and/or mechanism.

[0173] In some additional embodiments, the engineered GLA polypeptides are provided for delivery to cells or tissues via gene therapy, including viral delivery vectors, including but not limited to adenovirus (AV), adeno-associated virus (AAV), lentivirus (LV), or non-viral vectors (e.g., liposomes). In some embodiments, the engineered GLA polypeptides are provided for delivery to cells or tissues via mRNA therapy following formulation of polyribonucleotide sequences in an encapsulated delivery vehicle (e.g., liposomes). In some additional embodiments, the engineered GLA polypeptides are provided for delivery to cells or tissues via cell therapy, where the polynucleotide sequence encoding the engineered GLA polypeptides is introduced into exogenous cell and that cell (or cells) are introduced into a recipient (e.g., a patient exhibiting or at risk for developing Fabry disease).

[0174] In some additional embodiments, the engineered GLA polypeptides are provided in formulations comprising matrix-stabilized enzyme crystals. In some embodiments, the formulation comprises a cross-linked crystalline engineered GLA enzyme and a polymer with a reactive moiety that adheres to the enzyme crystals. The present invention also provides engineered GLA polypeptides in polymers.

[0175] In some embodiments, compositions comprising the engineered GLA polypeptides of the present invention include one or more commonly used carrier compounds, including but not limited to sugars (e.g., lactose, sucrose, mannitol, and/or sorbitol), starches (e.g., corn, wheat, rice, potato, or other plant starch), cellulose (e.g., methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose), gums (e.g., arabic, tragacanth, guar, etc.), and/or proteins (e.g., gelatin, collagen, etc.).

[0176] In some embodiments, the present invention provides engineered GLA polypeptides suitable for use in decreasing the concentration of glycolipids in fluids such as blood, cerebrospinal fluid, etc. The dosage of engineered GLA polypeptide(s) administered depends upon the condition or disease, the general condition of the subject, and other factors known to those in the art. In some embodiments, the compositions are intended for single or multiple administrations. In some embodiments, it is contemplated that the concentration of engineered GLA polypeptide(s) in the composition(s) administered to a human with Fabry disease is sufficient to effectively treat, and/or ameliorate disease (e.g., Fabry disease). In some embodiments, the engineered GLA polypeptides are administered in combination with other pharmaceutical and/or dietary compositions.

EXPERIMENTAL

[0177] The following Examples, including experiments and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the present invention.

In the experimental disclosure below, the following abbreviations apply: ppm (parts per million); M (molar); mM (millimolar), uM and μ M (micromolar); nM (nanomolar); mol (moles); gm and g (gram); mg (milligrams); ug and μ g (micrograms); L and l (liter); ml and mL (milliliter); cm (centimeters); mm (millimeters); um and μ m (micrometers); sec. (seconds); min(s) (minute(s)); h(s) and hr(s) (hour(s)); U (units); MW (molecular weight); rpm (rotations per minute); °C (degrees Centigrade); SEM (standard error of the mean); IV (intravenous); CDS (coding sequence); DNA (deoxyribonucleic acid); RNA (ribonucleic acid); *E. coli* W3110 (commonly used laboratory *E. coli* strain, available from the Coli Genetic Stock Center [CGSC], New Haven, CT); NHP (non-human primate); HPLC (high pressure liquid chromatography); MWCO (molecular weight cut-off); SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis); PBS (phosphate buffered saline); DPBS (Dulbecco's phosphate buffered saline); PES (polyethersulfone); CFSE (carboxyfluorescein succinimidyl ester); IPTG (isopropyl β -D-1-thiogalactopyranoside); PMBS (polymyxin B sulfate); NADPH (nicotinamide adenine dinucleotide phosphate); GIDH (glutamate

dehydrogenase); FIOPC (fold improvements over positive control); PBMC (peripheral blood mononuclear cells); LB (Luria broth); MeOH (methanol); $C_{\max}$ (maximal drug concentration during a dosing interval); RFU (relative fluorescence units); AUC_{0-t} (area under the curve, up to the last measurable concentration); CL (clearance); V_z (apparent volume of distribution during the terminal phase); TI (test item); Athens Research (Athens Research Technology, Athens, GA); ProSpec (ProSpec Tany Technogene, East Brunswick, NJ); Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO); Ram Scientific (Ram Scientific, Inc., Yonkers, NY); Pall Corp. (Pall, Corp., Pt. Washington, NY); Millipore (Millipore, Corp., Billerica MA); Difco (Difco Laboratories, BD Diagnostic Systems, Detroit, MI); PerkinElmer (PerkinElmer, Waltham, MA); Molecular Devices (Molecular Devices, LLC, Sunnyvale, CA); Kuhner (Adolf Kuhner, AG, Basel, Switzerland); Axygen (Axygen, Inc., Union City, CA); Toronto Research Chemicals (Toronto Research Chemicals Inc., Toronto, Ontario, Canada); Cambridge Isotope Laboratories, (Cambridge Isotope Laboratories, Inc., Tewksbury, MA); Applied Biosystems (Applied Biosystems, part of Life Technologies, Corp., Grand Island, NY); Agilent (Agilent Technologies, Inc., Santa Clara, CA); Thermo Scientific (part of ThermoFisher Scientific, Waltham, MA); Gibco (ThermoFisher Scientific); Pierce (Pierce Biotechnology (now part of Thermo Fisher Scientific), Rockford, IL); ThermoFisher Scientific (Thermo Fisher Scientific, Waltham, MA); Corning (Corning, Inc., Palo Alto, CA); XenoTech (Sekisui XenoTech, LLC, Kansas City, KS); Coriell Institute for Medical Research (Coriell Institute for Medical Research, Camden, NJ); VWR (VWR International, Radnor, PA); Jackson (The Jackson Laboratory, Bar Harbor, ME); Megazyme (Megazyme International, Wicklow, Ireland); Enzo (Enzo Life Sciences, Inc., Farmingdale, NY); GE Healthcare (GE Healthcare Bio-Sciences, Piscataway, NJ); LI-COR (LI-COR Biotechnology, Lincoln, NE); Amicus (Amicus Therapeutics, Cranbury, NJ); Phenomenex (Phenomenex, Inc., Torrance, CA); Optimal (Optimal Biotech Group, Belmont, CA); and Bio-Rad (Bio-Rad Laboratories, Hercules, CA).

[0178] The following polynucleotide and polypeptide sequences find use in the present invention. In some cases (as shown below), the polynucleotide sequence is followed by the encoded polypeptide.

Polynucleotide sequence of full length human GLA cDNA (SEQ ID NO.1):

ATGCAGCTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCCTTCGCTTCCTGGCC
CTCGTTTCTGGGACATCCCTGGGGCTAGAGCACTGGACAATGGATTGGCAAGGACGCCT
ACCATGGGCTGGCTGCACTGGGAGCGCTTCATGTGCAACCTTGACTGCCAGGAAGAGCC
AGATTCTGCATCAGTGAGAAGCTCTTCATGGAGATGGCAGAGCTCATGGTCTCAGAAG
GCTGGAAGGATGCAGGTTATGAGTACCTCTGCATTGATGACTGTTGGATGGCTCCCCAAA
GAGATTGAGAAGGCAGACTTCAGGCAGACCCTCAGCGCTTTCCTCATGGGATTGCGCCAGC
TAGCTAATTATGTTACAGCAAAGGACTGAAGCTAGGGATTTATGCAGATGTTGGAAT
AAAACCTGCGCAGGCTTCCCTGGGAGTTTTGGATACTACGACATTGATGCCAGACCTTT
GCTGACTGGGGAGTAGATCTGCTAAAATTTGATGGTTGTTACTGTGACAGTTTGGAAAAT
TTGGCAGATGGTTATAAGCACATGTCTTGGCCCTGAATAGGACTGGCAGAAGCATTGTG
TACTCTGTGAGTGGCCTTTTATATGTGGCCCTTTCAAAGCCCAATTATACAGAAATC
CGACAGTACTGCAATCACTGGCGAAATTTTCTGACATTGATGATTCTGGAAGTATA
AAGAGTATCTTGGACTGGACATCTTTTAACCAGGAGAGAATTGTTGATGTTGCTGGACCA

GGGGGTTGGAATGACCCAGATATGTTAGTGATTGGCAACTTTGGCCTCAGCTGGAATCAG
CAAGTAACTCAGATGGCCCTCTGGGCTATCATGGCTGCTCCTTTATTCATGTCTAATGACC
TCCGACACATCAGCCCTCAAGCCAAAGCTCTCCTTCAGGATAAGGACGTAATTGCCATCA
ATCAGGACCCCTTGGGCAAGCAAGGGTACCAGCTTAGACAGGGAGACAACCTTTGAAGTG
TGGGAACGACCTCTCTCAGGCTTAGCCTGGGCTGTAGCTATGATAAACCGGCAGGAGATT
GGTGGACCTCGCTCTTATAACCATCGCAGTTGCTTCCCTGGGTAAAGGAGTGGCCTGTAAT
CCTGCCTGCTTCATCACACAGCTCCTCCCTGTGAAAAGGAAGCTAGGGTTCTATGAATGG
ACTTCAAGGTTAAGAAAGTCACATAAATCCCACAGGCACTGTTTTGCTTCAGCTAGAAAAT
ACAATGCAGATGTCAATTAAGAGCTTACTTTAG (SEQ ID NO: 1)

Polypeptide sequence of full length human GLA:

MQLRNPELHLGCALALRFLALVSWDIPGARALDNLARTPTMGWLHWERFMCNLDQEEP
DSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAQRDSEGRQADPQRFPHGIRQLA
NYVHSGKGLKGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDLENLAD
GYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSILSD
WTSFNQERIVDVAGPGGWNDPDMVLIGNFGLSWNQVTQMALWAIMAAPLFMSNDRHIS
PQAKALLQDKDVIQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSY
TIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKD
LL (SEQ ID NO: 2)

Polynucleotide sequence of mature yeast codon-optimized (yCDS) human GLA:

TTGGATAACGGGTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTCATGGA
GATGGCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTGAGAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACTACGTACACAGCAAGGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCCAGGTTCAATCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGTTACATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTGATGGAAGTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGATA
GGGAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGCACCCCTATTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGCGTGGGC
TGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAAGGGTGTTCGTGCAATCCTGCCTGCTTACATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATGAGTGGACATCTAGGCTAAGAAGTCACATCAATCCTACT
GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTTGTTA
(SEQ ID NO: 3)

Polynucleotide sequence of mature human GLA (native hCDS):

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCCTGCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTGAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCCTCATGGGATTCGCCAGCTAGCTAATTATGTTACAGCAAAGGACTGAA

GCTAGGGATTTATGCAGATGTTGGAAAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
 ATACTACGACATTGATGCCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAAATTTGA
 TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGGC
 CCTGAATAGGACTGGCAGAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
 CTTTCAAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAAATTTTGC
 TGACATTGATGATTCTGGAAGTATAAAGAGTATCTTGGACTGGACATCTTTTAACCA
 GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTTGGAATGACCCAGATATGTTAGTGA
 TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAACTCAGATGGCCCTCTGGGCTATCA
 TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
 CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
 AGCTTAGACAGGGAGACAACCTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
 GCTGTAGCTATGATAAACCGGCAGGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
 GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCCTGCTTCATCACACAGCTCCTCCCT
 GTGAAAAGGAAGCTAGGGTTCTATGAATGGACTTCAAGGTTAAGAAGTCACATAAATCC
 CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGAACTTACT
 T (SEQ ID NO:4)

Polypeptide sequence of mature Human GLA:

LDNGLARTPTMGWLHWERFMCNLDQEEPDCISEKLFMEMAELMVSEGWKDAGYEYLCI
 DDCWMA PQRDSEGR LQADPQRFPHGIRQLANYVHSGKLKLG IYADVGNKTCAGFPGSFGYY
 DIDAQTFADWGV DLLKFDGCY CDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
 KPNYTEIRQYCNHWRNFADIDDSWKSISILDWTSFNQERIVDVAGPGGWNDPDM LVIGNFG
 LSWNQQTQMALWAIMAAPLFMSNDLRHISPAKALLQDKDVIINQDPLGKQGYQLRQG
 DNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGF
 YEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO:5)

Polynucleotide sequence of pCK110900i *E. coli* expression vector:

TCGAGTTAATTAAGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGC
 ACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATA
 ACAATTTACACAGGAAACGGCTATGACCATGATTACGGATTCAGTGGCCGTCGTTTTAC
 AATCTAGAGGCCAGCCTGGCCATAAGGAGATATACATATGAGTATTCAACATTTCCGTGT
 CGCCCTTATTCCCTTTTCTGCGGCATTTTGCCTTCCTGTTTTTGTCTACCCAGAAACGCTG
 GTGAAAGTAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGA
 TCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAGCGTTTTCCAATGATGAG
 CACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCA
 ACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTCACAGA
 AAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGA
 GTGATAACACTGCGGCCAACTTACTTCTGAGAACGATCGGAGGACCGAAGGAGCTAACC
 GTTTTTTTGACACCATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTG
 AATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTACAGCAATGGCAACAAC
 GTTGCGCAAACTATTAAGTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGA
 CTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTG
 GTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACT
 GGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAA
 CTATGGATGAACGTAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGG
 GGCCAAACTGGCCACCATCACCATCACCATTAGGGAAGAGCAGATGGGCAAGCTTGACC
 TGTGAAGTGAAAAATGGCGCACATTGTGCGACATTTTTTTTTTGAATTCTACGTAAAAAGC
 CGCCGATACATCGGCTGCTTTTTTTTTTGATAGAGGTTCAAACCTGTGGTATAATGAAATA
 AGATCACTCCGGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAA
 ATGGAGAAAAAATCACTGGATATACCAACGTTGATATATCCCAATGGCATCGTAAAGA
 ACATTTTGAGGCAATTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGTTGGA
 TATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTAT

TCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAGTTCCGTATGGCAATGAAAGACGG
TGAGCTGGTGATATGGGATAGTGTTACCCCTTGTTACACCGTTTTCCATGAGCAAACCTGA
AACGTTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATA
TTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGA
GAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTG
GCCAATATGGACAACCTTCTTCGCCCCCGTTTTTCACCATGGGCAAATATTATACGCAAGGC
GACAAGGTGCTGATGCCGCTGGCGATTACAGGTTTCATCATGCCGTCTGTGATGGCTTCCAT
GTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTA
ACTGCAGGAGCTCAAACAGCAGCCTGTATTACAGGCTGCTTTTTTCGTTTTTGGTCTGCGCGT
AATCTCTTGCTCTGAAAACGAAAAAACCGCCTTGCAAGGGCGGTTTTTCGAAGGTTCTCTG
AGCTACCAACTCTTTGAACCGAGGTAACCTGGCTTGAGGAGCGCAGTCACCAAACTTG
TCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGACTAACTCCTCTAAATCAATTAC
CAGTGGCTGCTGCCAGTGGTGCTTTTGCATGCTTTTCCGGGTGGACTCAAGACGATAGT
TACCGGATAAGGCGCAGCGGTGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTG
GAGCGAACTGCCTACCCGGAACCTGAGTGTACAGGCGTGGAATGAGACAAACGCGGCCATA
ACAGCGGAATGACACCGGTAAACCGAAAGGCAGGAACAGGAGAGCGCACGAGGGAGCC
GCCAGGGGGAAACGCCTGGTATCTTTATAGTCTGTGCGGGTTTCGCCACCACTGATTTGA
GCGTCAGATTTTCGTGATGCTTGTACAGGGGGGCGGAGCCTATGGAAAAACGGCTTTGCCG
CGGCCCTCTCACTTCCCTGTAAAGTATCTTCTGTCATCTTCCAGGAAATCTCCGCCCCGT
TCGTAAGCCATTTCCGCTCGCCGCAGTCGAACGACCGAGCGTAGCGAGTCAGTGAGCGA
GGAAGCGGAATATATCCTGTATCACATATTCTGCTGACGCACCGGTGCAGCCTTTTTTCT
CCTGCCACATGAAGCACTTCACTGACACCCTCATCAGTGAACCACCGCTGGTAGCGGTGG
TTTTTTTAGGCCTATGGCCTTTTTTTTTTGTGGGAAACCTTTTCGCGGTATGGTATTAAAGC
GCCCCGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTC
GCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTTCCCGGTGGTGAACCAGGCCAGCCAC
GTTTCTGCGAAACGCGGGAAAAAGTGGAAGCGCGATGGCGGAGCTGAATTACATTCC
CAACCGCGTGGCACAACAACCTGGCGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCT
CCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTGCGGCGGATTAAATCTCGCGCCGATC
AACTGGGTGCCAGCGTGGTGGTGTGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAA
GCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATCCGCTG
GATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTCTT
GATGTCTCTGACCAGACACCCATCAACAGTATTATTTCTCCCATGAAGACGGTACGCGA
CTGGGCGTGGAGCATCTGGTTCGATTGGGTACCAGCAAATCGCGCTGTTAGCGGGCCC
ATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAA
TCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAAC
AAACCATGCAAATGCTGAATGAGGGCATCGTTTCCACTGCGATGCTGGTTGCCAACGATC
AGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGGCGAC
ATCTCGGTAGTGGGATACGACGATACCGAAGACAGTCATGTTATATCCCGCCGTTAACC
ACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACAGCGTGGACCGCTTGTGCAAACTC
TCTCAGGGCCAGGCGGTTAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAA
AACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAATTAAT
GCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGGTACCCGATAAAA
GCGGCTTCCTGACAGGAGGCCGTTTTGTTC (SEQ ID NO:6)

Polynucleotide sequence of pYT-72Bgl secreted yeast expression vector:

TTGTACAAATATCATA
AAAAAAGAGAATCTTTTTAAGCAAGGATTTTCTTAACTTCTTCGGCGACAGCATCACCGA
CTTCGGTGGTACTGTTGGAACCACTAAATCACCAGTTCTGATACCTGCATCCAAAACCT
TTTTAACTGCATCTTCAATGGCTTTACCTTCTTCAGGCAAGTTCAATGACAATTTCAACAT
CATTGCAGCAGACAAGATAGTGGCGATAGGGTTGACCTTATTCTTTGGCAAATCTGGAGC
GGAACCATGGCATGGTTTCGTACAAACCAAATGCGGTGTTCTTGTCTGGCAAAGAGGCCA
AGGACGCAGATGGCAACAAACCCAAGGAGCCTGGGATAACGGAGGCTTCATCGGAGAT
GATATCACCAAACATGTTGCTGGTGATTATAATACCATTAGGTGGGTGGGTTCTTAAC
TAGGATCATGGCGGCAGAATCAATCAATTGATGTTGAACTTTCAATGTAGGGAATTCGTT

CTTGATGGTTTTCCTCCACAGTTTTTCTCCATAATCTTGAAGAGGCCAAAACATTAGCTTTA
TCCAAGGACCAAATAGGCAATGGTGGCTCATGTTGTAGGGCCATGAAAGCGGCCATTCT
TGTGATTCTTTGCACTTCTGGAACGGTGTATTGTTCACTATCCCAAGCGACACCATCACCA
TCGTCTTCCTTTCTCTTACCAAAGTAAATACCTCCCACTAATTCTCTAACAACAACGAAGT
CAGTACCTTTAGCAAATTTGTGGCTTGATTGGAGATAAGTCTAAAAGAGAGTCGGATGCA
AAGTTACATGGTCTTAAGTTGGCGTACAATTGAAGTTCTTTACGGATTTTTAGTAAACCTT
GTTACAGTCTAACACTACCGGTACCCCATTTAGGACCACCCACAGCACCTAACAAAACG
GCATCAGCCTTTTTGGAGGCTTCCAGCGCCTCATTTGGAAGTGGAACACCTGTAGCATCG
ATAGCAGCCCCCAATTAAATGATTTTCGAAATCGAACTTGACATTGGAACGAACATCA
GAAATAGCTTTAAGAACCTTAATGGCTTCGGCTGTGATTTCTTGACCAACGTGGTCACCT
GGCAAAACGACGATTTTTTTAGGGGCAGACATTACAATGGTATATCCTTGAAATATATAT
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCAGCTTCTCAATGATATTGCAATAC
GCTTTGAGGAGATACAGCCTAATATCCGACAAACTGTTTTACAGATTTACGATCGTACTT
GTTACCCATCATTGAATTTTGAACATCCGAACCTGGGAGTTTTCCCTGAAACAGATAGTA
TATTTGAACCTGTATAATAATATATAGTCTAGCGCTTTACGGAAGACAATGTATGTATTT
CGGTTCTTGAGAAACTATTGCATCTATTGCATAGGTAATCTTGACGTCGCATCCCCGG
TTCATTTTCTGCGTTTCCATCTTGCACTTCAATAGCATATCTTTGTTAACGAAGCATCTGT
GCTTCATTTTGTAGAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAACAAAGAATCT
GAGCTGCATTTTTACAGAACAGAAATGCAACGCGAAAGCGCTATTTTACCAACGAAGAA
TCTGTGCTTCATTTTGTAAAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAACAAA
GAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAGAGCGCTATTTTACCAAC
AAAGAATCTATACTTCTTTTTTGTCTACAAAAATGCATCCCGAGAGCGCTATTTTTCTAA
CAAAGCATCTTAGATTACTTTTTTCTCTTTGTGCGCTCTATAATGCAGTCTCTTGATAA
CTTTTTGCACTGTAGGTCCGTTAAGGTTAGAAGAAGGCTACTTTGGTGTCTATTTTCTCTT
CCATAAAAAAAGCCTGACTCCACTTCCCGCGTTTACTGATTACTAGCGAAGCTGCGGGTG
CATTTTTTCAAGATAAAGGCATCCCCGATTATATTCTATACCGATGTGGATTGCGCATCT
TTGTGAACAGAAAGTGATAGCGTTGATGATTCTTCATTGGTCAGAAAATTGAACCGTT
TCTTCTATTTTGTCTCTATATACTACGTATAGGAAATGTTTACATTTTCGTATTGTTTTCGA
TTCCTCTATGAATAGTTCTTACTACAATTTTTTGTCTAAAGAGTAATACTAGAGATAAA
CATAAAAAATGTAGAGGTGAGTTTAGATGCAAGTTCAAGGAGCGAAAGGTGGATGGGT
AGGTTATATAGGGATATAGCACAGAGATATATAGCAAAGAGATACTTTGAGCAATGTT
TGTGGAAGCGGTATTTCGCAATATTTTAGTAGCTCGTTACAGTCCGGTGCGTTTTTGGTTTT
TTGAAAGTGCGTCTTCAGAGCGCTTTTGGTTTTCAAAGCGCTCTGAAGTTCCTATACTTT
CTAGAGAATAGGAACTTCGGAATAGGAACTTCAAAGCGTTTCCGAAAACGAGCGCTTCC
GAAAAATGCAACGCGAGCTGCGCACATACAGCTCACTGTTACGTCGCACCTATATCTGCG
TGTTGCCTGTATATATATATACATGAGAAGAACGGCATAGTGCGTGTATTATGCTTAAATG
CGTACTTATATGCGTCTATTTATGTAGGATGAAAGGTAGTCTAGTACCTCCTGTGATATTA
TCCCATTCCATGCGGGGTATCGTATGCTTCTTCAGCACTACCCTTTAGCTGTTCTATATG
CTGCCACTCCTCAATTGGATTAGTCTCATCCTTCAATGCTATCATTTCTTTGATATTGGA
TCATATGCATAGTACCGAGAACTAGTGCGAAGTAGTGATCAGGTATTGCTGTTATCTGA
TGAGTATACGTTGTCTGGCCACGGCAGAAGCACGCTTATCGCTCCAATTTCCACAACA
TTAGTCAACTCCGTTAGGCCCTTCATTGAAAAGAAATGAGGTCATCAAATGTCTTCCAATG
TGAGATTTTTGGGCCATTTTTTATAGCAAAGATTGAATAAGGCGCATTTTTCTTCAAAGCTT
TATTGTACGATCTGACTAAGTTATCTTTTAAATAATTGGTATTCCTGTTTATTGCTTGAAGA
ATTGCCGGTCTTATTTACTCGTTTTAGGACTGGTTCAGAATTCCTCAAAAATTCATCCAAA
TATACAAGTGGATCGATGATAAGCTGTCAAACATGAGAATTCCTGAAGACGAAAGGGCC
TCGTGATACGCCTATTTTTATAGGTTAATGTATGATAATAATGGTTTCTTAGACGTCAGG
TGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCA
AATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG
AAGAGTATGAGTATTCACATTTCCGTGTGCGCCCTTATTCCTTTTTTGGCGCATTTTGCC
TTCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGG
GTGACAGGATGGGTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTC
GCCCGAAGAAGCTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGTAT
TATCCCGTGTGACGCGGGCAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATG
ACTTGGTTGAGTACTACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGA

GAATTATGCAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAACTTACTTCTGACA
ACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAAAC
TCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACA
CCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGGCGAACTACTT
ACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAAGTTGCAGGACC
ACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGA
GCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGT
AGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTG
AGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATAC
TTTAGATTGATTTAAACTTTCATTTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTTGA
TAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCTGTTCCACTGAGCGTCAGACCCCGT
AGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGTGCA
AACAAAAAACCCGCTACCGAGCGGTGGTTTGTGTTGCCGGATCAAGAGCTACCAACTC
TTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCTTCTAGTGT
AGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGC
TAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACT
CAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTCGTGCACA
CAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATG
AGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGG
GTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAG
TCCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGGAGCCTATGGA AAAACGCCAGCAACGCGGCCTTTTTACGGTTCCCTGGCCTTTTGCTGG
CCTTTTGCTCATATGTTCTTTCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCG
CCTTTGAGTGAGCTGATACCGCTCGCCGAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATT
TCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAG
TATACACTCCGCTATCGCTACGTGACTGGGTCTATGGCTGCGCCCCGACACCCGCCAACAC
CCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGA
CCGTCTCCGGGAGCTGCATGTGTGTCAGAGGTTTTACCGTCATCACCGAAACGCGCGAGGC
AGCTGCGGTAAAGCTCATCAGCGTGGTCTGTGAAGCGATTACAGATGTCTGCCTGTTTCAT
CCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGG
CCATGTAAAGGGCGGTTTTTCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCT
GTTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTG
ATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACA ACTGGCGGTATGGATG
CGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGT
AGGTGTTCCACAGGGTAGCCAGCAGCATCTGCGATGCAGATCCGGAACATAATGGTGC
AGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTTCAT
GTTGTTGCTCAGGTCGACAGCGTTTTGCAGCAGCAGTCGCTTACGTTTCGCTCGCGTATC
GGTGATTCATTCTGCTAACCAAGTAAGGCAACCCCGCAGCCTAGCCGGGTCTCAACGAC
AGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGATGCGCCGCGT
GCGGCTGCTGGAGATGGCGGACGCGATGGATATGTTCTGCCAAGGGTTGGTTTGCGCATT
CACAGTTCTCCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATCCGTTAGCGAG
GTGCCCGCGGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGC
GGGGAGGCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTTCCATGTGC
TCGCCGAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAATGATCGAAGTTAGGCTG
GTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTTCGTCATCTACCTGCCTGGAC
AGCATGGCCTGCAACGCGGGCATCCCAGTCCCGCGGAAGCGAGAAGAATCATAATGGG
GAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTCGGCCG
CCATGCCGCGGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACG
AAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGT
CGCGCTCCAGCGAAAGCGGTCTCTCGCCGAAATGACCCAGAGCGCTGCCGGCACCTGTC
CTACGAGTTGATGATAAAGAAGACAGTAAAGTGCGGCGACGATAGTCATGCCCGCG
GCCCCAGGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAGGATGG
GCAAAACGTAAGGGCAAAACAAACGGAAAAATCGTTTCTCAAATTTTCTGATGCCAAGAA
CTCTAACCACTTATCTAAAAATTGCCTTATGATCCGTCTCTCCGGTTACAGCCTGTGTA

ACTGATTAATCCTGCCTTTCTAATCACCATTCTAATGTTTTAATTAAGGGATTTTGTCTTC
ATTAACGGCTTTTCGCTCATAAAAATGTTATGACGTTTTGCCCCGAGGCGGGAAACCATCC
ACTTCACGAGACTGATCTCCTCTGCCGGAACACCGGGCATCTCCAAC TTATAAGTTGGAG
AAATAAGAGAATTTT CAGATTGAGAGAATGAAAAAAAAAAAAAAAAAAGGCAGAGGAG
AGCATAGAAATGGGGTTCAC TTTTTTGGTAAAGCTATAGCATGCCTATCACATATAAATAG
AGTGCCAGTAGCGACTTTTTTTCACACTCGAAATACTCTTACTACTGCTCTCTTGTGTTTT
TATCACTTCTTGT TTTCTTCTTGGTAAATAGAATATCAAGCTACAAAAAGCATACAATCAA
CTATCAACTATTA ACTATATCGTAATACACAGGATCCACCATGAAGGCTGCTGCGCTTTC
CTGCCTCTTCGGCAGTACCTTGCCGTTGCAGGCGCCATTGAATCGAGAAAGGTTACCA
GAAGCCCCCTCGCGAGATCTGAACCTTTTTACCCGTCGCCATGGATGAATCCCAACGCCAT
CGGCTGGGCGGAGGCCATATGCCAGGCCAAGTCCTTTGTCTCCCAAATGACTCTGCTAGA
GAAGGTCAAATTGACCACGGGAGTCGGCTGGGGGGAGGAGCAGTGCGTCGGCAACGTG
GGCGGATCCCTCGCTTGGACTTCGCACTCTGTGCATGCATGACTCCCTCTCGGCGTG
CGAGGAACCGACTACA ACTCAGCGTTCCCTCTGGCCAGACCGTTGCTGTACCTGGGAT
CGCGGTCTGATGTACCGTCGCGGCTACGCAATGGGCCAGGAGGCCAAAGGCAAGGGCAT
CAATGTCTTCTCGGACCAGTCGCCGGCCCCCTTGCCGCATGCCCGAGGGCGGTCTGTAA
CTGGGAAGGCTTCGCTCCGGATCCCGTCCTTACCGGCATCGGCATGTCCGAGACGATCAA
GGGCATT CAGGATGCTGGCGTCATCGCTTGTGCGAAGCACTTTATTGGAACGAGCAGG
AGCACTTCAGACAGGTGCCAGAAAGCCAGGGATACGGTTACAACATCAGCGAAACCCTC
TCCTCCAACATTGACGACAAGACCATGCACGAGCTCTACCTTTGGCCGTTTGCCGATGCC
GTCCGGGCGCGGCTCGGCTCTGT CATGTGCTCGTACAACCAGGGCAACA ACTCGTACGCC
TGCCAGAACTCGAAGCTGCTGAACGACCTCCTCAAGAACGAGCTTGGGTTTCAGGGCTTC
GTCATGAGCGACTGGTGGGCACAGCACACTGGCGCAGCAAGCGCCGTGGCTGGTCTCGA
TATGTCCATGCCGGGCGACACCATGGTCAACACTGGCGTCAGTTTCTGGGGCGCCAATCT
CACCCTCGCCGCTCTCAACGGCACAGTCCCTGCCTACCGTCTCGACGACATGTGCATGT
CATCTGGCCGCCCTCTTCAAGGTCACCAAGACACCGACCTGGAACCGATCAACTTCTC
CTTCTGGACCCGCGACACTTATGGCCCGATCCACTGGGCCGCCAAGCAGGGCTACCAGG
AGATTAATTCCCACGTTGACGTCCGCGCCGACCACGGCAACCTCATCCGGAACATTGCCG
CCAAGGGTACGGTGCTGCTGAAGAATACCGGCTCTCTACCCCTGAACAAGCCAAAGTTC
GTGGCCGT CATCGGCGAGGATGCTGGGCGGAGCCCCAACGGGCCCAACGGCTGCAGCGA
CCGCGGCTGTAACGAAGGCACGCTCGCCATGGGCTGGGGATCCGGCACAGCCAACTATC
CGTACCTCGTTTCCCCCGACGCCGCGCTCCAGGCGCGGGCCATCCAGGACGGCACGAGG
TACGAGAGCGTCTGTCCA ACTACGCCGAGGAAAATACAAAGGCTCTGGTCTCGCAGGC
CAATGCAACCGCCATCGTCTTCGTCAATGCCGACTCAGGCGAGGGCTACATCAACGTGG
ACGGTAACGAGGGGCGACCGTAAGAACCTGACTCTCTGGAACAACGGTGATACTCTGGTC
AAGAACGTCTCGAGCTGGTGCAGCAACACCATCGTCGTCATCCACTCGGTGCGCCCCGGTC
CTCCTGACCGATTGGTACGACAACCCCAACATCACGGCCATTCTCTGGGCTGGTCTTCCG
GGCCAGGAGTCGGGCAACTCCATCACCGACGTGCTTTACGGCAAGGTCAACCCCGCCGC
CCGCTCGCCCTTCACTTGGGGCAAGACCCGCGAAAGCTATGGCGCGGACGTCTGTACA
AGCCGAATAATGGCAATTGGGCGCCCCAACAGGACTTCACCGAGGGCGTCTTCATCGAC
TACCGCTACTTCGACAAGGTTGACGATGACTCGGT CATCTACGAGTTCGGCCACGGCCTG
AGCTACACCACCTTCGAGTACAGCAACATCCGCGTCGTCAAGTCCAACGTCAGCGAGTA
CCGGCCCACGACGGGCACACGATTACGGCCCCGACGTTTGGA ACTTCTCCACCGACCT
CGAGGACTATCTCTTCCCCAAGGACGAGTTCCCTACATCCCGCAGTACATCTACCCGTA
CCTCAACACGACCGACCCCCGGAGGGCCTCGGGCGATCCCCACTACGGCCAGACCGCCG
AGGAGTTCCTCCCGCCCCACGCCACCGATGACGACCCCCAGCCGCTCCTCCGGTCTCTCGG
GCGGAAACTCCCCCGGCGGCAACCGCCAGCTGTACGACATTGTCTACACAATCACGGCC
GACATCACGAATACGGGCTCCGTTGTAGGCGAGGAGGTACCGCAGCTCTACGTCTCGCT
GGGCGGTCCCAGGATCCCAAGGTGCAGCTGCGCGACTTTGACAGGATGCGGATCGAAC
CCGGCGAGACGAGGCAGTTACCGGCCGCTGACGCGCAGAGATCTGAGCAACTGGGAC
GTCACGGTGCAGGACTGGGT CATCAGCAGGTATCCCAAGACGGCATATGTTGGGAGGAG
CAGCCGGAAGTTGGATCTCAAGATTGAGCTTCTTGATAAGTCGACCTCGACTTTGTTC
CACTGTACTTTT GACTCGTACAAAATACAATACTTTTCA TTTCTCCGTAAACAACATGT
TTTCCCATGTAATATCCTTTTCTATTTTTCGTTCCGTTACCAACTTTACACATACTTTATAT
AGCTATTCAC TTTCTATACACTAAAAAACTAAGACAATTTTAATTTTGCTGCCTGCCATATT

TCAATTTGTTATAAATTCCTATAATTTATCCTATTAGTAGCTAAAAAAGATGAATGTGA
ATCGAATCCTAAGAGAATTGGATCTGATCCACAGGACGGGTGTGGTCGCCATGATCGCG
TAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTG
GGACAGTGTCTCCGAGAACGGGTGCGCATAGAAATTGCATCAACGCATATAGCGCTAGCA
GCACGCCATAGTGA CTGGCGATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGC
AGTACCGGCATAACCAAGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGAC
GATGAGCGCATTGTTAGATTTTCATACACGGTGCCTGACTGCGTTAGCAATTTAACTGTGA
TAAACTACCGCATTAAGGCTTTTTCTTTCCAATTTTTTTTTTTTCGTCATTATAAAAAATCAT
TACGACCGAGATTCCCGGGTAATAACTGATATAATTAATTGAAGCTCTAATTTGTGAGT
T TAGTATACATGCATTTACTTATAATACAGTTTTTTAGTTTTTGCTGGCCGCATCTTCTCAA
ATATGCTTCCCAGCCTGCTTTTCTGTAACGTTTACCCTCTACCTTAGCATCCCTTCCCTTTG
CAAATAGTCCCTCTTCCAACAATAATAATGTCAGATCCTGTAGAGACCACATCCACAGG
TTCTATACTGTTGACCCAATGCGTCTCCCTTGTCATCTAAACCCACACCGGGTGTCATAAT
CAACCAATCGTAACCTTCATCTCTTCCACCCATGTCTCTTTGAGCAATAAAGCCGATAAC
AAAATCTTTGTGCTCTTTCGCAATGTCAACAGTACCCTTAGTATAATTCTCCAGTAGATAG
GGAGCCCTTGCATGACAATTCTGCTAACATCAAAAAGGCCTCTAGGTTCCCTTTGTTACTTCT
TCTGCCGCTGCTTCAAACCGCTAACAATACCTGGGCCACCACACCGTGTGCATTCTGTA
ATGTCTGCCCATTTCTGCTATTCTGTATACACCCGCAGAGTACTGCAATTTGACTGTATTAC
CAATGTCAGCAAATTTTCTGTCTTTCGAAGAGTAAAAAATTGTACTTGGCGGATAATGCCT
TTAGCGGCTTAACTGTGCCCTCCATGGAAAAATCAGTCAAGATATCCACATGTGTTTTTA
GTAAACAAATTTTGGGACCTAATGCTTCAACTAACTCCAGTAATTCCTTGGTGGTACGAA
CATCCAATGAAGCACACAAGTTTGTGTTTTCTGTCATGATATTAAATAGCTTGGCAG
CAACAGGACTAGGATGAGTAGCAGCACGTTCCCTTATATGTAGCTTTCGACATGATTTATC
TTCGTTTTCTGCAGGTTTTTGTCTGTGCAAGTTGGGTTAAGAATACTGGGCAATTTTCATGT
TTCTTCAACACTACATATGCGTATATATACCAATCTAAGTCTGTGCTCCTTCTCTGTTCT
TCCTTCTGTTGCGAGATTACCGAATCAAAAAAATTTCAAGGAAACCGAAATCAAAAAA
AGAATAAAAAAATGATGAATTGAAAAGCTTATCGATCCTACCCCTTGCGCTAAAGA
AGTATATGTGCCTACTAACGCTTGTCTTTGTCTCTGTCACTAAACACTGGATTATTACTCC
CAGATACTTATTTTGGACTAATTTAAATGATTTCCGGATCAACGTTCTTAATATCGCTGAAT
CTTCCACAATTGATGAAAGTAGCTAGGAAGAGGAATTGGTATAAAGTTTTTGTGTTTGTGTA
AATCTCGAAGTATACTCAAACGAATTTAGTATTTTCTCAGTGATCTCCAGATGCTTTTCC
CCTCACTTAGAAGTGCTTTAAGCATTTTTTTTACTGTGGCTATTTCCCTTATCTGCTTCTTCC
GATGATTCGAAGTGAATTGCAAACACTTACAATATCAGTGATATCAGATTGATGTTTT
TGTCCATAGTAAGGAATAATTGTAAATCCCAAGCAGGAATCAATTTCTTTAATGAGGCT
TCCAGAAATTGTTGCTTTTTGCGTCTTGTATTTAACTGGAGTGATTTATTGACAATATCGA
AACTCAGCGAATTGCTTATGATAGTATTATAGCTCATGAATGTGGCTCTCTTGATTGCTGT
TCCGTTATGTGTAATCATCCAACATAAATAGGTTAGTTCAGCAGCACATAATGCTATTTT
CTCACCTGAAGGTCTTTCAAACCTTTCCACAACTGACGAACAAGCACCTTAGGTGGTGT
TTTACATAATATATCAAATTGTGGCATGCTTAGCGCCGATCTTGTGTGCAATTGATATCTA
GTTTCAACTACTCTATTTATCTTGTATCTTGCAGTATTCAAACACGCTAACTCGAAAAACT
AACTTTAATTGTCTGTTTGTCTCGCGTCTTTTCGAAAAATGCACCGGCCGCGCATTATTT
GTACTGCGAAAAATAATTGGTACTGCGGTATCTTCATTTTCATATTTTAAAAATGCACCTTTG
CTGCTTTTCTTAAATTTTTAGACGGCCCGCAGGTTTCGTTTTGCGGTACTATCTTGTGATAA
AAAGTTGTTTTGACATGTGATCTGCACAGATTTTATAATGTAATAAGCAAGAATACATTA
TCAAACGAACAATACTGGTAAAAGAAAACCAAAATGGACGACATTGAAACAGCCAAGA
ATCTGACGGTAAAAGCACGTACAGCTTATAGCGTCTGGGATGTATGTGGCTGTTTATTG
AAATGATTGCTCCTGATGTAGATATTGATATAGAGAGTAAACGTAAGTCTGATGAGCTAC
TCTTTCCAGGATATGTCATAAGGCCCATGGAATCTCTCACAAACCGGTAGGCCGTATGGTC
TTGATTCTAGCGCAGAAGATTCCAGCGTATCTTCTGACTCCAGTGCTGAGGTAATTTTGC
CTGCTGCGAAGATGGTTAAGGAAAGGTTTGATTTCGATTGGAAATGGTATGCTCTCTTAC
AAGAAGCAAGTCAGGCTGCCATAGATTTGATGCTACAGAATAACAAGCTGTTAGACAA
AGAAGAGCTATACAAATCTATTGCTATAATAATAGGAAGATTGCCCGAGAAAGACAA
GAAGAGAGCTACCGAAATGCTCATGAGAAAAATGGATTGTACACAGTTATTAGTCCAC
CAGCTCCAACGGAAGAAGATGTTATGAAGCTCGTAAGCGTCGTTACCCAATTGCTTACTT
TAGTTCCACCAGATCGTCAAGCTGCTTTAATAGGTGATTTATTCATCCCGAATCTCTAA

AGGATATATTCAATAGTTTCAATGAACTGGCGGCAGAGAATCGTTTACAGCAAAAAAAG
AGTGAGTTGGAAGGAAGGACTGAAGTGAACCATGCTAATACAAATGAAGAAGTTCCCTC
CAGGCGAACAAGAAGTAGAGACACAAATGCAAGAGGAGCATATAAATTACAAAACACC
ATCACTGAGGGCCCTAAAGCGGTTCCACGAAAAAAGGAGAGTAGCAACGAGGGTAA
GGGGCAGAAAAATCACGTAATACTTCTAGGGTATGATCCAATATCAAAGGAAATGATAGC
ATTGAAGGATGAGACTAATCCAATTGAGGAGTGGCAGCATATAGAACAGCTAAAGGGTA
GTGCTGAAGGAAGCATACGATACCCCGCATGGAATGGGATAATATCACAGGAGGTACTA
GACTACCTTTTCATCCTACATAAATAGACGCATATAAGTACGCATTTAAGCATAAACACGC
ACTATGCCGTTCTTCTCATGTATATATATACAGGCAACACGCAGATATAGGTGCGACG
TGAACAGTGAGCTGTATGTGCGCAGCTCGCGTTGCATTTTCGGAAGCGCTCGTTTTCGGA
AACGCTTTGAAGTTCTATTCCGAAGTTCTATTCTCTAGAAAAGTATAGGAACTTCAGAG
CGCTTTTGAAAACCAAAAGCGCTCTGAAGACGCACCTTTCAAAAAACCAAAACGCACCG
GACTGTAACGAGCTACTAAAATATTGCGAATACCGCTTCCACAAACATTGCTCAAAAAGTA
TCTCTTTGCTATATATCTCTGTGCTATATCCCTATATAACCTACCCATCCACCTTTTCGCTCC
TTGAACTTGCATCTAACTCGACCTCTACATCAACAGGCTTCCAATGCTCTTCAAATTTTA
CTGTCAAGTAGACCCATACGGCTGTAATATGCTGCTCTTCATAATGTAAGCTTATCTTTAT
CGAATCGTGTGAAAACTACTACCGCGATAAACCTTTACGGTTCCTGAGATTGAATTAG
TTCCTTTAGTATATGATACAAGACACTTTTGAACCTTTGTACGACGAATTTTGAGGTTTCGCC
ATCCTCTGGCTATTTCCAATTATCCTGTGCGCTATTATCTCCGCCTCAGTTTGATCTTCCGC
TTCAGACTGCCATTTTTCACATAATGAATCTATTTACCCCAACAATCCTTCATCCGCCTCC
GCATCTTGTTCCGTTAAACTATTGACTTCATGTTGTACATTGTTTAGTTACAGAGAAGGGT
CCTCTTCAGGCGGTAGCTCCTGATCTCCTATATGACCTTTATCCTGTTCTCTTTCCACAAA
CTTAGAAATGTATTCATGAATTATGGAGCACCTAATAACATTCTTCAAGGCGGAGAAGTT
TGGGCCAGATGCCCAATATGCTTGACATGAAAACGTGAGAATGAATTTAGTATTATTGTG
ATATTCTGAGGCAATTTTATTATAATCTCGAAGATAAGAGAAGAATGCAGTGACCTTTGT
ATTGACAAATGGAGATTCCATGTATCTAAAAAATACGCCTTTAGGCCTTCTGATACCCCT
TCCCCTGCGGTTTAGCGTGCCCTTTTACATTAATATCTAAACCCTCTCCGATGGTGCCCTT
AACTGACTAATAAATGCAACCGATATAAACTGTGATAATTCTGGGTGATTTATGATTTCGA
TCGACAAATTGTATTGTACACTAGTGCAGGATCAGGCCAATCCAGTTCTTTTTCAATTACC
GGTGTGTCGTCTGTATTACGTACATGTCCAACAAATGCAAATGCTAACGTTTTGTATTTCT
TATAATTGTCAGGAACTGGAAAAGTCCCCCTTGTCGTCTCGATTACACACCTACTTTTCATC
GTACACCATAGGTTGGAAGTGCTGCATAATACATTGCTTAATACAAGCAAGCAGTCTCTC
GCCATTTCATATTTTCAGTTATTTTCCATTACAGCTGATGTCATTGTATATCAGCGCTGTAAA
AATCTATCTGTTACAGAAGGTTTTTCGCGGTTTTTATAAAACAAAACCTTTTCGTTACGAAATC
GAGCAATCACCCAGCTGCGTATTTTGAAATTCGGGAAAAAGTAGAGCAACGCGAGTTG
CATTTTTTACACCATAATGCATGATTAACCTTCGAGAAGGGATTAAGGCTAATTTCACTAG
TATGTTTTCAAAAACCTCAATCTGTCCATTGAATGCCTTATAAAACAGCTATAGATTGCAT
AGAAGAGTTAGCTACTCAATGCTTTTGTCAAAGCTTACTGATGATGATGTGTCTACTTTC
AGGCGGGTCTGTAGTAAGGAGAATGACATTATAAAGCTGGCACTTAGAATTCACGGAC
TATAGACTATACTAGTATACTCCGTCTACTGTACGATACACTTCCGCTCAGGTCCTTGTC
TTAACGAGGCCTTACCACTCTTTTGTACTCTATTGATCCAGCTCAGCAAAGGCAGTGTG
ATCTAAGATTCTATCTTCGCGATGTAGTAAACTAGCTAGACCGAGAAAGAGACTAGAA
ATGCAAAAGGCACCTTCTACAATGGCTGCCATCATTATTATCCGATGTGACGCTGCA (SEQ
ID NO:7)

Polynucleotide sequence of Variant No. 73 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTCATGGA
GATGGCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTCCAGAAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTACGCTTGCAAACTACGTACACAGCAAGGGTCTAAAG
TTAGGCATCTACGCTGATGTGCGAACAAGACATGTGCTGGTTTCCAGGTTTCATCCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTTGTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT

CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGACATGTGGCCG
TTTCAGAAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTCTATA
GGGAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGCACCCCTATTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACCTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGCGTGGGC
TGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAAGGGTGTGCGTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATGAGTGGACATCTAGGCTAAGAAGTCACATCAATCCTACT
GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTGTGTA
(SEQ ID NO:8)

Polynucleotide sequence of Variant No. 73:

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCCTGCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTCAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCCTCATGGGATTCGCCAGCTAGCTAATTATGTTACAGCAAAGGACTGAA
GCTAGGGATTTATGCAGATGTTGGAAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
ATACTACGACATTGATGCCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAAATTTGA
TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGGC
CCTGAATAGGACTGGCAGAAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
CTTTCAAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAATTTTGC
TGACATTGATGATTCTGGGCGAGTATAAAGAGTATCTTGGACTGGACATCTTTTAAACCA
GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTTGGAATGACCCAGATATGTTAGTGA
TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAACTCAGATGGCCCTCTGGGCTATCA
TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
AGCTTAGACAGGGAGACAACCTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
GCTGTAGCTATGATAAACCGGCAGGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCCTGCTTCATCACACAGCTCCTCCCT
GTGAAAAGGAAGCTAGGGTTCTATGAATGGACTTCAAGGTTAAGAAGTCACATAAATCC
CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGAGACTTACT
T (SEQ ID NO:9)

Polypeptide sequence of Variant No. 73:

LDNGLARTPTMGWLHWERFMCNLDQEEPDCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMA PQRDSEGR LQADPQRFPHGIRQLANYVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGV DLLKFDGCYCD SLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSFNQERIVDVAGPGGWNDPDLVIGNFG
LSWNQQVTQMALWAIMAAPLFMSNDLRHISPAKALLQDKDVIAINQDPLGKQGYQLRQG
DNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGF
YEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO:10)

Polynucleotide sequence of Variant No. 218 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAAACTATTCATGGA
GATGGCTGAACATAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTGAGAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCACATGGCATAACGTCAGCTTGCAAACTACGTACACAGCAAGGGTCTAAAG

TTAGGCATCTACGCTGATGTCGGAAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCCGGT
TACTATGACATAGATGCGCAGACGTTTGTCTGATTGGGGTGTTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGATCATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTGGCGTAACTTTGCT
GACATAGATGATTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTCTATA
GGGAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGCACCCCTATTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGGCTGGGC
TGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATAACTGGACATCTAGGCTAAAAAGTCACATTAATCCTACT
GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTTGTGA
(SEQ ID NO:11)

Polynucleotide sequence of Variant No. 218 hCDS:

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCTGTCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTCAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCCTCATGGGATTCGCCAGCTAGCTAATTATGTTTACAGCAAAGGACTGAA
GCTAGGGATTTATGCAGATGTTGGAAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
ATACTACGACATTTGATGCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAAATTTGA
TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGGC
CCTGAATAGGACTGGCAGAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
CTTTCAAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAATTTTGC
TGACATTGATGATTCTGGGCGAGTATAAAGAGTATCTTGGACTGGACATCTTTTAACCA
GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTTGGAATGACCCAGATATGTTAGTGA
TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAAGTCAAGTGGCCCTCTGGGCTATCA
TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
AGCTTAGACAGGGAGACAACTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
GCTGTAGCTATTATAAACCAGGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCCTGCTTCATCACACAGCTCCTCCCT
GTGAAAAGGAAGCTAGGGTTCTATAACTGGACTTCAAGGTAAAAAGTCACATAAATCC
CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGAGACTTACT
T (SEQ ID NO:12)

Polypeptide sequence of Variant No. 218:

LDNGLARTPTMGWLHWERFMCNLDQEEPDCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLQADPQRFPHGIRQLANYVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSFNQERIVDVAGPGGWNDPDLVIGNFG
LSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQG
DNFEVWERPLSGLAWAVAIINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFY
NWTSLRLKSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO:13)

Polynucleotide sequence of Variant No. 326 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTTCATGGA

GATGGCTGAACGGATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCTACGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGACATGTGGCCG
TTTCAGAAAGCCAAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTTCATGGGCTTCAATCAAATCTATCTTGATTGGACTTCTCGTAACCAAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGCTATA
GGGAACTTTGGGCTATCATGGGACCAACAAGTTACACAAATGGCTTTGTGGGCGATCAT
GGCCGCACCCCTATTTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTT
ACTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGTTAAACAAGGTTATCA
ATTGAGAAAAGGTGACAACTTTGAAGTGTGGGAAAGACCATTGTCTGGAGATGCGTGGG
CTGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCCCGGTAG
CCTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGT
TAAGAGACAATTGGGTTTCTATAACTGGACCTCTAGGCTAAAAAGTCACATTAATCCTAC
TGGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTGTGTA
(SEQ ID NO:14)

Polypeptide sequence of Variant No. 326:

LDNGLARTPTMGWLHWERFMCNLDQEEPDCISEKLFMEMAERMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLQADPQRFPHGIRQLANYVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRSIVYSEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSRNQERIVDVAGPGGWNPDMLVIGNF
GLSWDQQVTQMALWAIMAAPLFMSNDLRHISPAKALLQDKDVIAINQDPLGKQGYQLRK
GDNFEVWERPLSGDAWAVAIINRQEIGGPRSYTIPVASLGKGVACNPACFITQLLPVKRQLGF
YNWTSRLKSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO:15)

Polynucleotide sequence of Variant No. 206 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTCATGGA
GATGGCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCTACGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGACATGTGGCCG
TTTCAGAAAGCCAAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTTCATGGGCTTCAATCAAATCTATCTTGATTGGACTTCTTTCAACCAAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGCTATA
GGGAACTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGCACCCCTATTTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGTTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGCGTGGGC
TGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATAATTGGACCTCTAGGCTAAGAAGTCACATCAATCCTACT
GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTGTGTA
(SEQ ID NO:16)

Polynucleotide sequence of Variant No. 206 hCDS:

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCCTGCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTGAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCCTCATGGGATTGCGCAGCTAGCTAATTATGTTACAGCAAAGGACTGAA
GCTAGGGATTTATGCAGATGTTGAAAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
ATACTACGACATTGATGCCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAAATTTGA
TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGGC
CCTGAATAGGACTGGCAGAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
CTTTCAAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAAATTTTGC
TGACATTGATGATTCTGGGCGAGTATAAAGAGTATCTTGGACTGGACATCTTTTAACCA
GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTGGAAATGACCCAGATATGTTAGTGA
TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAACTCAGATGGCCCTCTGGGCTATCA
TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
AGCTTAGACAGGGAGACAACTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
GCTGTAGCTATGATAAACCAGGAGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCTGCTTCATCACACAGCTCCTCCCT
GTGAAAAGGAAGCTAGGGTTCTATAACTGGACTTCAAGGTTAAGAAGTCACATAAATCC
CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGAACTTACT
T (SEQ ID NO:17)

Polypeptide sequence of Variant No. 206:

LDNGLARTPTMGWLHWERFMCNLDCQEEPSCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMA PQRDSEGR LQADPQRFP HIRQLANYVH SKGLKLG IYADVGNKTCAGFPGSFGYY
DIDAQTFADWGV DDLKFDG CYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSFNQERIVDVAGPGGWNDPDM LVIGNFG
LSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIINQDPLGKQGYQLRQG
DNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGF
YNWTSRLRSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO:18)

Polynucleotide sequence of Variant No. 205 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTCATGGA
GATGGCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTGAGAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCACATGGCATAACGTCAGCTTGCAAACTACGTACACAGCAAGGGTCTAAAG
TTAGGCATCTACGCTGATGTCCGAAACAAGACATGTGCTGGTTTCCCAGGTTCAATCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTGGCGTAACCTTTGCT
GACATAGATGATTGCTGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTCATA
GGGAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGCACCCCTATTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACCTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGCGTGGGC
TGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAAGGGTGTGCGTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATGATTGGGACTCTAGGCTAAGAAGTCACATCAATCCTACT

GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTTGTTA
(SEQ ID NO: 19)

Polynucleotide sequence of Variant No. 205 hCDS:

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCCTGCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTCAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCTCATGGGATTCGCCAGCTAGCTAATTATGTTACAGCAAAGGACTGAA
GCTAGGGATTTATGCAGATGTTGGAAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
ATACTACGACATTGATGCCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAATTTGA
TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGCC
CCTGAATAGGACTGGCAGAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
CTTTCAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAATTTTGC
TGACATTGATGATTCTGGGCGAGTATAAAGAGTATCTTGGACTGGACATCTTTTAACCA
GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTTGGAATGACCCAGATATGTTAGTGA
TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAACTCAGATGGCCCTCTGGGCTATCA
TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
AGCTTAGACAGGGAGACAACCTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
GCTGTAGCTATGATAAACCGGCAGGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCCTGCTTCATCACACAGCTCCTCCCT
GTGAAAAGGAAGCTAGGGTTCTATGATTGGGATTCAAGGTAAAGAAGTCACATAAATCC
CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGACTTACT
T (SEQ ID NO: 20)

Polypeptide sequence of Variant No. 205:

LDNGLARTPTMGWLHWERFMCNLDQEEPDSICSEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLADPQRFPHGIRQLANYVHSGKLGKLIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSFNQERIVDVAGPGGWNDPMLVIGNFG
LSWNQQVTQMALWAIMAAPLFMSNDLRHISPAKALLQDKDVIAINQDPLGKQGYQLRQG
DNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGF
YDWDSRLRSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO: 21)

Polynucleotide sequence of Variant No. 76 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAAACTATTTCATGGA
GATGGCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTGAGAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACTACGTACACAGCAAGGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACTTTGCT
GACATAGATGATTTCATGGAGGTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGATA
GGGAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATG
GCCGACCCCTATTTCATGTCTAATGATCTACGTACATATCACCCCAAGCAAAGGCTTTA
CTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAA
TTGAGACAAGGTGACAACCTTTGAAGTGTGGGAAGACCATTGTCTGGACTTGCCTGGGC

TGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGC
CTCTTTGGGTAAAGGGTGTGCGTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTT
AAGAGAAAGTTGGGTTTCTATGAGTGGACATCTAGGCTAAGAAGTCACATCAATCCTACT
GGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTTGTTA
(SEQ ID NO: 22)

Polynucleotide sequence of Variant No. 76 hCDS:

CTGGACAATGGATTGGCAAGGACGCCTACCATGGGCTGGCTGCACTGGGAGCGCTTCAT
GTGCAACCTTGACTGCCAGGAAGAGCCAGATTCTGCATCAGTGAGAAGCTCTTCATGG
AGATGGCAGAGCTCATGGTCTCAGAAGGCTGGAAGGATGCAGGTTATGAGTACCTCTGC
ATTGATGACTGTTGGATGGCTCCCCAAAGAGATTGAGAAGGCAGACTTCAGGCAGACCC
TCAGCGCTTTCCTCATGGGATTGCGCAGCTAGCTAATTATGTTTCACAGCAAAGGACTGAA
GCTAGGGATTTATGCAGATGTTGGAATAAAACCTGCGCAGGCTTCCCTGGGAGTTTTGG
ATACTACGACATTGATGCCCAGACCTTTGCTGACTGGGGAGTAGATCTGCTAAAATTTGA
TGGTTGTTACTGTGACAGTTTGGAAAATTTGGCAGATGGTTATAAGCACATGTCCTTGGC
CCTGAATAGGACTGGCAGAAGCATTGTGTACTCCTGTGAGTGGCCTCTTTATATGTGGCC
CTTTCAAAGCCCAATTATACAGAAATCCGACAGTACTGCAATCACTGGCGAAAATTTTGC
TGACATTGATGATTCTGGCGTAGTATAAAGAGTATCTTGGACTGGACATCTTTTAACCA
GGAGAGAATTGTTGATGTTGCTGGACCAGGGGGTTGGAATGACCCAGATATGTTAGTGA
TTGGCAACTTTGGCCTCAGCTGGAATCAGCAAGTAACTCAGATGGCCCTCTGGGCTATCA
TGGCTGCTCCTTTATTCATGTCTAATGACCTCCGACACATCAGCCCTCAAGCCAAAGCTCT
CCTTCAGGATAAGGACGTAATTGCCATCAATCAGGACCCCTTGGGCAAGCAAGGGTACC
AGCTTAGACAGGGAGACAACCTTTGAAGTGTGGGAACGACCTCTCTCAGGCTTAGCCTGG
GCTGTAGCTATGATAAACCAGGAGATTGGTGGACCTCGCTCTTATACCATCGCAGTT
GCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCTGCCTGCTTCATCACACAGCTCCTCCCT
GTGAAAAGGAAGCTAGGGTTCTATGAATGGACTTCAAGGTAAAGAAGTCACATAAATCC
CACAGGCACTGTTTTGCTTCAGCTAGAAAATACAATGCAGATGTCATTAAGAACTTACT
T (SEQ ID NO: 23)

Polypeptide sequence of Variant No. 76:

LDNGLARTPTMGWLHWERFMCNLDQEEPSCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMA PQRDSEGR LQADPQRFP HIRQLANYVH SKGLKLG IYADVGNKTCAGFP GSFGYY
DIDAQTFADWGV DLLKFDG CYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWP FQ
KPNYTEIRQYCNHWRNFADIDDSWRSIKSILDWTSFNQERIVDVAGPGGWNDP DMLVIGNFG
LSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQG
DNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIASVSLGKGVACNPACFITQLLPVKRKLGF
YEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO: 24)

Polynucleotide sequence of Mfalpa signal peptide:

ATGAGATTTCTTCAATTTTTACTGCAGTTTTATTTCGCAGCATCCTCCGCATTAGCT (SEQ
ID NO: 25)

Polypeptide sequence of Mfalpa signal peptide:

MRFPSIFTAVLFAASSALA (SEQ ID NO: 26)

Polynucleotide sequence of MMO435:

ttactatatcgaatacacagatccaccATGAGATTTCTTCAATTTTTACTG (SEQ ID NO: 27)

Polynucleotide sequence of MMO439:

AGTAGGTGTACGGGCTAACCCGTTATCCAAAGCTAATGCGGAGGATGC (SEQ ID NO: 28)

Polynucleotide sequence of MMO514:

TTTTACTGCAGTTTTATTTCGCAGCATCCTCCGCATTAGCTTTGGATAACGGGTTAGCCCCG
(SEQ ID NO: 29)

Polynucleotide sequence of MMO481:

GAGCTAAAAGTACAGTGGGAACAAAGTCGAGGTCGACTTATAACAAATCTTTCAAAGAC
A (SEQ ID NO: 30)

Polynucleotide sequence of Synthetic mammalian signal peptide:

ATGGAATGGAGCTGGGTCTTTCTTCTTCTCCTGTCAGTAACGACTGGTGTCCACTCC (SEQ
ID NO: 31)

Polynucleotide sequence of LAKE Fw:

CGATCGAAGCTTCGCCACCA (SEQ ID NO: 32)

Polynucleotide sequence of Br reverse:

CTTGCCAATCCATTGTCCAGGGAGTGGACACCAGTCGTTA (SEQ ID NO: 33)

Polynucleotide sequence of Br Fw:

TAACGACTGGTGTCCACTCCCTGGACAATGGATTGGCAAG (SEQ ID NO: 34)

Polynucleotide sequence of hGLA Rv:

CGATCGGCGGCCGCTCAAAGTAAGTCTTTTAATGACA (SEQ ID NO: 35)

Polynucleotide sequence of SP-GLA (yCDS):

ATGAGATTTTCCTTCAATTTTTACTGCAGTTTTATTTCGCAGCATCCTCCGCATTAGCTTTGG
ATAACGGGTTAGCCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTCATGTGTGA
ACTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTCATGGAGATG
GCTGAACTAATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTATTGA
TGATTGCTGGATGGCTCCACAGCGTGATTGAGAAGGTAGGTTACAAGCTGACCCCCAGA
GATTCCCACATGGCATAACGTCAGCTTGCAAACCTACGTACACAGCAAGGGTCTAAAGTTA
GGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCGGTTAC
TATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTTGTTGAAGTTTGATGGA
TGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCTCTA
AACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCGTTT
CAGAAGCCAACTACACTGAGATAAGACAATACTGTAAACCATTTGGCGTAACTTTGCTGA
CATAGATGATTTCATGGAAGTCAATCAAATCTATCTTGGATTGGACTTCTTTCAACCAGGA
AAGAAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTTCATAGG
GAACCTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTTTGTGGGCGATCATGGC
CGCACCCCTATTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTTACT
TCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCAATT
GAGACAAGGTGACAACCTTTGAAGTGTGGGAAAGACCATTGTCTGGACTTGCGTGGGCTG
TTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCGCGGTAGCCT

CTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGTTAA
GAGAAAGTTGGGTTTCTATGAGTGGACATCTAGGCTAAGAAGTCACATCAATCCTACTGG
TACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTTGTTA (SEQ
ID NO: 36)

Polynucleotide Sequence of MFleader-GLA (yCDS):

ATGAGATTTCTTCAATTTTTACTGCAGTTTTATTCGCAGCATCCTCCGCATTAGCTGCTC
CAGTCAACACTACAACAGAAGATGAAACGGCACAAATTCGGGCTGAAGCTGTCATCGGT
TACTTAGATTTAGAAGGGGATTTGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAAT
AACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTA
TCTTTGGATAAAAGATTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCAC
TGGGAAAGATTGATGTTGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGA
GAAACTATTTCATGGAGATGGCTGAACATAATGGTAAGTGAAGGATGGAAGGATGCTGGTT
ATGAATACCTATGTATTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAGGTAGGT
TACAAGCTGACCCCCAGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCTACGTACACA
GCAAGGGTCTAAAGTTAGGCATCTACGCTGATGTCGGAAACAAGACATGTGCTGGTTTCC
CAGGTTTCATTTCGGTTACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATT
TGTTGAAGTTTGATGGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAAC
ACATGAGTTTGGCTCTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCT
TGACATGTGGCCGTTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATT
GGCGTAACTTTGCTGACATAGATGATTCATGGAAGTCAATCAAATCTATCTTGGATTGGA
CTTCTTTCAACCAGGAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCCTG
ATATGCTTGTCATAGGGAACTTTGGGCTATCATGGAATCAACAAGTTACACAAATGGCTT
TGTGGGCGATCATGGCCGCACCCCTATTTCATGTCTAATGATCTACGTCACATATCACCCC
AAGCAAAGGCTTTACTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGTTA
AACAAGGTTATCAATTGAGACAAGGTGACAACCTTGAAGTGTGGGAAAGACCATTGTGTT
GGACTTGCGTGGGCTGTTGCTATGATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTA
CACTATCGCGGTAGCCTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTAC
ACAATTGCTTCCAGTTAAGAGAAAGTTGGGTTTCTATGAGTGGACATCTAGGCTAAGAAG
TCACATCAATCCTACTGGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTT
GAAAGATTTGTTA (SEQ ID NO: 37)

Polypeptide Sequence of MFleader:

MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVL PFSNSTNGLL
FINTTASIAAKEEGVSLDKR (SEQ ID NO: 38)

Polynucleotide sequence of Variant No. 395 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAAACTATTTCATGGA
GATGGCTGAACGGATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCATGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTGTTGTAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGAGCATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTGGCGTAACTTTGCT
GACATAGATGATTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTCGTAACCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTCATA
GGGAACCTTTGGGCTATCATGGGACCAAGTTACACAAATGGCTTTGTGGGCGATCA
GGCCGCACCCCTATTTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTT
ACTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCA

ATTGAGAAAAGGTGACAACTTTGAAGTGTGGGAAAAGACCATTGTCTGGAGATGCGTGGG
CTGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCCCGGTAG
CCTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGT
TAAGAGACAATTGGGTTTCTATAACTGGACCTCTAGGCTAAAAAGTCACATTAATCCTAC
TGGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTGTGA
(SEQ ID NO: 39)

Polypeptide sequence of Variant No. 395:

LDNGLARTPTMGWLHWERFMCNLDQEEPDSCISEKLFMEMAERMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLADPQRFPHGIRQLANHVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSRNQERIVDVAGPGGWNDPMDLVIGNF
GLSWDQQVTQMALWAIMAAPLFMSNDRHISPQAKALLQDKDVIAINQDPLGKQGYQLRK
GDNFEVWERPLSGDAWAVAIINRQEIGGPRSYTIPVASLGKGVACNPACFITQLLPVKRQLGF
YNWTSRLKSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO: 40)

Polynucleotide sequence of Variant No. 402 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTTCATGGA
GATGGCTGAACGGATGGTAAGTGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTGAGAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACTACGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTGTTGTAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGCCGATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAGCCAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTCGTAACCA
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGATA
GGGAACCTTTGGGCTATCATGGGACCAACAAGTTACACAAATGGCTTTGTGGGCGATCAT
GGCCGCACCCCTATTTCATGTCTAATGATCTACGTCACATATCACCCCAAGCAAAGGCTTT
ACTTCAAGATAAGGATGTCATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCA
ATTGAGAAAAGGTGACAACTTTGAAGTGTGGGAAAAGACCATTGTCTGGAGATGCGTGGG
CTGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCCCGGTAG
CCTCTTTGGGTAAGGGTGTTCGCTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGT
TAAGAGACAATTGGGTTTCTATAACTGGACCTCTAGGCTAAAAAGTCACATTAATCCTAC
TGGTACGGTATTGTTGCAATTGGAGAACACAATGCAAATGTCTTTGAAAGATTGTGA
(SEQ ID NO: 41)

Polypeptide sequence of Variant No. 402:

LDNGLARTPTMGWLHWERFMCNLDQEEPDSCISEKLFMEMAERMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLADPQRFPHGIRQLANYVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRPIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSRNQERIVDVAGPGGWNDPMDLVIGNF
GLSWDQQVTQMALWAIMAAPLFMSNDRHISPQAKALLQDKDVIAINQDPLGKQGYQLRK
GDNFEVWERPLSGDAWAVAIINRQEIGGPRSYTIPVASLGKGVACNPACFITQLLPVKRQLGF
YNWTSRLKSHINPTGTVLLQLENTMQMSLKDLL (SEQ ID NO: 42)

Polynucleotide sequence of Variant No. 625 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTACTATGGGTTGGCTTCACTGGGAAAAGATTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTTCATGGA

GATGGCTGAACGGATGGTAACCGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCATGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGCCGATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAAGCCAAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTCGTAACCCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGCTATA
GGGAACCTTTGGGCTATCATGGGACCAACAAGTTACACAAATGGCTTTGTGGGCGATCAT
GGCCGCACCCCTATTTCATGTCTAATGATCTACGTGCGATATCACCCCAAGCAAAGGCTTT
ACTTCAAGATAAGGATGTGATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCA
ATTGAGAAAAGGTGACAACCTTTGAAGTGTGGGAAAGACCATTGTCTGGAGATGCGTGGG
CTGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCCCGGTAG
CCTCTTTGGGTAAGGGTGTGCGTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGT
TAAGAGACAATTGGGTTTCTATAACTGGACCTCTAGGCTAAAAAGTCACATTAATCCTAC
TGGTACGGTATTGTTGCAATTGGAGAACAATGCAAACCTCTTTGAAAGATTGTGTA
(SEQ ID NO: 43)

Polypeptide sequence of Variant No. 625:

LDNGLARTPTMGWLHWERFMCNLDQEEPSCISEKLFMEMAERMVTEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLQADPQRFPHGIRQLANHVHSGKLGKIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRPIVYSCEWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSRNQERIVDVAGPGGWNDPMDLVIGNF
GLSWDQQVTQMALWAIMAAPLFMSNDLRAISPQAKALLQDKDVIAINQDPLGKQGYQLRK
GDNFEVWERPLSGDAWAVAIINRQEIGGPRSYTIPVASLGKGVACNPACFITQLLPVKRQLGF
YNWTSRLKSHINPTGTVLLQLENTMQTSLKDLL (SEQ ID NO: 44)

Polynucleotide sequence of Variant No. 648 yCDS:

TTGGATAACGGGTTAGCCCGTACACCTCCGATGGGTTGGCTTCACTGGGAAAGATTTCATG
TGTAACCTTAGATTGCCAAGAAGAGCCTGACAGCTGTATCTCAGAGAACTATTTCGAAGA
GATGGCTGAACGGATGGTAACCGAAGGATGGAAGGATGCTGGTTATGAATACCTATGTA
TTGATGATTGCTGGATGGCTCCACAGCGTGATTTCAGAAAGGTAGGTTACAAGCTGACCCCC
AGAGATTCCCACATGGCATAACGTCAGCTTGCAAACCATGTACACAGCAAAGGTCTAAAG
TTAGGCATCTACGCTGATGTCGGAACAAGACATGTGCTGGTTTCCAGGTTTCATTCGGT
TACTATGACATAGATGCGCAGACGTTTGCTGATTGGGGTGTGATTTGTTGAAGTTTGAT
GGATGCTACTGCGATTCCCTGGAGAACCTAGCCGATGGGTACAAACACATGAGTTTGGCT
CTAAACAGGACTGGTAGGCCGATCGTCTATAGTTGTGAATGGCCCTTGTACATGTGGCCG
TTTCAGAAAGCCAAACTACACTGAGATAAGACAATACTGTAACCATTTGGCGTAACCTTGCT
GACATAGATGATTTCATGGGCTTCAATCAAATCTATCTTGGATTGGACTTCTCGTAACCCAG
GAAAGAATTGTTGATGTTGCAGGTCCAGGTGGATGGAATGACCCTGATATGCTTGTGCTATA
GGGAACCTTTGGGCTATCATGGGACCAACAAGTTACACAAATGGCTTTGTGGGCGATCAT
GGCCGGCCCCCTATTTCATGTCTAATGATCTACGTGCGATATCACCCCAAGCAAAGGCTTT
ACTTCAAGATAAGGATGTGATAGCGATCAACCAAGATCCTCTTGGTAAACAAGGTTATCA
ATTGAGAAAAGGTGACAACCTTTGAAGTGTGGGAAAGACCATTGTCTGGAGATGCGTGGG
CTGTTGCTATTATCAACCGTCAAGAGATCGGAGGGCCAAGATCTTACACTATCCCGGTAG
CCTCTTTGGGTAAGGGTGTGCGTGCAATCCTGCCTGCTTCATTACACAATTGCTTCCAGT
TAAGAGACAATTGGGTTTCTATAACGCAACCTCTAGGCTAAAAAGTCACATTAATCCTAC
TGGTACGGTATTGTTGCAATTGGAGAACAATGCAAACCTCTTTGAAAGATTGTGTA
(SEQ ID NO: 45)

Polypeptide sequence of Variant No. 648:

LDNGLARTPPMGWLHWERFMCNLDCEEPDSCISEKLFEEMAERMVTEGWKDAGYEYLCI
DDCWMAPQRDSEGRQLADPQRFPHGIRQLANHVHSGKGLKGIYADVGNKTCAGFPGSFGYY
DIDAQTFADWGVDLLKFDGCYCDLENLADGYKHMSLALNRTGRPIVYSCWPLYMWPFQ
KPNYTEIRQYCNHWRNFADIDDSWASIKSILDWTSRNQERIVDVAGPGGWNDPDLVIGNF
GLSWDQQVTQMALWAIMAGPLFMSNDLRAISPQAKALLQDKDVIAINQDPLGKQGYQLRK
GDNFEVWERPLSGDAWAVAIINRQEIGGPRSYTIPVASLGKGVACNPACFITQLLPVKRQLGF
YNATSRCLKSHINPTGTVLLQLENTMQTSLKDLL (SEQ ID NO: 46)

EXAMPLE 1

GLA Gene Acquisition and Construction of Expression Vectors

[0179] Synthetic genes (SEQ ID NO: 1) coding for the WT human GLA sequence (SEQ ID NO: 2) and derived variants (SEQ ID NO: 4, SEQ ID NO: 6) were constructed as previously described (See e.g. US Pat. Appln. Publn. No. 2017/0360900 A1). For secreted expression and transient transfection in mammalian cells, a chimeric GLA expression construct comprising a polynucleotide encoding a synthetic mouse IG signal peptide fused to a synthetic gene coding for the different GLA variants was generated as follows. Oligonucleotides BamHI-pcDNA-GLA-F (SEQ ID NO: 63) and XhoI-pcDNA-GLA-R (SEQ ID NO: 64) were used to amplify a fragment coding for a signal peptide and the coding sequence for the mature form of GLA variants. The PCR product was ligated into the BamHI/XhoI linearized mammalian expression vector pcDNA3.1(+) (Invitrogen), or a vector containing a CMV promoter and BGH-pA (bovine growth hormone polyadenylation) sequence. Directed evolution techniques generally known by those skilled in the art were used to generate gene variants derived from SEQ ID NO: 8 within this plasmid construct (See e.g., US Pat. No. 8,383,346 and WO2010/144103).

EXAMPLE 2

High-Throughput Growth and Assays

High-Throughput (HTP) Growth of GLA and GLA Variants

[0180] HEK 293T cells were transfected with pcDNA 3.1(+) or a CMV promoter and BGH-pA containing vectors encoding a synthetic mouse IG signal peptide fused to wild type GLA or GLA variants using the lipofection method with LIPOFECTAMINE[®] 3000 Reagent (ThermoFisher Scientific). HEK 293T cells were cultured in growth medium (DMEM with 10% fetal bovine serum [both from Corning]). 24 hours before transfection, cells were seeded to NUNC[®] Edge 2.0 96-well plate (ThermoFisher Scientific) at densities of 10⁵ cells/well/250 μ L in growth medium, and incubated at 37 °C, 5% CO₂ in an incubator. Cells were incubated for 24-72 hours at 37 °C and 5% CO₂ to allow for expression and secretion of GLA variants. Conditioned media (50-100 μ L) from the HEK293T transfections were transferred into Corning 96-well solid black plates (Corning) for activity and/or stability analysis.

HTP-Analysis of Supernatants

[0181] GLA variant activity was determined by measuring the hydrolysis of 4-methylumbelliferyl α -D-galactopyranoside (MUGal). For an unchallenged assay, 50 μ L of HEK 293T conditioned media produced as described above were mixed with 50 μ L of 1 mM MUGal in McIlvaine Buffer (McIlvaine, J. Biol. Chem., 49:183-186 [1921]), pH 4.8, in a 96-well, black, opaque bottom microtiter plate. The reactions were mixed briefly and incubated at 37 °C for 30-180 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Results from this assay are presented in Table 2-1.

HTP-Analysis of Supernatants Pretreated with Acid

[0182] GLA variants were challenged with acidic buffer to simulate the extreme pH that the variants may encounter within lysosomes. First, 50 μ L of HEK 293T conditioned media and 50 μ L of McIlvaine buffer (pH 3.3-4.3) were added to the wells of a 96-well round bottom microtiter plate. The plates were sealed with a PlateLoc® thermal microplate sealer (Agilent), and incubated at 37 °C for 1-2 h. For the pH 4 challenge assay, 50 μ L of acid-pH-challenged sample were mixed with 50 μ L of 1 mM MUGal in McIlvaine buffer pH 4.4. The reactions were mixed briefly and incubated at 37 °C for 30-180 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate, pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Results from this assay are presented in Table 2-1.

HTP-Analysis of Supernatants Pretreated with Base

[0183] GLA variants were challenged with basic (neutral) buffer to simulate the pHs that the variants encounter in the blood following administration to a patient. First, 50 μ L of GLA variants HEK 293T conditioned media and 50 μ L of McIlvaine buffer (pH 7.0-8.2) were added to the wells of a 96-well round bottom microtiter plate. The plates were sealed and incubated at 37 °C for 1-18 h. For the pH 7 challenge assay, 50 μ L of basic-pH-challenged sample was mixed with 50 μ L of 1 mM MUGal in McIlvaine buffer pH 4.4. The reactions were mixed briefly and incubated at 37 °C for 30-180 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Results from this assay are presented in Table 2-1.

Table 2-1. Activity of GLA Variants Relative to SEQ ID NO: 8 After No Challenge (Unchallenged) or Challenge at the Indicated pH ¹				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 8)	Unchallenged FIOPC	pH 4 Challenge FIOPC	pH 7 Challenge FIOPC
7/8		++	++	++
9/10	R44L/D247N/P337A	++	++++	
11/12	R44L/K302Q	++	++++	+
13/14	R44L/D247N/K302Q	++	++++	
15/16	R217F/K373R		++++	+
17/18	I322M/P337A	++++	++++	++
19/20	R44L/D247N/K302Q/I322M	++	++++	
21/22	K302Q/I322M/Q362K/K373R	+++	++++	+
23/24	I322M	+++	+++	++
25/26	K302Q/P337A	++	+++	+
27/28	R44L/R217F/I322M	+++	+++	++
29/30	R44L/D247N/I322M	++	+++	
31/32	R44L/P337A	++	+++	+
33/34	R44L/K373R	++	+++	+
35/36	R44L/D247N	+++	+++	++
37/38	R217F/I322M	+++	+++	+
39/40	R44L/R217F/D316L	++	+++	+
41/42	D247N/Q362K	++	+++	
43/44	R44L/R217F	+++	+++	++
45/46	K373R	++	++	+
47/48	D247N/I322M	++	++	
49/50	R44L	++	++	+
51/52	D316L	++	++	+
53/54	R44L/D247N/Q362K	++	++	
55/56	D316L/P337A	++	++	
57/58	Q362K/K373R	++	+	
59/60	R44L/R217F/I322M/P337A		+	
¹ Levels of increased activity were determined relative to the reference polypeptide of SEQ ID NO: 8, and defined as follows: "+" > 0.75; "++" > 0.9; "+++ > 1.1; and "++++" > 1.2.				

EXAMPLE 3

Production of GLA Variants

Production of GLA in HEK293T Cells

[0184] Secreted expression of GLA variants in mammalian cells was performed by transient transfection of HEK293, HEK293T, or Expi293 cells. Cells were transfected with GLA variants (SEQ ID NOS: 3, 4, 9, 12, 17, 20, 23, and 41) fused to an N-terminal synthetic mammalian signal peptide and subcloned into the mammalian expression vector pLEV113, as described in Example 1. HEK293 cells were transfected with plasmid DNA and grown in suspension for 4 days using standard techniques known to those skilled in the art. Supernatants were collected and stored at 4 °C until analyzed.

EXAMPLE 4

Purification of GLA Variants

Purification of GLA Variants From Mammalian Cell Supernatants

[0185] WT GLA (SEQ ID NO: 2) was purified from mammalian culture supernatant as described in the literature (Yasuda et al., Prot. Exp. Pur., 37:499-506 [2004]). All other GLA variants were purified as follows. GLA variants were purified from mammalian culture supernatant essentially as known in the art (See, Yasuda et al., Prot. Exp. Pur., 37:499-506 [2004]). Concanavalin A resin (Sigma Aldrich) was equilibrated with 0.1 M sodium acetate, 0.1 M NaCl, 1 mM MgCl₂, CaCl₂, and MnCl₂, pH 6.0 (Concanavalin A binding buffer). Supernatant was sterile-filtered with 0.2 µm bottle-top filter before it was loaded onto the column. After loading, the column was washed with 10 column volumes of Concanavalin A binding buffer and the bound protein was eluted with Concanavalin A binding buffer supplemented with 0.9 M methyl-α-D-mannopyranoside and 0.9 M methyl-α-D-glucopyranoside. Eluted protein was concentrated and the buffer exchanged into storage buffer (20 mM sodium phosphate, 150 mM sodium chloride, 185 µM TWEEN®-20 non-ionic detergent, pH 6.0) using an Amicon® Ultra 15mL filtration unit with a 30 kDa molecular weight cut off (Millipore) membrane. The GLA in storage buffer was sterile filtered through ANOTOP® 0.2 µm syringe filters (Whatman), and stored at -80°C. Purification provided 2.4-50 µg of purified protein/ml of culture supernatant based on BCA quantitation.

Protein Quantification by the BCA Protein Assay

[0186] A bicinchoninic acid (BCA) protein assay (Sigma Aldrich) was used to quantify purified GLA. In microtiter plate, 25 µL of protein standards and purified GLA with proper dilution were mixed with 200µL of working reagent containing 50 parts of BCA reagent A and 1 part of BCA reagent B. The plate was thoroughly mixed on a plate shaker for 30 seconds and incubated at 37°C for

30 minutes. After the plates cooled down to room temperature, absorbance of the samples was measured at 562 nm using a plate reader.

EXAMPLE 5

In vitro Characterization of GLA Variants

Thermostability of GLA Variants Expressed in HEK 293T Cells

[0187] GLA variants were exposed to various temperature challenges to assess the overall stability of the enzyme. First, 50 μ L of purified HEK 293T expressed GLA and GLA variants in 1X PBS pH 6.2 were added to the wells of a 96-well PCR plate (Biorad, HSP-9601). The plates were sealed and incubated at 30-50°C for 1h using the gradient program of a thermocycler. For the assay, 25 μ L of challenged supernatant was mixed with 25 μ L of 1 mM MUGal in McIlvaine buffer pH 4.4. The reactions were mixed briefly and incubated at 37°C for 60 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate, pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). The percent residual activity was calculated for 1h incubations at temperatures ranging from 30°C to 50°C, by dividing the activity of challenged samples by the activity of unchallenged samples, in which “unchallenged” is the hydrolysis measured at time 0, and “challenged” is hydrolysis measured at 1 hour at the specified temperature for each variant. Results from this assay are shown in Table 5-1. Figure 1 provides a graph showing the residual activity of GLA variants after 1 hr incubation at various temperatures.

Serum Stability of GLA Variants Expressed in HEK 293T Cells

[0188] To assess the relative stability of variants in the presence of blood, samples were exposed to serum. First, 100 μ L of 7.5ug/mL purified GLA variants in 1X PBS pH 6.2 and 90uL of human serum were added to the wells of a COSTAR® 96-well round bottom plate (Corning). The plates were sealed and incubated at 37 °C for 0-24h. For the assay, 50 μ L of challenged supernatant were mixed with 50 μ L of 1 mM MUGal in McIlvaine buffer pH 4.4. The reactions were mixed briefly and incubated at 37°C for 90 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate, pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Percent residual activity in serum after 24h was calculated by dividing the activity of challenged samples by the activity of unchallenged samples, in which “unchallenged” is hydrolysis measured at time 0 and “challenged” is hydrolysis measured at the specified time points for each variant. The results are shown in Table 5.1. Figure 2 provides a graph showing the residual activity of GLA variants after a challenge with human serum for 0-24 hrs.

Lysosomal Stability of GLA Variants Expressed in HEK 293T Cells

[0189] To assess the relative stability of variants in the presence of lysosomal proteases and other lysosomal components, GLA variants were exposed to human lysosomal lysate (XenoTech,

#H0610.L) following the manufacturer's instructions with some modifications, as described herein. Briefly, GLA variants were diluted to an appropriate concentration range (0.0625-0.0078125 mM) and 10 μ L of the dilutions were combined with 10 μ L of a 1:20 dilution of human lysosomal lysate in 2x catabolic buffer (XenoTech, #K5200) in a COSTAR® 96-well round bottom plate (#3798, Corning). The plates were sealed and incubated at 37 °C for 0-24h. For the assay, 50 μ L of challenged supernatant was mixed with 50 μ L of 1 mM MUGal in McIlvaine buffer pH 4.4. The reactions were mixed briefly and incubated at 37 °C for 90 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Percent residual activity in lysosomal extract after 24h was calculated by dividing the activity of challenged samples by the activity of unchallenged samples, in which "unchallenged" is hydrolysis measured at time 0 and "challenged" is hydrolysis measured at 4 and 24 hours for each variant. The results are provided in Table 5.1. Figure 3 provides a graph showing the residual activity of GLA variants after challenge with human lysosomal extract for 0 to 24 hrs.

Cellular Uptake in Fabry Fibroblasts of Purified GLA Variants Expressed in HEK293T Cells

[0190] Cellular uptake of GLA variants as compared to a reference enzyme (WT GLA [SEQ ID NO: 2]), was determined to assess the overall ability of the variants to be endocytosed into cultured cells. Fabry fibroblasts (GMO2775, Coriell Institute for Medical Research) were seeded into a 12-well culture dish (VWR, #10861-698) containing Minimal Essential Media (MEM; Gibco #11095-080, supplemented with 1% non-essential amino acids (NEAA; Gibco #11140-050) and 15% fetal bovine serum (Corning #35-016-CV)) and allowed to grow to confluency (2-3 days at 37 °C, 5% CO₂). After reaching confluency, supplemented MEM was removed by sterile vacuum and replaced with 1 mL/well serum-free MEM +1% NEAA. Enzymes purified as described in Example 4, were added to cells at 10 μ g GLA/mL and allowed to incubate for 4 hours at 37 °C, 5% CO₂. Serum-free media was aspirated by sterile vacuum, the cells briefly washed with 1 mL 1xPBS /well, and PBS aspirated by sterile vacuum. Cells were then trypsinized with 200 μ L/well 0.25% trypsin-EDTA (VWR #02-0154-0100) and incubated for ~5 minutes at room temperature to dislodge adherent cells from the plate and degrade remaining extracellular GLA. Then, 500 μ L serum-free MEM was added to each well, and the samples transferred to 1.5 mL microcentrifuge tubes. Samples were centrifuged at 8000 RPM for 5 min. to pellet the cells. Media was gently aspirated with a 1000 μ L pipette. The cell pellets were resuspended in 500 μ L 1xPBS, re-pelleted at 8000 RPM for 5 min, and the PBS was gently removed. Then, 100 μ L Lysis Buffer (0.2% TRITON X-100™ non-ionic surfactant (Sigma #93443) diluted in 1xPBS) was added to each sample, followed by sonication for 1-2 minutes, and centrifugation at 12,000-14,000 RPM for 10 minutes at 4 °C. Supernatant was transferred to a sterile PCR tube for protein and activity assay. For the activity assay, 10 μ L of cell lysis sample was mixed with 50 μ L of 2.5 mM MUGal in McIlvaine buffer, pH 4.6. The reaction plates were sealed and incubated at 37 °C

for 60 minutes, prior to reaction quenching with 140 μ L of 0.5 M sodium carbonate pH 10.2, per well. MUGal hydrolysis was determined using a SPECTRAMAX[®] M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). For the protein quantification, the BCA assay was carried out following the manufacturer's instructions (Pierce, #23225) with the following modifications: 10 μ L of cell lysis sample were mixed with 190 μ L BCA Working Reagent, and the plates sealed and incubated at 37°C for 60 minutes. Samples were analyzed using a SPECTRAMAX[®] M2 microplate reader monitoring absorbance (562 nm). The protein concentrations were calculated from a BSA standard curve. Cellular uptake of each GLA variant was calculated by first subtracting background non-enzymatic fluorescence of the untreated cells from enzyme-treated samples, and then normalizing to the protein concentration in each well. Cellular uptake FIOPC was calculated by dividing the normalized GLA variant intracellular activity by the corresponding activity of the control (WT). Figure 4 provides a graph of the cellular uptake of purified GLA variants in cultured Fabry patient fibroblasts, expressed as relative activity compared to wild type (SEQ ID NO: 2), after 4 hours incubation at 37°C.

**Table 5-1. Relative Activity and Cellular Uptake of GLA Variants
Produced in HEK293T Cells¹**

SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 8)	Lysosomal Stability % Residual Activity at 24h	% Residual Activity at 37°C (1h)	% Residual Activity at 50°C (1h)	Serum Stability % Residual Activity at 24h
1/2	P10T/E39M/R44L/T47S /H92Y/P166S/A206K/R 217F/D247N/G261A/A2 71H/K302Q/D316L/I32 2M/P337A/Q362K/A36 8W/K373R/T392M		+	+	
7/8		+++	++++	+++	+++
15/16	R217F/K373R	+++	++++	++++	
57/58	Q362K/K373R	+++	++++	++++	+
59/60	R44L/R217F/I322M/P3 37A	+++	++++	++++	
39/40	R44L/R217F/D316L	+++	++++	++++	
61/62	P166A/Q362K	+++	++++	++++	+++
¹ The percent (%) residual activity at 35°C and 50°C, as well as lysosomal and serum stability percent (%) residual activity, were determined relative to each individual variant and defined as follows: "+"					

Table 5-1. Relative Activity and Cellular Uptake of GLA Variants Produced in HEK293T Cells ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 8)	Lysosomal Stability % Residual Activity at 24h	% Residual Activity at 37°C (1h)	% Residual Activity at 50°C (1h)	Serum Stability % Residual Activity at 24h
> 50%; "++" > 60%; "+++" > 80%; and "++++" > 95%. The residual activity for each variant at 1 hour was determined, relative to its activity at time 0.					

HTP-Analysis of GLA Activity in Lysates of Fabry Fibroblasts

[0191] GLA variants produced in HTP were challenged to be taken up into cells and retain activity over 24 to 96 hours. Fabry fibroblasts (GMO2775, Coriell Institute for Medical Research) were plated and allowed to grow to confluency over 24 – 72 hours. After reaching confluency, media was removed using an automated BioMek i5 liquid handling robot. Conditioned media from HEK293T cells transiently transfected as described above, were added to the Fabry fibroblasts and the cells allowed to incubate with the GLA variants for 2 - 4 hours at 37°C, 5% CO₂. GLA-containing conditioned media were removed with an automated BioMek i5 liquid handling robot. Then, the cells were briefly washed with 150 µL 1xDPBS /well, and the DPBS was removed with an automated BioMek i5 liquid handling robot. Then, 200 µL of the complete growth medium were added to each well, and the plates were returned to the incubator for 24-72 hours. At the conclusion of incubation, complete growth media was removed with an automated BioMek i5 liquid handling robot. The cells were washed with 150 µL 1xDPBS /well, and the DPBS was removed with an automated BioMek i5 liquid handling robot. The cells were lysed via addition of 50 µL of McIlvaine buffer, pH 4.4, supplemented with 0.2% TRITON X-100™ non-ionic surfactant (Sigma #93443) and agitation at room temperature for 30 minutes. Activity was assessed by addition of 50 µL of 1.5 mM MuGal in McIlvaine buffer, pH 4.4. The plates were sealed and incubated at 37 °C for 360 minutes with agitation at 400 rpm, prior to quenching with 100 µL of 0.5 M sodium carbonate, pH 10.2. Hydrolysis was analyzed using a SPECTRAMAX® M2 microplate reader monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Cellular uptake FIOPC was calculated by dividing normalized GLA variant intracellular activity by the corresponding activity of the reference sequence.

HTP-Analysis of GLA Induced Depletion of Globotriaosylceramide in Fabry Fibroblasts

[0192] GLA variants produced in HTP were challenged to be taken up into cells and reduce the cellular load of globotriaosylceramide. Fabry fibroblasts (GMO2775, Coriell Institute for Medical Research) were plated and allowed to grow to confluency over 24 – 72 hours. After reaching confluency, media were removed by automated a BioMek i5 liquid handling robot. Conditioned media produced by HEK293T cells transiently transfected as described above, were added to the

fibroblast cells and allowed to incubate for 2 - 4 hours at 37°C, 5% CO₂. GLA-containing conditioned media were removed with an automated BioMek i5 liquid handling robot. Then, the cells were briefly washed with 150 µL 1xDPBS /well, and the DPBS was removed with an automated BioMek i5 liquid handling robot. Then, 200 µL of the complete growth medium was added to each well, and the plates were returned to the incubator for 24-72 hours. At the conclusion of incubation, the complete growth media was removed with an automated BioMek i5 liquid handling robot. Then, the cells were washed with 150 µL 1xDPBS /well, and the DPBS was removed with an automated BioMek i5 liquid handling robot. Globotriaosylceramide was extracted into 200 uL methanol supplemented with 10 ng/mL N-heptadecanoyl-ceramide trihexoside for 30 minutes at room temperature with gentle agitation. Methanol extractions were filtered through a Millipore hydrophobic filter stack into round bottom 96-well plates. Cellular globotriaosylceramide was quantified essentially as known in the art (See, Provencal et al., *Bioanal.*, 8:1793-1807 [2016]) by LC-MS/MS. The sum of peak integrations for each cell sample was determined and globotriaosylceramide FIOPC was calculated by dividing the change in normalized GLA variant globotriaosylceramide levels by the reference sequence.

EXAMPLE 6

GLA Variants Derived from SEQ ID NO: 58

[0193] In this Example, experiments conducted to assess activity of and Gb3 clearance by GLA variants in Fabry fibroblasts are described. In this Example, SEQ ID NO: 58 was used as the reference sequence (i.e., the amino acid differences in the variants are indicated relative to SEQ ID NO: 58, and the assay results are reported relative to the results obtained for SEQ ID NO: 58). In these experiments, the GLA variants were tested for MU-Gal activity without pre-incubation, as described in Example 5. Variants were also tested for Gb3 depletion in Fabry fibroblasts as described in Example 5.

Table 6-1. Relative Performance of GLA Variants in Unchallenged Conditions and in Depletion of Gb3 in Fabry Fibroblast Cells (Relative to SEQ ID NO: 58)¹			
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 58)	Unchallenged FIOPC	Gb3 Depletion in Fabry Fibroblast Cells
67/68	R7L/Y120H	+	+
69/70	R7L/F365V	+	
71/72	R7L/Q88A/Y120H/N305G/F365V	++	
73/74	R7L/N305G	++	+
75/76	Q88A	++	
77/78	D282N	++	+
79/80	Q299R/L300I	++	

Table 6-1. Relative Performance of GLA Variants in Unchallenged Conditions and in Depletion of Gb3 in Fabry Fibroblast Cells (Relative to SEQ ID NO: 58)¹			
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 58)	Unchallenged FIOPC	Gb3 Depletion in Fabry Fibroblast Cells
81/82	Y120H	++	
83/84	R7L	+++	+
85/86	R7L/N305G/F365V	+++	
87/88	Y120H/Q299R/N305G	+++	
89/90	R7L/E48D/Q68E/Y120H/D282N/Q299R	+++	++
91/92	E48D	+++	++
93/94	Q68E	+++	++
95/96	R7L/D130E	+++	++
97/98	P67T/F180G	+++	
99/100	R7L/E48D/F180G	+++	
101/102	F365V	+++	
103/104	L300I	+++	++
105/106	R7L/E48D/Q68E	+++	++
107/108	E48D/F180G/D282N	+++	
109/110	F180G	+++	
111/112	Q299R/L300I/N305G/F365V	+++	
113/114	D282N/F365V	++++	
115/116	E48D/D282N/N305G	++++	+
117/118	R7L/Q68E/F180G	++++	
119/120	N305G	++++	++
121/122	Q68E/Q299R/L300I	++++	++
123/124	R7L/E48D/D130E/D282N	++++	++
125/126	E48D/Q68E	++++	+++
127/128	N305G/F365V	++++	
129/130	R7L/D282N	++++	+
131/132	R7L/Q68E/D130E/D282N/F365V	++++	++
133/134	E48D/D282N	++++	++
135/136	A206S	++	
137/138	K343D		+++
139/140	K343G	++	++

Table 6-1. Relative Performance of GLA Variants in Unchallenged Conditions and in Depletion of Gb3 in Fabry Fibroblast Cells (Relative to SEQ ID NO: 58)¹			
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 58)	Unchallenged FIOPC	Gb3 Depletion in Fabry Fibroblast Cells
141/142	K96L	++	+++
143/144	K96L/P312Q/K343G	++	
145/146	K96L/S273P	+	+++
147/148	L158A/R162K/S273G		++
149/150	L158R	+	
151/152	N91Q/S95E		+++
153/154	N91Q/S95E/K96L		+++
155/156	R162H/K343D	+	
157/158	R162K	++	+++
159/160	R162K/S273P	+	+++
161/162	R162S	++	+++
163/164	R87K/K96I/H155N/S273P/K343G		++
165/166	R87K/N91Q/S95E/K96L/A206S/K343G	+	
167/168	R87K/N91Q/S95E/K96L/L158A/R162K		+++
169/170	S273P		+++
171/172	S273P/K343G	++	
173/174	T47D	++	++
175/176	T47D/K343G	+	++
177/178	T47D/R87K/S95E/K96L/L158R/R162H		++
179/180	T47D/S273P	++	+++
181/182	T47D/S95E		+++
183/184	W178G	+	
185/186	T389K	+	
187/188	F180T	+++	
189/190	F365A	++++	
191/192	F180V	++++	
193/194	L158A	+	
195/196	F180L	+	
197/198	S370G	++	

Table 6-1. Relative Performance of GLA Variants in Unchallenged Conditions and in Depletion of Gb3 in Fabry Fibroblast Cells (Relative to SEQ ID NO: 58)¹			
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 58)	Unchallenged FIOPC	Gb3 Depletion in Fabry Fibroblast Cells
199/200	L398S	+++	
201/202	L397A	++	
203/204	A206K	++++	
205/206	P166K	+++	
207/208	A271R	+	
209/210	D396G/L398T	++	
211/212	W178S	+	+
213/214	S314A	+	+
215/216	S71P	++	+
217/218	L394K		+
219/220	Q181A	+	+
221/222	V345A	++	+
223/224	V93I		+
225/226	F365Q	++	+
227/228	I336V	++	+
229/230	H92F	+	+
231/232	L398V	+++	+
233/234	L398P	+++	++
235/236	R301M	++++	++
237/238	P337R	++	++
239/240	S333G	+++	++
241/242	L363Q	++++	++
243/244	T47V		++
245/246	H92T	++++	++
247/248	S393V	+	++
249/250	D151L		++
251/252	S333F	++++	++
253/254	L293P/Q391A	++	++
255/256	V345Q	+	++
257/258	E39V		++
259/260	R217K	++	++

Table 6-1. Relative Performance of GLA Variants in Unchallenged Conditions and in Depletion of Gb3 in Fabry Fibroblast Cells (Relative to SEQ ID NO: 58)¹			
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 58)	Unchallenged FIOPC	Gb3 Depletion in Fabry Fibroblast Cells
261/262	L398A		+++
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 58. Levels of increased activity are defined as follows: "+" = 0.9 to 1.1; "++" > 1.1; "+++" > 1.5; and "++++" > 2.			

EXAMPLE 7**GLA Variants Derived from SEQ ID NO: 158**

[0194] In this Example, experiments conducted to assess the activity, stability at pH 7.4, and intracellular activity in Fabry fibroblasts of GLA variants are described. In this Example, the reference sequence was SEQ ID NO: 158 (i.e., the amino acid differences in the variants are indicated relative to SEQ ID NO: 158, and the assay results are reported relative to the results for SEQ ID NO: 158). The variants were tested for GLA MU-Gal activity without pre-incubation (unchallenged) and after pH 7.4 pre-incubation as described in Example 5. Variants were also tested for MU-Gal activity after lysis of Fabry fibroblasts incubated with GLA variants as described in Example 5.

Table 7-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 158)				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 158)	Unchallenged FIOPC	Lysate FIOPC	Stability after pH 7.4 Preincubation FIOPC
263/264	E48D	++	+	++++
265/266	E48D/Q68E	+		++++
267/268	E48D/Q68E/R217K/S333F/Q391A/S393V	+		++++
269/270	E48D/Q68E/S333F	+		++++
271/272	E48D/R217K	+	+	++++
273/274	E48D/S333F			++++
275/276	E48D/S333G	+	+	++++
277/278	E48D/S393V	+	+	+++
279/280	E48D/V345Q/S393V			+++
281/282	Q68E	+		+++
283/284	Q68E/V345Q	++	++	++++

Table 7-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 158)				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 158)	Unchallenged FIOPC	Lysate FIOPC	Stability after pH 7.4 Preincubation FIOPC
285/286	R217K/S333F	+	+	+++
287/288	R217K/S333G	+	+	++++
289/290	S333F/V345Q	+	++	++
291/292	S333G	++	++	++++
293/294	D130E		+	
295/296	D151L/A206S/D282N/P337R/K343D /V345Q/L398A	++	+	
297/298	D130E/V345Q/S393V		+	
299/300	E39V/P337R/K343G/L398A	+		
301/302	T47V/D151L	+	+	
303/304	T47V/D130E	+	+	
305/306	T47V/K343D/V345Q/S393V	+	+	
307/308	A206S/R217K	+		
309/310	P337R/K343G/V345Q/L398A	+		
311/312	D282N/S393V	+		
313/314	K343D	+	+	
315/316	K343D/V345Q/S393V/L398A	+		
317/318	E39V/T47V/R217K	+		
319/320	A206S	+		
321/322	S393V/L398A	+		
323/324	E39V/D282N/P337R/L398A	+	+	
325/326	D151L	+		
327/328	S393V	+	+	
329/330	R217K/P337R/V345Q/L398A	+	+	
331/332	D151L/D282N/S393V	+		+
333/334	E39V/S393V/L398A	+		+
335/336	L158R			+
337/338	D151L/L158R/R217K/K343G/V345 Q/S393V	+	++	+
339/340	D130E/L158R		+	+

Table 7-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 158)				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 158)	Unchallenged FIOPC	Lysate FIOPC	Stability after pH 7.4 Preincubation FIOPC
341/342	D151L/S393V		+	+
343/344	R217K	+	+	+
345/346	D130E/L158R/S393V	+	++	+++
347/348	E39V/D151L	+		+++
349/350	D151L/V345Q/S393V/L398A	+	++	+++
351/352	E39V/T47D	++	+	++++
353/354	L158R/S393V	++	+	++++
355/356	C59A/C143S			+
357/358	A271N		++	
359/360	D202N			++++
361/362	D24S/D202N	+		
363/364	S333N	+		
365/366	C143S/S333N	+		
367/368	C143S/A271N	++		+++
369/370	C143S/E387N	++		++
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 158. Levels of increased activity are defined as follows: "+" = 0.9 to 1.1; "++" > 1.1; "+++" > 1.5; and "++++" > 2.5.				

EXAMPLE 8

GLA Variants Derived from SEQ ID NO: 372

[0195] In this Example, experiments conducted to assess the activity, stability at pH 7.4, Gb3 clearance, and intracellular activity in Fabry fibroblasts of GLA variants are described. In this Example, the reference sequence was SEQ ID NO: 372 (i.e., the amino acid differences in the variants are indicated relative to SEQ ID NO: 372, and the assay results are reported relative to the results for SEQ ID NO: 372). These variants were tested for MU-Gal activity without pre-incubation ("unchallenged") and after pH 7.4 pre-incubation as described in Example 5. Variants were also tested for MU-Gal activity in Fabry fibroblasts incubated with GLA variants as described in Example 5 ("Lysate FIOPC"). Variants were also tested for depletion of Gb3 in Fabry fibroblasts after incubation with GLA variants as described in Example 5 ("Gb3 FIOPC").

Table 8-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 372)					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 372)	Unchallenged FIOPC	Stability After pH 7.4 Preincubation FIOPC	Lysate FIOPC	Gb3 FIOPC
375/376	F217R/N247D/L316D/M322I/ A337P/W368A	+	++++		
377/378	H271A	+			+
379/380	H271A/L316D/M322I	+++	++		
381/382	H271A/Q302K/M322I	+++	++++	++	
383/384	K206A/F217R/H271A/M392T	++	++++	+++	+
385/386	L44R/K206A/A337P	+++	+++	++++	++
387/388	L44R/N247D/A261G/Q302K/ L316D	++		++	
389/390	L44R/N247D/A261G/Q302K/ L316D/M322I	++	+	+	
391/392	L44R/S47T/K206A/F217R/N2 47D/H271A/M322I	+	++++	++++	
393/394	L44R/S47T/N247D/M322I/W 368A	+++	++++	++	
395/396	L44R/S47T/Q302K/L316D/M 322I	+++	++++	+++	
397/398	L44R/S47T/Y92H/K206A/F21 7R/L316D/M322I	++++	++++	++++	
399/400	L44R/S47T/Y92H/N247D/A2 61G/H271A/L316D/A337P/W 368A	++	+	+	
401/402	L44R/Y92H/K206A/N247D/ W368A	++	+	+++	++
403/404	L89I/F217R/N247D/A261G/Q 302K/L316D	++	+		
405/406	M39E/L44R/Y92H/F217R/M3 22I	+++	+	+++	
407/408	M39E/L44R/Y92H/N247D/H2 71A/Q302K	++		++	+

Table 8-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 372)					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 372)	Unchallenged FIOPC	Stability After pH 7.4 Preincubation FIOPC	Lysate FIOPC	Gb3 FIOPC
409/410	M39E/L44R/Y92H/R162M/N 247D/Q302K/L316D/M322I	++	+	++	
411/412	M39E/M322I	+++	+	++	
413/414	M39E/N247D/H271A	+	+	+	+
415/416	M39E/N247D/H271A/L316D	+++	+++		
417/418	M39E/S47T/F217R/N247D/W 368A	++++	++++		
419/420	M39E/S47T/N247D	+++	+	+	
421/422	M39E/S47T/Y92H/N247D/Q3 02K/L316D/M322I	+	+++	+	
423/424	M39E/Y92H/L316D/M322I	+	+	++	+
425/426	M39E/Y92H/N247D/Q302K/ L316D/A337P/W368A	++++	++++	+	
427/428	N247D	+	++++	+	
433/434	N247D/H271A	+++	++	+	
435/436	N247D/Q302K	++	++++	++	+
437/438	Q302K/M322I/W368A	++	+	+	
439/440	S47T/F217R/Q302K	+++	+++	+++	
441/442	S47T/N247D	++	++++	+	
443/444	S47T/N247D/H271A	+++	++++	++	
445/446	S47T/Y92H/N247D/H271A	++	++	+	+
447/448	T10P	++	++	++	++
449/450	T10P/A261G	+	+	++	
451/452	T10P/A337P/M392T	++	++	+	++
453/454	T10P/H271A/Q302K	+++	++++	++	+
455/456	T10P/K206A/A261G/H271A/ L316D	+	+	++	
457/458	T10P/K206A/F217R/H271A	++	++++	++++	
459/460	T10P/K206A/N247D	++++	++++	++++	
461/462	T10P/L316D/M322I	+++	++++	++	+

Table 8-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 372)					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 372)	Unchallenged FIOPC	Stability After pH 7.4 Preincubation FIOPC	Lysate FIOPC	Gb3 FIOPC
463/464	T10P/L44R	+++	+	+++	++
465/466	T10P/L44R/A261G/Q302K/L 316D	++		++	+
467/468	T10P/L44R/Q302K/A337P/W 368A	++++	++++	++++	
469/470	T10P/L44R/S47T/A261G/Q30 2K/M322I/W368A	+++	+	+++	
471/472	T10P/L44R/S47T/Y92H/N247 D	+	+++	+++	
473/474	T10P/L44R/Y92H/L316D/M3 22I	++++	+++	+++	
475/476	T10P/M39E/L44R/M322I	+++		+++	+
477/478	T10P/M39E/Y92H/K206A/F2 17R/H271A	++	+++	+++	
479/480	T10P/M39E/Y92H/N247D	+++	+++	+	
481/482	T10P/M39E/Y92H/N247D/H2 71A/L316D	+	+++		
483/484	T10P/Q302K	++	+	+++	+++
485/486	T10P/Q302K/L316D	++	+++	++	+
487/488	T10P/Q302K/M322I/A337P	+++	++++	+++	++
489/490	T10P/S47T/F217R/M322I	+	+++	++	+
491/492	T10P/S47T/F217R/N247D/L3 16D/M392T	+++	++++	+	
493/494	T10P/S47T/H271A	+++	++	++	
495/496	T10P/W368A	+++	++	+	
497/498	T10P/Y92H	+	+	++	
499/500	T10P/Y92H/F217R/A261G/Q 302K/A337P	++	+	++	
501/502	T10P/Y92H/K206A/F217R/N 247D	+	++++	+++	+

Table 8-1. Relative performance of GLA Variants (Relative to SEQ ID NO: 372)					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 372)	Unchallenged FIOPC	Stability After pH 7.4 Preincubation FIOPC	Lysate FIOPC	Gb3 FIOPC
503/504	T10P/Y92H/K206A/N247D/L 316D/M322I/M392T	+	++++	++	
505/506	T10P/Y92H/K206A/N247D/M 322I/W368A	+	++++	+++	++
507/508	W368A	+		+	
509/510	Y92H/F217R/H271A	++	+	+	
511/512	Y92H/H271A/A337P	++	+	+	
513/514	Y92H/L316D	+++	+		+
515/516	Y92H/N247D	+++	++	++	
517/518	Y92H/N247D/H271A/M322I	++	++	+	+
519/520	Y92H/N247D/Q302K/M322I/ A337P	+	+++	+	
521/522	Y92H/Q302K	++		++	+
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 372. Levels of increased activity are defined as follows: "+" = 0.9 to 1.1; "++" > 1.1; "+++" > 1.5; and "++++" > 2.					

EXAMPLE 9**GLA Variants Derived from SEQ ID NO: 374**

[0196] In this Example, experiments conducted to determine GLA variant activity by assaying the enzyme activity after a series or independent challenges are described. These variants were tested for GLA MU-Gal activity after no pre-incubation and after pH 7.4 pre-incubation, as described in Example 5. Variants were also tested for MU-Gal activity after lysis of Fabry fibroblasts incubated with variants as described in Example 5. Variants were also tested for Gb3 depletion in Fabry fibroblasts after incubation, as described in Example 5.

Table 9-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
523/524	P10T/E39M/R44L/T47S/P337A	+			
525/526	P10T/R44L/H92Y	++			
527/528	R44L/T47S/P166S	+			
529/530	A206K/R217F	++			
531/532	E39M/T47S/H92Y/T392M		+		
533/534	P10T/E39M/H92Y/W131G/P166S/A271H/D316L/I322M	+		+	
535/536	E39M/T47S/R217F/D247N/A368W				+
537/538	H92Y/P166S/D247N				+
539/540	H92Y/R217F				+
541/542	P10T/A206K				++
543/544	P10T/D316L/T392M				++
545/546	P10T/E39M/R44L/H92Y/P166S/G261A/D316L/I322M				+
547/548	P10T/E39M/R44L/H92Y/P166S/K302Q/I322M				+
549/550	P10T/E39M/R44L/H92Y/R217F/K302Q/I322M				+
551/552	P10T/E39M/R44L/T47S/D316L				+
553/554	P10T/E39M/R44L/T47S/H92Y/A206K/R217F				++
555/556	P10T/H92Y/K302Q/P337A				+
557/558	P10T/R44L/H92Y/R217F/D247N/A271H/K302Q/D316L/T392M				+
559/560	P10T/R44L/T47S/P166S/A271H/I322M/A368W				++
561/562	P10T/R44L/T47S/R217F/A271H/D316L/I322M				+
563/564	R44L/T47S/H92Y/T392M				+

Table 9-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
565/566	T47S/A271H				++
567/568	T47S/P166S/A206K/R217F/D24 7N/P337A				+
569/570	E39M/R44L/P166S/A271H/P33 7A/A368W/T392M				+
571/572	E39M/R44L/T47S/H92Y/P166S /A206K/T392M				+
573/574	H92Y/A206K/I322M				+
575/576	P10T/E39M/R44L/H92Y/K302 Q/I322M				+
577/578	P10T/E39M/R44L/T392M				+
579/580	R44L/T47S				+
581/582	D247N/D316L				+
583/584	D316L/P337A/T392M				+
585/586	D52N/R217F/K302Q/D316L				+
587/588	H92Y/P166S/A206K/A271H/D3 16L				+
589/590	P10T/G261A/P337A/T392M				+
591/592	P10T/K36M/H92Y/P166S/D247 N/G261A/D316L/T392M				++
593/594	H92Y/R217F/A271H/P337A				++
595/596	P10T/A368W				+
597/598	P10T/E39M/H92Y/P166S/R217 F/D247N/A271H				+
599/600	P10T/R44L/T47S/P166S/G261A /A271H				+
601/602	R44L/D316L/I322M/T392M				++
603/604	E39M/R44L/T47S/A206K/P337 A/A368W/T392M	+			++
605/606	P10T/R44L/A206K/D316L/I322 M	+			+

Table 9-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
607/608	E39M/R44L/P166S/A271H	++			++
609/610	E39M/T47S/D247N	++			+
611/612	P10T/A206K/D247N/G261A	+++			++
613/614	P10T/E39M/R44L/H92Y/P166S /T392M	+			++
615/616	P10T/R44L/P166S/K302Q	+++			++
617/618	P10T/T47S/H92Y/A271H/K302 Q	+			+
619/620	R44L/T47S/P166S/A271H	++			++
621/622	E39M/R44L/T47S/H92Y/A206 K/D247N/G261A	+++	+++		++
623/624	E39M/R44L/T47S/H92Y/A206 K/T392M	+++	++++		+++
625/626	P10T/E39M/T47S/H92Y/P337A	++	+++		+
627/628	P10T/H92Y/P166S/R217F/D247 N/G261A/A271H			++	+
629/630	P10T/T47S/P166S/D316L			+	++
631/632	P10T/T47S/H92Y/D316L/I322 M/T392M			++	++
633/634	R217F/T392M			++	+
635/636	E39M/P166S/R217F/G261A/D3 16L/A368W			+++	+++
637/638	E39M/T47S/P166S/R217F/G261 A/T392M			++	++
639/640	P10T/E39M/H92Y/R217F/D316 L			+++	++
641/642	D316L/I322M/A368W	+		+++	++
643/644	H92Y/P166S/D316L	+		+++	+++
645/646	H92Y/P166S/R217F/D316L/P33 7A/T392M	+		+++	+++

Table 9-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
647/648	H92Y/P166S/R217F/G261A/A271H/T392M	+++		+++	+++
649/650	P10T/H92Y/D316L/I322M	+++		++++	+++
651/652	P10T/H92Y/P166S	+		++	+++
653/654	P10T/H92Y/P166S/P337A/A368W	+		++	++
655/656	P10T/R217F/I322M	+		+++	+++
657/658	P10T/T47S/H92Y/P166S/A271H/D316L/P337A	+		+++	++
659/660	P10T/T47S/P166S/A271H	++		++	++
661/662	P166S/D247N/A271H/D316L	+		++	+
663/664	P166S/D316L/I322M/P337A	+		+	+
665/666	P166S/R217F/D316L/I322M/P337A	+		+++	++
667/668	R44L/T47S/D247N/A271H/T392M	+++		+++	++
669/670	T47S/A206K	+++		+	+++
671/672	T47S/P166S/R217F/A271H/P337A	+		+	+++
673/674	R44L/T47S/H92Y/R217F/A271H	++		+++	+++
675/676	H92Y/G261A/A271H		+++	++	++
677/678	P10T/E39M/R44L/P166S/G261A/A271H/D316L/I322M		+	++	+++
679/680	P10T/H92Y/P166S/G261A/A271H/T392M		+++	+	+++
681/682	T47S/R217F/D247N/G261A		+	+++	+
683/684	E39M/H92Y/G261A/K302Q	+++	++++	+	+
685/686	E39M/H92Y/P166S/R217F/T392M	+++	+++	+++	++
687/688	E39M/I322M	+++	+++	++	++

Table 9-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
689/690	E39M/R44L/H92Y/P166S/D247 N/G261A/K302Q/P337A	+++	++++	+	+
691/692	E39M/T392M	+	+++	++	+
693/694	E39M/T47S/H92Y/D316L/I322 M	+	+++	+	+
695/696	H92Y/A271H	+++	++++	++++	+++
697/698	P10T/E39M	+++	+++	++++	+++
699/700	P10T/G261A	++	++++	+++	++
701/702	P10T/H92Y/P166S/G261A/D31 6L/I322M/P337A	++	+++	+++	+++
429/430	R44L/P337A	+	+	+	+++
431/432	R44L/T47S/H92Y/R217F/D316 L/I322M/T392M	+++	++	+++	+++
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 374. Levels of increased activity are defined as follows: "+" = 0.75-0.9; "++" > 0.9; "+++ > 1.1; and "++++" > 2.					

EXAMPLE 10

In vivo Characterization of GLA Variants

[0197] GLA variants were characterized *in vivo* for their activity towards accumulated Gb3. Fabry mice (5 month old females; Jackson, stock #3535) and age/sex matched wildtype mice with the identical genetic background were used. Mice were administered a single IV injection via tail vein with Codexis enzyme variants (1.0 mg/kg). Animals were sacrificed using CO₂ anesthesia at scheduled time points (1 and 2 weeks post-injection), and disease relevant tissues (e.g., heart and kidney) were dissected into two portions (one for enzyme activity assay, the other for Gb3 quantification), frozen on dry ice, and stored at -80°C until analysis. For the enzyme assay, mouse tissues were homogenized in 20x volume (w/v) in Lysis Buffer (0.2% TRITON X-100™ non-ionic surfactant (Sigma #93443) diluted in 1xPBS) using motor-driven TEFLON® coated pestle in a glass homogenizer. Lysates were sonicated, centrifuged at 14,000 rpm for 15 min at 4°C, and the supernatants used for enzyme assay. α -Gal A activity was measured by the standard fluorometric assay using 5mM 4-methylumbelliferyl- α -D-galactopyranoside at pH 4.4, in the presence of 0.1M N-acetylgalactosamine (i.e., a specific inhibitor of α -galactosidase B). Protein concentrations were

measured using the BCA protein assay kit (Pierce, #23225). The activity was normalized to the protein concentration and expressed as nmol/mg protein/hour. Gb3 concentrations were measured by mass-spectrometry as previously described (See, Durant et al., J. Lipid Res., 52:1742-6 [2011]). Briefly, mouse tissues were homogenized in ice-cold 20x volume of ultra-pure water in a glass homogenizer, and the lysates corresponding to 200 µg total protein were subjected to glycosphingolipid extraction, saponification, and subsequent analysis of Gb₃ by mass-spectrometry. The Gb₃ concentration was expressed as ng/mg protein. Figure 5 provides a graph showing *in vivo* enzyme activity in the heart in the Fabry mouse model 1, 2 and 4 weeks post-treatment. Figure 6 provides a graph of Gb₃ degradation in heart tissue in Fabry mouse models 1 and 2 weeks post-treatment compared to untreated animals.

EXAMPLE 11

GLA Variants Derived from SEQ ID NO: 704

[0198] In this Example, experiments conducted to assess activity, serum stability, intracellular activity in Fabry fibroblasts and Gb3 clearance by GLA variants in Fabry fibroblasts are described. In these experiments, the GLA variants were tested for MU-Gal activity without pre-incubation, after serum incubation, in lysates of Fabry fibroblasts relative to SEQ ID NO: 704 (SEQ ID NO: 704 is the amino acid sequence from SEQ ID NO: 703 which is the mammalian codon optimized version of the yeast codon optimized SEQ ID NO: 275) as described in Example 5. Variants were also tested for Gb3 depletion in Fabry fibroblasts as described in Example 5.

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
705/706	A254T/L398F			++	
707/708	A271N	+	+		
709/710	A271N/F352N/Q391N	++	+++		
711/712	A271N/G333N	+++	++		
713/714	A271N/G333N/M390N/ Q391N	++	+		
715/716	A271N/G333N/Q391N	++	+		
717/718	A278N			++	+
719/720	A278R	++	++		
721/722	A278S	+++	+++	++	++

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
723/724	A287R	+	+	+++	
725/726	A339G	++	+	+++	+
727/728	A339N	+++	+++	+++	
729/730	A339Q	+++	+++	+++	
731/732	A339V	++	+	++	++
733/734	C143S	+++	+++	+++	++
735/736	C143S/A271N	++	+++	+	
737/738	C143S/A271N/F352N/M 390N	+++	+++		
739/740	C143S/D202N	++	+++	+	+
741/742	C143S/E387N/Q391N	++	++		
743/744	C143S/G333N	++	++		
745/746	C143S/G333N/E387N/M 390T	+++	+++		+
747/748	C59A	+++	+++	+++	++
749/750	C59A/C143S	+++	+++	+++	++
751/752	C59A/C143S/A271N	+	++		
753/754	C59A/D202N	++	+++	++	++
755/756	C59T	+			++
757/758	C59T/C143S/D202N	+++	+++	+	++
759/760	C59T/C143S/G333N	++			
761/762	C59T/D202N/G333N	++			+
763/764	C59V/A271N/E387N/M3 90T	+++			
765/766	C59V/C143S/D202N/A2 71N/G333N	++			
767/768	D122E	++	+++	+	
769/770	D122N	++	++	+	
771/772	D122S	+		++	
773/774	D202N	+	++		

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
775/776	D202N/G333N	+			++
777/778	D24S/A271N/F352N	++			
779/780	D24S/C143S/D144N	++			+
781/782	D24S/C143S/D202N/F352N/M390N/Q391N	++	++		
783/784	D24S/C143S/D202N/G333N	++			+
785/786	D24S/C143S/G333N/F352N/E387N/M390T/Q391N	+++			
787/788	D24S/C143S/M390T/Q391N	+			++
789/790	D24S/C59A	++			++
791/792	D24S/D202N	++	++		++
793/794	D24S/D202N/A271N	++	++		
795/796	D24S/D202N/G333N/F352N	+			
797/798	D24S/E387N/Q391N	++	+		
799/800	D24S/F352N/E387N/M390N/Q391N	+++	++		
801/802	D284A	++	++	+++	
803/804	D284E	+++	+++	+++	
805/806	D284G	+		+++	+
807/808	D284L			+++	+
809/810	D284M	++	++	+++	
811/812	D284R	++	+	+++	
813/814	D284S	++	++	++++	
815/816	D2S	++			+++
817/818	D304T	++	++		+++
819/820	D304V	+			+++
821/822	D304W			++	+++

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
823/824	E147L	++			
825/826	E147S	++	++		
827/828	E367A	+++	+++		
829/830	E367D	++	++	+	+
831/832	E367L	++	+++	+++	+
833/834	E367M	++	+	+++	
835/836	E387N/Q391N	+++	+++		
837/838	E40Q	+		++	
839/840	G164E	++			
841/842	G303A	++	++	+	
843/844	G303C	++	+	++	
845/846	G303W	+++	+++	+++	
847/848	G333N/F352N	++			
849/850	G333N/M390N/Q391N	+++	+++		
851/852	G333N/M390S/Q391N	+++	+		
853/854	G333N/Q391N	+++	++		+
855/856	G4L	+			++
857/858	G73A				++
859/860	H155A	+++	+++	+	
861/862	H155D	+++	+++		
863/864	H155F	+++	++	+++	+++
865/866	H155L	++			+++
867/868	H155R	++	+++		
869/870	H155T	++	+++	+	
871/872	H375L	++	++		++
873/874	H375Q	++	+++		
875/876	H84G	++	++	+	++
877/878	H84K	+++	+++	+++	+++
879/880	H84R	+		+++	
881/882	I123Q	++	+++	++	

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
883/884	I123R	++	+	+++	
885/886	I123S	+		++	+
887/888	I123T	++	++	++	
889/890	I336F	++	++	++	
891/892	I336G				++
893/894	I336S			+	++
895/896	I336T	++	++	++	++
897/898	K277Q				+++
899/900	K277V			++	+++
901/902	K283L	++	+	+++	
903/904	K283P	++	+++	+++	
905/906	K283T	+	+	+++	++
907/908	K283V	+	+	+++	
909/910	K343L	++	++	++	++
911/912	K343R	+++	+++	+++	
913/914	K343S	++	++	+	
915/916	K343W			++	
917/918	K360H	++	++	+	+
919/920	K360V				++
921/922	K362H	++	+++		
923/924	L280G				++
925/926	L300F	++	+	+++	
927/928	L341F	++	+	++	++
929/930	L341M	++	++	++	
931/932	L398F	++	++	+++	
933/934	L5M	+	++		
935/936	L5V	+++	+++	++	
937/938	M390S	++	++		
939/940	N218Y	++	+	+++	
941/942	N218Y/L398F	+++	+	+++	

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
943/944	N218Y/R361T	++		+++	
945/946	N218Y/R361T/L398F	++	+	+++	
947/948	N377Q	++			
949/950	N91S/T215S/R361T	++		++	
951/952	P179H	+++	+++		+++
953/954	P179L				++
955/956	P179R	+++	+++		
957/958	P179W	++			
959/960	P331M	++	+		
961/962	P83R				+++
963/964	P83S				+++
965/966	Q275A	+++	+++	+++	+++
967/968	Q275G	+	++	++	
969/970	Q281I				++
971/972	Q281M				++
973/974	Q385R	+	+	+++	
975/976	Q76A	+		++	
977/978	Q76F	+		+++	
979/980	Q76M	++	+++	++	
981/982	Q76S			+++	
983/984	Q80T	++	+++	++	
985/986	R165I	++			
987/988	R325A	++			
989/990	R332G	++			
991/992	R332H	+++			
993/994	R361T	++	++	+++	
995/996	R361V	++	+++	+++	+++
997/998	R371G	+++	+++	+++	
999/1000	R373L	+++	+++	+	
1001/1002	R373S	+++	++	++	

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1003/1004	S210I				+++
1005/1006	S273L	+		+++	
1007/1008	S31F	++	+	++	
1009/1010	S31H	++	+++	+	++
1011/1012	S31L	++	+++	+++	
1013/1014	S31T	++	++	+++	
1015/1016	S31W				++
1017/1018	S340H	+++	+++	++	++
1019/1020	S340I	+++	+++	+++	
1021/1022	S340K	+++	+++	+++	+++
1023/1024	S340M	+++	+++	+++	
1025/1026	S340P	++	++	+++	
1027/1028	S340W	++	++	+++	
1029/1030	T186E	++	++		
1031/1032	T186F	++	++		
1033/1034	T186M	+++	++		
1035/1036	T186P	++			
1037/1038	T186R	++	+		
1039/1040	T186S	+++	++		
1041/1042	T186Y	++	+++		
1043/1044	T215S/N218Y	++	+	+++	
1045/1046	T335A	+	+	++	++
1047/1048	T335L	++	+	++	
1049/1050	T369D	+++	+++	+++	
1051/1052	V338L	++	++	++	
1053/1054	V359F	++	++	++	
1055/1056	V359L	+++	+++	++	
1057/1058	V359R	++	++	++	
1059/1060	V382I			+++	
1061/1062	V382I/L398F	++	++	+++	

Table 11-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 704) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 704)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1063/1064	W246Y	++	++	++	++
1065/1066	Y334C	++	++	+++	++
1067/1068	Y334V	+++	+++	+++	+
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 704. Levels of increased activity are defined as follows: "+" = 0.75-0.9; "++" > 0.9; "+++" > 1.1; and "++++" > 2.					

EXAMPLE 12

GLA Variants Derived from SEQ ID NO: 374

[0199] In this Example, experiments conducted to assess activity, serum stability, intracellular activity in Fabry fibroblasts and Gb3 clearance by GLA variants in Fabry fibroblasts are described. In these experiments, the GLA variants were tested for MU-Gal activity without pre-incubation, after serum incubation, in lysates of Fabry fibroblasts as described in Example 5. Variants were also tested for Gb3 depletion in Fabry fibroblasts as described in Example 5.

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1069/1070	A206C	+	+	+	+++
1071/1072	A206D	+	+	+	+
1073/1074	A206E	+++	+++	++	+++
1075/1076	A206F	++	++	+	+++
1077/1078	A206G	+++	++	+	++
1079/1080	A206H	+++	+++	++	++
1081/1082	A206I	++	+++	+++	++++
1083/1084	A206K	++	++	+	++++
1085/1086	A206L	++	++	+	++
1087/1088	A206M	++	+++++	+++	+++
1089/1090	A206N	++	++	++	+

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1091/1092	A206P	+	+	-	+++
1093/1094	A206Q	++	++	+++	++++
1095/1096	A206R	++	+++	+++	+
1097/1098	A206S	-	-	-	+
1099/1100	A206T	+++	+++	+++	++
1101/1102	A206V	++	+++	+++	+++
1103/1104	A206W	+	+	+	+++
1105/1106	A206Y	++	++	++	++++
1107/1108	A271C	+	+	+	+
1109/1110	A271D	++	++	+	++
1111/1112	A271E	+++	++++	++	+
1113/1114	A271F	+	+	+	+
1115/1116	A271G	++	+	++	+
1117/1118	A271H	+	+	+	+
1119/1120	A271I	+	+	+	++++
1121/1122	A271K	+++	++++	++++	+
1123/1124	A271L	+	+	++	+
1125/1126	A271M	+	+	+	+
1127/1128	A271N	++++	++++	++	+
1129/1130	A271P	+	+	-	++++
1131/1132	A271Q	+	+	+	+
1133/1134	A271R	+++	++++	++++	+
1135/1136	A271S	++++	+++++	+	+
1137/1138	A271T	++	++++	+	-
1139/1140	A271V	+++	++	++	+
1141/1142	A271W	+	+	++++	++
1143/1144	A271Y	+	-	-	-
1145/1146	A368C	+++	++++	+++	+
1147/1148	A368D	+++	++++	++++	+
1149/1150	A368E	+++	+++	++	+++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1151/1152	A368F	+++	++	++	+
1153/1154	A368G	+	++++	+	-
1155/1156	A368H	+++	++	+++	+
1157/1158	A368I	++	+++	+++	+
1159/1160	A368K	+	+	+	+
1161/1162	A368L	++	+	+	+
1163/1164	A368M	++++	++++	+++	+
1165/1166	A368N	+++	+++	++	+
1167/1168	A368P	++	+++	+++	+
1169/1170	A368Q	+	++	+++	++
1171/1172	A368R	++	++	++	+
1173/1174	A368S	++	++	+	+
1175/1176	A368T	+++	+	+	+
1177/1178	A368V	+	+	+	+
1179/1180	A368W	++	+++	+++	+
1181/1182	A368Y	+++	+++	++++	+
1183/1184	D247A	+	++	+	+
1185/1186	D247C	+	+	+	-
1187/1188	D247E	+	+	++	+
1189/1190	D247F	+	-	+	+
1191/1192	D247G	+	++++	+	++
1193/1194	D247H	+	++++	+	+++
1195/1196	D247I	+	-	+	+
1197/1198	D247K	-	-	+	-
1199/1200	D247L	+	+	+	+
1201/1202	D247M	+	+	+++	+
1203/1204	D247N	++	++	+	++
1205/1206	D247P	+	+	+	++
1207/1208	D247Q	+	+	+	+
1209/1210	D247R	+	-	+	-

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1211/1212	D247S	++	+++	+	+
1213/1214	D247T	+	+	++	++
1215/1216	D247V	+	-	+	-
1217/1218	D247W	+	+++	+	+
1219/1220	D247Y	+	+	+	+
1221/1222	D316A	+	+	+++	+
1223/1224	D316C	+	+	+	+++
1225/1226	D316E	++	+	++	++
1227/1228	D316F	+	+	++	+
1229/1230	D316G	+++	++++	++	+
1231/1232	D316H	+++	+++++	++++	+++
1233/1234	D316I	++	+	+++	+
1235/1236	D316K	++	++	+++	+
1237/1238	D316L	++	+++++	++	+
1239/1240	D316M	+	+	++	++
1241/1242	D316N	+++	+++	+++	++
1243/1244	D316P	+	+	+	+
1245/1246	D316Q	+	+	+	+
1247/1248	D316R	++	+++	+++	+
1249/1250	D316S	++	+++	+++	+
1251/1252	D316T	+	+++	++++	+
1253/1254	D316V	+	+	++	+
1255/1256	D316W	+	+	++	+
1257/1258	D316Y	++	+++	+++	+
1259/1260	E39A	+	+	+++	+
1261/1262	E39C	+	+	+	++
1263/1264	E39D	-	-	-	-
1265/1266	E39F	+	+	+	++++
1267/1268	E39G	-	-	-	+
1269/1270	E39H	++	++	++	+++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1271/1272	E39I	+	+	++	+
1273/1274	E39K	++	++	++++	+++
1275/1276	E39L	++	+++	+++	++++
1277/1278	E39M	++	+++	+	+++
1279/1280	E39N	+	+	+	+++
1281/1282	E39P	-	-	+	+
1283/1284	E39Q	+	+	++	++++
1285/1286	E39R	-	-	-	+
1287/1288	E39S	+	+	+	+++
1289/1290	E39T	+	+	++	++++
1291/1292	E39V	++	++	+	++++
1293/1294	E39W	+	+	+++	+++
1295/1296	E39Y	++	+++	++	+
1297/1298	G261A	++++	++++	+++++	+
1299/1300	G261C	++	+	+	+
1301/1302	G261D	-	-	-	-
1303/1304	G261E	-	+	-	+
1305/1306	G261F	-	-	+	+
1307/1308	G261H	-	-	+	-
1309/1310	G261I	-	-	+	-
1311/1312	G261K	-	-	-	-
1313/1314	G261L	-	-	+	-
1315/1316	G261M	-	-	+	-
1317/1318	G261N	-	-	-	-
1319/1320	G261P	+	-	+	+
1321/1322	G261Q	-	-	+	-
1323/1324	G261R	-	+	-	-
1325/1326	G261S	++++	++++	++++	+
1327/1328	G261T	++	-	+	-
1329/1330	G261V	+	-	+	+

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1331/1332	G261W	-	-	+	-
1333/1334	G261Y	-	-	-	+
1335/1336	H92A	+	+	+++	+
1337/1338	H92C	+	+	+	+
1339/1340	H92D	+	+	+	+
1341/1342	H92E	+	+	+++	++
1343/1344	H92F	+++	+++	+++	+
1345/1346	H92G	+	+	+	+
1347/1348	H92I	++	+	+	+
1349/1350	H92K	+++	+++	+++	+
1351/1352	H92L	++	+++	+++	+
1353/1354	H92M	+	+	+	+
1355/1356	H92N	+	+	+	++
1357/1358	H92P	-	-	-	-
1359/1360	H92Q	++	++	++	++++
1361/1362	H92R	++	++	+	+++
1363/1364	H92S	++	+++	+++	+
1365/1366	H92T	++++	+++++	++++	+
1367/1368	H92V	+++	+++++	+++	++++
1369/1370	H92W	++	++	++	+++
1371/1372	H92Y	++	++	+++	++
1373/1374	I322A	+	+	+	+
1375/1376	I322C	+	+	+	+
1377/1378	I322D	-	-	-	+
1379/1380	I322E	+	+	+	+
1381/1382	I322F	+	+	++	+
1383/1384	I322G	+	-	+	-
1385/1386	I322H	-	-	+	-
1387/1388	I322K	+	+	+	-
1389/1390	I322L	+	++	++	+

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1391/1392	I322M	+	+++	++++	+
1393/1394	I322N	-	+	+	-
1395/1396	I322P	-	-	+	+
1397/1398	I322Q	+	+	+	+
1399/1400	I322R	-	-	+	-
1401/1402	I322S	+	-	+	++
1403/1404	I322T	+	+	+	++
1405/1406	I322V	+	+	+	+
1407/1408	I322W	+	+	+	-
1409/1410	I322Y	+	+	+	-
1411/1412	K302A	+	+	+	+
1413/1414	K302C	+++	+++	+++	+
1415/1416	K302D	+	+	+	+
1417/1418	K302E	+	+	+	+
1419/1420	K302F	++	+++	+++	+
1421/1422	K302G	+++	++++	++	+
1423/1424	K302H	++++	++++	++++	+
1425/1426	K302I	+	+	++	+
1427/1428	K302L	+++	+++++	++++	++++
1429/1430	K302M	++	++++	+++	+
1431/1432	K302N	+	+	+	+
1433/1434	K302P	+	+	+	+
1435/1436	K302Q	++	+	++	++
1437/1438	K302R	+	+	++	+
1439/1440	K302S	++	+	+	+
1441/1442	K302T	+++	++++	++++	++
1443/1444	K302V	++	+++	++	+
1445/1446	K302W	+	+++++	+++	+
1447/1448	K302Y	+++	+++	++++	+
1449/1450	P10A	++	+	+	++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1451/1452	P10C	+	++	+	-
1453/1454	P10D	+	-	+	+
1455/1456	P10E	+	-	+	+
1457/1458	P10F	-	+	-	-
1459/1460	P10G	+++	++++	+++	+++
1461/1462	P10H	+	-	+	+
1463/1464	P10I	+	+	+	++++
1465/1466	P10K	+	-	+	+
1467/1468	P10L	-	-	-	-
1469/1470	P10M	++	-	+	+++
1471/1472	P10N	+	-	+	+
1473/1474	P10Q	+	+	+	+++
1475/1476	P10R	+	+	+	++++
1477/1478	P10S	+	+	+	+++
1479/1480	P10T	+	++	++	+
1481/1482	P10V	+	+	+	+
1483/1484	P10W	-	-	-	-
1485/1486	P10Y	-	-	-	++
1487/1488	P166A	++	+	++	+
1489/1490	P166C	+	-	+	+
1491/1492	P166D	++++	++++	+++	+
1493/1494	P166E	++	++	+	++
1495/1496	P166F	+	+	+	+
1497/1498	P166G	-	-	-	-
1499/1500	P166H	+	+	++	+
1501/1502	P166I	+	-	+	+
1503/1504	P166K	++	+	+	++
1505/1506	P166L	+	+	+	++++
1507/1508	P166M	+	+	+	+
1509/1510	P166N	+	+	+	++++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1511/1512	P166Q	-	-	-	-
1513/1514	P166R	+	+	++	+++
1515/1516	P166S	+	+	+	+++
1517/1518	P166T	+	+	+	+++
1519/1520	P166V	-	-	-	-
1521/1522	P166W	-	-	-	+
1523/1524	P166Y	++	+	++	+
1525/1526	P337A	+	+	+	+
1527/1528	P337C	+	+	+	+++
1529/1530	P337D	++	++++	++	-
1531/1532	P337E	+	+	+	-
1533/1534	P337F	++	+++++	++++	++++
1535/1536	P337G	+	+	+	+
1537/1538	P337H	++	+++	+	++
1539/1540	P337I	++	+	++++	+
1541/1542	P337K	+	++	++	+
1543/1544	P337L	++	+	++	+
1545/1546	P337M	+	+	+	+++
1547/1548	P337N	++	++	+	+
1549/1550	P337Q	+	++	+	+
1551/1552	P337R	++	+++	+++	+
1553/1554	P337S	+++	+++++	++++	+
1555/1556	P337T	+	++	++	+
1557/1558	P337V	+	+	+	+
1559/1560	P337W	+	+	+++++	++
1561/1562	P337Y	+++	+	+++	-
1563/1564	R217A	++	+++	++	+
1565/1566	R217C	+	+	+	++++
1567/1568	R217D	+	++	+	++++
1569/1570	R217E	+++	+++	+++	+

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1571/1572	R217F	++	+	+++	+++
1573/1574	R217G	+++	+++	+++	+
1575/1576	R217H	++	++	+	+++
1577/1578	R217I	+++	+++	+++	+++
1579/1580	R217K	++	++	+	++++
1581/1582	R217L	+	+	+	++
1583/1584	R217M	+	+	+	++
1585/1586	R217N	+++	+++	++	+++
1587/1588	R217P	++	+	+	+++
1589/1590	R217Q	++	++	++	+
1591/1592	R217S	+++	+++	+++	+++
1593/1594	R217T	+	-	+	+++
1595/1596	R217V	++	++	+	++
1597/1598	R217W	+++	+	++++	++
1599/1600	R217Y	+	+	++	+
1601/1602	R44A	++	+	+	+
1603/1604	R44C	++	+++	+	+
1605/1606	R44D	+	-	+	+
1607/1608	R44E	++	+	+	+
1609/1610	R44F	+++	+++	++	+
1611/1612	R44G	+	+	+	+
1613/1614	R44H	+	+	+	++
1615/1616	R44I	+++	+++	+	++
1617/1618	R44K	+++	+++	++	+
1619/1620	R44L	+	+	+	+++
1621/1622	R44N	+	++	++	+
1623/1624	R44P	-	-	+	+
1625/1626	R44Q	+++	++++	+++	+
1627/1628	R44S	++	++	++	++++
1629/1630	R44T	+	+	+	++++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1631/1632	R44V	+++	+++	++++	+
1633/1634	R44W	+	+	+	+
1635/1636	R44Y	+	+	+	++++
1637/1638	T392A	++	++	++	++++
1639/1640	T392C	+	+	+	+++
1641/1642	T392D	+++	++++	+++	++
1643/1644	T392E	+++	+++++	++++	++++
1645/1646	T392F	+	+	+	++
1647/1648	T392G	+	++	+	++
1649/1650	T392H	++	+++	++	+
1651/1652	T392I	+	+	+++	+
1653/1654	T392K	++	+++	+	+++
1655/1656	T392L	++	++	+	+++
1657/1658	T392M	+	++	+	+++
1659/1660	T392N	++	+++	++++	+
1661/1662	T392P	+++	+++	++	+++
1663/1664	T392Q	++	+	+	+++
1665/1666	T392R	++	+++	+	++
1667/1668	T392S	++	+++	+++	++++
1669/1670	T392V	++	+++	++	++
1671/1672	T392W	+	+	+++	++++
1673/1674	T392Y	+	+	+	+
1675/1676	T47A	++	+++	+++	+
1677/1678	T47C	+	+	+	-
1679/1680	T47D	+	+	+	+
1681/1682	T47E	+	+	+	+++
1683/1684	T47F	+	+	+	+++
1685/1686	T47G	+	+	+	+++
1687/1688	T47H	++	+	+++	+
1689/1690	T47I	++	+	++	++

Table 12-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 374) ¹					
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 374)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC	Gb3 Depletion FIOPC
1691/1692	T47K	+	++	+++	+
1693/1694	T47L	+	+	+	+
1695/1696	T47M	+	+	+++	+
1697/1698	T47N	++	++	++	+++
1699/1700	T47P	-	-	-	++
1701/1702	T47Q	+	+	+	++++
1703/1704	T47R	+++	++++	++++	+
1705/1706	T47S	+	+	+	++
1707/1708	T47V	++	+++	++++	+
1709/1710	T47W	+	+	+	+
1711/1712	T47Y	+	+	++	+++
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 374. Levels of increased activity are defined as follows: "-" < 0.1; "+" 0.1-0.9; "++" > 0.9; "+++ > 1.1; "++++" > 1.5; and "+++++" > 2.5.					

EXAMPLE 13**GLA Variants Derived from SEQ ID NO: 1022**

[0200] In this Example, experiments conducted to assess activity, serum stability and intracellular activity in Fabry fibroblasts are described. In these experiments, the GLA variants were tested for MU-Gal activity without pre-incubation, after serum incubation, in lysates of Fabry fibroblasts as described in Example 5.

Table 13-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 1022) ¹				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 1022)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC
1713/1714	D284S	+++	+++	++++
1715/1716	H92T/A368E	+++	++++	++++
1717/1718	K283T	+++	+++	++++
1719/1720	K283T/D284E	++	+	++++

Table 13-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 1022) ¹				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 1022)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC
1721/1722	D284M	+	++	+++
1723/1724	H92T	+++	+++	+++
1725/1726	H92Q	+++	+++	+++
1727/1728	S31T/T47R	++	+	+++
1729/1730	E39V/R44V/T47R/G261S/K283L/D284A	+	+	+++
1731/1732	E39L/D284S	++	+++	+++
1733/1734	A206I	+++	+++	+++
1735/1736	E39V/R44V/K283T	+++	+++	+++
1737/1738	H92V/Q275A/D284S	+	+	+++
1739/1740	H92T/K283P	+++	+++	+++
1741/1742	H92T/D284M	++	+	+++
1743/1744	H155F	+++	++	+++
1745/1746	K302L	+++	+++	+++
1747/1748	G261S	+++	+++	+++
1749/1750	A271K/A368E	+++	+++	+++
1751/1752	H84K/H92V	+++	+++	+++
1753/1754	H92T/A271K	+++	+++	+++
1755/1756	H92V/A206E/D284S	+++	+++	+++
1757/1758	G261S/K283L	+	+	+++
1759/1760	S31T	+	+	+++
1761/1762	H84K/D284S/K302L/T392A	++	++	+++
1763/1764	E39V/R44V/T47R	+++	++	+++
1765/1766	H84K/A368E/T392A	++	+++	+++
1767/1768	D316H	+++	+++	+++
1769/1770	S31T/K283L/D284A			+++
1771/1772	A271K	++	+++	+++
1773/1774	A368E/T392W	+++	+++	+++
1775/1776	R44V	+++	++	+++
1777/1778	A206Q	++	++	+++

Table 13-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 1022) ¹				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 1022)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC
1779/1780	E39L	+++	++	++
1781/1782	H84K/D316H	++	+	++
1783/1784	H92T/K283V/T392W	++	+	++
1785/1786	K283L	+	+	++
1787/1788	P166D/K283L/D284A			++
1789/1790	S31T/E39V/R44V/P166D/K302Y	+		++
1791/1792	A339N	+++	+++	++
1793/1794	Y334C	+	+	++
1795/1796	E39L/H92V	+	+	++
1797/1798	H155F/A368E	++	++	++
1799/1800	H92V	+++	+++	++
1801/1802	H92V/D284S	+	+	++
1803/1804	D284E	++	++	++
1805/1806	T392W	++	+	++
1807/1808	H92V/D316H	+++	+++	++
1809/1810	K283P/T392W	+	+	++
1811/1812	A206T/Y334C	+		++
1813/1814	A368E	+++	++	++
1815/1816	E39V/T47R/G261S			++
1817/1818	Q275A	+++	++	++
1819/1820	H92V/A206Y/Q275A	+++	++	++
1821/1822	P10G	+++		+
1823/1824	H92T/A206E/R217N	+++	+++	+
1825/1826	T392A	+++	+++	+
1827/1828	T392D	++	+	+
1829/1830	E39V/R44V/A339N	+++	++	+
1831/1832	E39V/R44V	+++	+++	+
1833/1834	A206Y	++	+++	+
1835/1836	H92T/A271K/K277R	++	+	+

Table 13-1. Relative Performance of GLA Variants (Relative to SEQ ID NO: 1022) ¹				
SEQ ID NO: (nt/aa)	Amino Acid Differences (Relative to SEQ ID NO: 1022)	Unchallenged FIOPC	Stability FIOPC	Lysate FIOPC
1837/1838	H92T/A206E/K302T/A368E	+++	+	+
1839/1840	A206E	++	+	+
1841/1842	H84K	++	++	+
1843/1844	P166D	+++	+	+
1845/1846	A206E/R217N	++	++	+
1847/1848	H155F/R217I	++	+	+
1849/1850	P10G/T392D	++		+
1851/1852	E39L/A206E	++	++	+
1853/1854	K302Y	+++	+++	+
1855/1856	H92V/K302L	++	+	+
1857/1858	H92T/K302L	++	+	+
1859/1860	P166D/K302Y	++		
1861/1862	R44V/D284E/K302Y	++	+	
1863/1864	P166D/K283T	+		+
¹ All activities were determined relative to the reference polypeptide of SEQ ID NO: 1022. Levels of increased activity are defined as follows: "+" = 0.5-0.9; "++" > 0.9; "+++" > 1.1; and "++++" > 2.				

Serum Stability of Purified GLA Variants Produced in Suspension Cultures

[0201] To assess the relative stability of variants in the presence of blood, samples were exposed to serum. First, 100 μ L of 7.5 μ g/mL purified GLA variants in 1X PBS, pH 6.2, and 90 μ L of human serum were added to the wells of a COSTAR® 96-well round bottom plate (Corning). The plates were sealed and incubated at 37°C, for 0-24h. For the assay, 50 μ L of challenged supernatant were mixed with 50 μ L of 1 mM MUGal in McIlvaine buffer, pH 4.4. The reactions were mixed briefly and incubated at 37°C for 90 minutes, prior to quenching with 100 μ L of 0.5 M sodium carbonate, pH 10.2. Hydrolysis was analyzed using an ENVISION® microplate reader (PerkinElmer) monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Percent residual activity in serum after 24h was calculated by dividing the activity of challenged samples by the activity of unchallenged samples, in which “unchallenged” is hydrolysis measured at time 0 and “challenged” is hydrolysis measured at the

specified time points for each variant. Figure 7 provides a graph showing the residual activity of GLA variants after a challenge with human serum for 0-24 hrs.

Cellular Uptake in Fabry Fibroblasts of Purified GLA Variants Produced in Suspension

Cultures

[0202] Cellular uptake of GLA variants as compared to a reference enzyme (WT GLA [SEQ ID NO: 2]), was determined to assess the overall ability of the variants to be endocytosed into cultured cells. Fabry fibroblasts (GMO2775, Coriell Institute for Medical Research) were seeded into a 96-well culture dish (VWR, #10861-698) containing Minimal Essential Media (MEM; Gibco #11095-080, supplemented with 1% non-essential amino acids (NEAA; Gibco #11140-050) and 15% fetal bovine serum [Corning #35-016-CV]) and allowed to grow to confluency (1-3 days at 37°C, 5% CO₂). After reaching confluency, supplemented MEM was removed by sterile vacuum and replaced with 1 mL/well serum-free MEM +1% NEAA. Enzymes purified as described in Example 4, were added to the cells in a dose response from 220 nM to 2 nM and allowed to incubate for 4 hours at 37°C, 5% CO₂. Cells were washed twice with 100 µL sterile 1xPBS /well, and the PBS was aspirated by sterile vacuum. Cells were then incubated in containing Minimal Essential Media (MEM; Gibco #11095-080, supplemented with 1% non-essential amino acids (NEAA; Gibco #11140-050) and 15% fetal bovine serum [Corning #35-016-CV]) and allowed to incubate at 37°C, 5% CO₂ for 3 days. After 3 days, the cells were washed twice with 100 µL sterile 1xPBS /well, and the PBS was aspirated by sterile vacuum. Then, 25 µL Lysis Buffer (0.2% TRITON X-100™ non-ionic surfactant [Sigma #93443] diluted in 1xPBS) was added to each sample, followed by sonication for 1-2 minutes, and centrifugation at 12,000-14,000 RPM for 10 minutes at 4°C. For the activity assay, 25 µL of cell lysis sample was mixed with 25 µL of 2.5 mM MUGal in McIlvaine buffer, pH 4.6. The reaction plates were sealed and incubated at 37°C for 60 minutes, prior to reaction quenching with 150 µL of 0.5 M sodium carbonate, pH 10.2 per well. MUGal hydrolysis was determined using an ENVISION® microplate reader (PerkinElmer) monitoring fluorescence (Ex. 355 nm, Em. 460 nm). Figure 8 provides a graph of the cellular uptake of purified GLA variants in cultured Fabry patient fibroblasts after 4 hours incubation and 3 day washout at 37°C.

EXAMPLE 14

***In vivo* Characterization of GLA Variants**

[0203] In this Example, experiments conducted using animal models to characterize some GLA variants are described. A summary of the study design to assess the pharmacokinetic profiles in mice is provided in Table 14-1. The study was conducted in a single phase and included 36 male C57Bl/6 mice (20 – 25g). Animals were acclimated for at least three days prior to the experiment. All animals received a 1 mg/kg single IV injection, via tail vein, of either WT GLA (SEQ ID NO: 2) or GLA variants. Individual doses were calculated based on body weights taken on the day of dosing.

Table 14-1. Summary of Study Design				
Group #/Enzyme SEQ ID NO:	Number of Mice	CDX-variant (mg/kg)	Dose Vol (mL)	Post-Dose Blood Collection Time Points
1/ SEQ ID NO: 2	6	1	0.2	5, 20, 40, and 240 minutes
2/ SEQ ID NO: 4	6	1	0.2	
3/ SEQ ID NO: 58	6	1	0.2	
4/ SEQ ID NO: 2	6	1	0.2	10, 30, 60, and 360 minutes
5/ SEQ ID NO: 4	6	1	0.2	
6/ SEQ ID NO: 58	6	1	0.2	

[0204] At the pre-determined time points, approximately 150 μ L of whole blood was collected from six mice per test article (alternating between the two groups of 6 for each time point according to Table 14-1) into heparinized capillary tubes, processed immediately for plasma, and stored at -80°C until assay. Plasma GLA activity was measured using a the standard fluorometric MuGal assay, as described in Example 5. Overall, GLA variants demonstrated superior plasma pharmacokinetic profiles compared to SEQ ID NO: 2, with the latter having the fastest clearance with an estimated half-life ($t_{1/2}$) of about 10 min. In comparison, the $t_{1/2}$ for GLA variants were approximately 10 times higher. The data are provided in Table 14-2.

Table 14-2. PK Parameters for GLA Variants Following IV Administration in Mice					
Enzyme (SEQ ID NO:)	Half Life (hr)	C _{max} (μ g/mL)	AUC _{0-t} (μ g*h/mL)	CL (L/h/kg)	V _z (L/kg)
SEQ ID NO: 2	0.15	4.96	1.26	0.792	0.170
SEQ ID NO: 4	1.58	13.3	12.37	0.076	0.174
SEQ ID NO: 58	1.70	26.6	18.25	0.051	0.125

[0205] In addition to the mouse studies described above, experiments conducted to determine the pharmacokinetics of some GLA variants in healthy rats. A brief study design is shown in Table 14-3. The first study was conducted in 3 phases and included 21 rats. Animals were acclimated for at least three days prior to experiment. All animals received an IV injection, via jugular cannula, of either WT GLA (SEQ ID NO: 2) or a GLA variant. Individual doses were calculated based on body weights taken on the day of dosing.

Table 14-3. Summary of Study Design				
Group # /Enzyme SEQ ID NO:	Number of Rats	CDX-variant (mg/kg)	Dose Vol (mL/kg)	Blood Collection Time Points
1/ SEQ ID NO: 2	3	1	0.5	5, 10, 20, 30, 60 minutes; 4 and 8 hours
2/ SEQ ID NO: 6	3	1	0.5	
3/ SEQ ID NO: 16	3	1	0.5	
4/ SEQ ID NO: 58	3	1	0.5	
5/ SEQ ID NO: 60	3	1	0.5	
6/ SEQ ID NO: 40	3	1	0.5	
7/ SEQ ID NO: 62	3	1	0.5	

[0206] Blood (approximately 0.25 mL) was collected at the pre-determined time points, shown in Table 14-3, from each rat, into EDTA separator tubes, processed immediately for plasma, and stored at -80°C until assay. Plasma GLA activity was measured using the standard fluorometric MuGal assay, as described in Example 5. All GLA variants demonstrated improved PK properties when compared to SEQ ID NO: 2. The data for all PK parameters are provided in Table 14-4.

Table 14-4. PK Parameters for GLA Variants Following IV Administration in Rats						
Enzyme (SEQ ID NO:)	Half Life (hr)	C _{max} (μRFU/mL)	AUC _{0-t} (RFU*hr/mL)	AUC _{0-inf} (RFU*hr/mL)	CL (mL/h/kg per RFU/ng)	V _z (mL/kg per RFU/ng)
SEQ ID NO: 2	0.29	27928	25119	30043	33.29	177.7
SEQ ID NO: 6	4.03	31448	151918	204505	4.89	28.5
SEQ ID NO: 16	1.90	29612	103002	108390	9.23	25.3
SEQ ID NO: 58	2.36	28501	80216	88512	11.3	38.5
SEQ ID NO: 60	2.24	32473	79210	86890	11.5	37.2
SEQ ID NO: 40	2.03	28158	60334	64303	15.6	45.5
SEQ ID NO: 62	2.11	32811	104884	113191	8.83	26.9

[0207] A brief study design for rat PK study number 2 is provided in Table 14-5. The study was conducted in 1 phase and included 18 rats. Animals were acclimated for at least three days prior to experiment. All animals received an IV injection, via jugular vein cannula, of either WT GLA (SEQ ID NO: 2) or a GLA variant. Individual doses were calculated based on body weights taken on the day of dosing.

Table 14-5. Summary of Study Design				
Group # / Enzyme SEQ ID NO:	Number of Rats	CDX-variant (mg/kg)	Dose Vol (mL/kg)	Blood Collection Time Points
1/ SEQ ID NO: 2	3	1	0.5	5, 10, 20, 30, 60 minutes; 4 and 8 hours
3/ SEQ ID NO: 4	3	1	0.5	
4/ SEQ ID NO: 6	3	1	0.5	
5/ SEQ ID NO: 8	3	1	0.5	
6/ SEQ ID NO: 58				

[0208] Blood (approximately 0.25 mL) was collected at the pre-determined time points, shown in Table 14-5, into EDTA separator tubes, processed immediately for plasma, and stored at -80°C until assay. Plasma GLA activity was measured using the standard fluorometric MuGal assay, as described in Example 5. All doses of GLA variants resulted in improved PK properties when compared to SEQ ID NO: 2. Data for all PK parameters are provided in Table 14-6.

Table 14-6. PK Parameters for GLA Variants Following IV Administration in Rats					
Enzyme (SEQ ID NO:)	Half Life (hr)	C _{max} (μRFU/mL)	AUC _{0-t} (RFU*h/mL)	CL (mL/h/kg per RFU/ng)	V _z (mL/kg per RFU/ng)
SEQ ID NO: 2	0.23	21119	14268	70.1	23.6
SEQ ID NO: 4	4.24	23545	96634	7.47	45.7
SEQ ID NO: 6	2.94	21708	72432	11.68	49.5
SEQ ID NO: 8	3.43	23922	86509	9.34	46.2
SEQ ID NO: 58	2.02	23055	55193	16.96	49.3

[0209] In addition to the mouse and rat studies described above, experiments were conducted in a primate model. A brief study design is shown in Table 14-7. The study was conducted in 1 phase and

included 12 male cynomolgus monkeys (2 – 3 kg). Animals were sourced from the test facility's colony and were considered protein naive. All animals received an IV injection, of either WT GLA (SEQ ID NO: 2) or a GLA variant. Individual doses were calculated based on body weights taken on the day of dosing

Table 14-7. Summary of Study Design				
Group #/Enzyme SEQ ID NO:	Number of Monkeys	CDX-variant (mg/kg)	Dose Vol (mL/kg)	Blood Collection Time Points
1/ SEQ ID NO: 2	4	1	1	15, 30, 45, 60, 90 minutes; 2, 4, 6, 8, 12, 24 and 48 hours
2/ SEQ ID NO: 4	4	1	1	
3/ SEQ ID NO: 58	4	1	1	

[0210] Blood (approximately 0.5 mL) was collected at the pre-determined time points, shown in Table 14-7, into EDTA separator tubes, processed immediately for plasma, and stored at -80°C until assay. Plasma GLA activity was measured using the standard fluorometric MuGal assay, as described in Example 5. All doses of GLA variants resulted in improved PK properties when compared to SEQ ID NO: 2. Data for all PK parameters are provided in Table 14-8).

Table 14-8. PK Parameters for GLA Variants Following IV Administration in Cynomolgus Monkeys					
Enzyme (SEQ ID NO:)	Half Life (hr)	C_{max} (µg/mL)	AUC_{0-t} (µg *h/mL)	CL (L/h/kg)	V_z (L/kg)
SEQ ID NO: 2	0.19	21.9	10.2	0.15	0.04
SEQ ID NO: 4	5.2	33.5	108	0.009	0.07
SEQ ID NO: 58	1.32	26.5	35.2	0.03	0.05

[0211] A brief study design is shown in Table 14-9 for the second PK study in monkeys. The study was conducted in 1 phase and included 12 cynomolgus monkeys (3 animals/group). Animals were sourced from the test facility's colony and were considered GLA protein naive. All animals received an IV injection, of either WT GLA (SEQ ID NO: 2) or a GLA variant. Individual doses were calculated based on body weights taken on the day of dosing. Blood samples were taken at the following time points: pre-dose (up to 3 hr), 1, 5, 15, 30 minutes, 1, 2, 4, 8, 12 and 24 hours post dose.

Table 14-9. Summary of Study Design				
Enzyme (SEQ ID NO:)	Route of Administration	TI Dose Level (mg/kg)	TI Concentration (mg/mL)	TI Dose Volume (mL/kg)
SEQ ID NO: 2	IV	1	1	1
SEQ ID NO: 158				
SEQ ID NO: 704				
SEQ ID NO: 1022				

[0212] Blood (approximately 1 mL) was collected at the pre-determined time points, shown in Table 14-7, into EDTA separator tubes, processed immediately for plasma, and stored at -80°C until assay. Plasma GLA activity was measured using the standard fluorometric MuGal assay, as described in Example 5. All doses of GLA variants resulted in improved PK properties when compared to SEQ ID NO: 2. Data for all PK parameters are provided in Table 14-10.

Table 14-10. PK Parameters for GLA Variants Following IV Administration in Monkeys					
Enzyme (SEQ ID NO:)	Half Life (hr)	C _{max} (µg/mL)	AUC _{0-t} (µg *h/mL)	CL (L/h/kg)	V _z (L/kg)
SEQ ID NO: 2	0.23	19.7	5.63	0.185	0.061
SEQ ID NO: 158	1.96	33.2	19.8	0.051	0.144
SEQ ID NO: 704	2.46	24.5	14.8	0.074	0.266
SEQ ID NO: 1022	3.60	24.9	14.1	0.071	0.370

Efficacy of GLA Variants Compared to rhGLA in Fabry Knockout Mice

[0213] Fabry mice (5 month old females; Jackson, stock #3535) and age/sex matched wildtype mice with the identical genetic background were used to assess the efficacy of six GLA variants (SEQ ID NO: 4, 58, 158, 704, 1022, and 1864) compared to WT GLA (SEQ ID NO: 2). Mice were administered enzyme variants (0.1, 0.3, or 1.0 mg/kg, via tail vein injection), once a week for 4 weeks (n = 5/group). 7 days after the last injection, animals were anesthetized to perform a cardiac puncture for blood collection in K3 EDTA tubes, and then euthanized. Whole body perfusion, through the heart, was performed with cold saline to remove contaminating blood from tissues. Disease relevant tissues (e.g., heart and kidney) were dissected into two portions (one for enzyme activity assay, the other for Gb3 and lyso-Gb3 quantification), frozen on dry ice, and stored at -80°C until analysis. Blood was processed immediately for plasma, and stored at -80°C until assay. Plasma and tissue GLA activity was measured using the standard fluorometric MuGal assay, as described in Example 5. Plasma and tissue Gb3 and lyso Gb3 levels were assessed using the method referenced in

Example 10, and tissues were homogenized as described in Example 10. With the exception in some cases of SEQ ID NO: 1864, all GLA variants were more efficacious than SEQ ID NO: 2 in the Fabry mouse model.

[0214] Figures 9 and 10 provide graphs showing *in vivo* enzyme activity in the heart and kidney, respectively, in the Fabry mouse model, 7 days after the last treatment. In Figure 9, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2; " $\wedge$ ", $p < 0.0001$, non-favorable significant improvements over SEQ ID NO: 2 are not shown in this Figure. In Figure 10, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2; "***" $p < 0.05$; "***" $p < 0.005$; and " $\wedge$ ", $p < 0.0001$, non-favorable significant improvements over SEQ ID NO: 2 are not shown in this Figure. Figures 11 and 12 provide graphs of Gb3 degradation in heart and kidney tissue, respectively. In Figure 11, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2; at 0.1 mg/kg dose, "***", $p < 0.05$ for SEQ ID NOS: 158 and 1022; and at 0.3 mg/kg dose, " $\wedge$ ", $p < 0.0001$, for SEQ ID NO: 158; "***", $p < 0.005$ for SEQ ID NOS: 58, 704, 1022, and 1864. In Figure 12, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2; at 0.1 mg/kg dose, " $\wedge$ ", $p < 0.0001$ for SEQ ID NOS: 4, 58, 158, 704, and 1022; and at 0.3 mg/kg dose, " $\wedge$ ", $p < 0.0001$, for SEQ ID NO: 158; "***", $p < 0.005$ for SEQ ID NOS: 4, 58, 704, and 1022. Figures 13 and 14 provide graphs of lyso-Gb3 degradation in heart and kidney tissue, respectively. In Figure 13, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2. In Figure 14, the data are represented as the mean $\pm$ SEM. Two-way ANOVA with Dunnett's post-test was used to compare the results with those of SEQ ID NO: 2; at 0.1 mg/kg dose, "***", $p < 0.005$ for SEQ ID NOS: 4, 58, 158; "***", $p < 0.05$ for SEQ ID NO: 704.

[0215] While the invention has been described with reference to the specific embodiments, various changes can be made and equivalents can be substituted to adapt to a particular situation, material, composition of matter, process, process step or steps, thereby achieving benefits of the invention without departing from the scope of what is claimed.

[0216] For all purposes in the United States of America, each and every publication and patent document cited in this disclosure is incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an indication that any such document is pertinent prior art, nor does it constitute an admission as to its contents or date.

CLAIMS

WHAT IS CLAIMED IS:

1. A recombinant alpha galactosidase A and/or biologically active recombinant alpha galactosidase A fragment comprising an amino acid sequence comprising at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 374, 704, and/or 1022.
2. The recombinant alpha galactosidase A of Claim 1, wherein said recombinant alpha galactosidase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 2, 4, 5, 24/59, 24/143/144, 24/143/202/333, 24/143/202/352/390/391, 24/143/333/352/387/390/391, 24/143/390/391, 24/202, 24/202/271, 24/202/333/352, 24/271/352, 24/352/387/390/391, 24/387/391, 31, 40, 59, 59/143, 59/143/202, 59/143/202/271/333, 59/143/271, 59/143/333, 59/202, 59/202/333, 59/271/387/390, 73, 76, 80, 83, 84, 91/215/361, 122, 123, 143, 143/202, 143/271, 143/271/352/390, 143/333, 143/333/387/390, 143/387/391, 147, 155, 164, 165, 179, 186, 202, 202/333, 210, 215/218, 218, 218/361, 218/361/398, 218/398, 246, 254/398, 271, 271/333, 271/333/390/391, 271/333/391, 271/352/391, 273, 275, 277, 278, 280, 281, 283, 284, 287, 300, 303, 304, 325, 331, 332, 333/352, 333/390/391, 333/391, 334, 335, 336, 338, 339, 340, 341, 343, 359, 360, 361, 362, 367, 369, 371, 373, 375, 377, 382, 382/398, 385, 387/391, 390, and 398, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 704.
3. The recombinant alpha galactosidase A of Claim 1, wherein said recombinant alpha galactosidase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 39, 44, 47, 92, 166, 206, 217, 247, 261, 271, 302, 316, 322, 337, 368, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 374.
4. The recombinant alpha galactosidase A of Claim 1, wherein said recombinant alpha galactosidase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%,

91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO:58, or a functional fragment thereof, and wherein said recombinant alpha galactosidase A comprises at least one substitution or substitution set at one or more positions selected from 10, 10/392, 31, 31/39/44/166/302, 31/47, 31/283/284, 39, 39/44, 39/44/47, 39/44/47/261/283/284, 39/44/283, 39/44/339, 39/47/261, 39/92, 39/206, 39/284, 44, 44/284/302, 84, 84/92, 84/284/302/392, 84/316, 84/368/392, 92, 92/206/217, 92/206/275, 92/206/284, 92/206/302/368, 92/271, 92/271/277, 92/275/284, 92/283, 92/283/392, 92/284, 92/302, 92/316, 92/368, 155, 155/217, 155/368, 166, 166/283/284, 166/302, 206, 206/217, 206/334, 261, 261/283, 271, 271/368, 275, 283, 283/284, 283/392, 284, 302, 316, 334, 339, 368, 368/392, and 392, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1022.

5. The recombinant alpha galactosidase A of Claim 1, wherein said alpha galactosidase A comprises at least one mutation in at least one position as provided in Tables 11.1, 12.1, and/or 13.1.

6. The recombinant alpha galactosidase A of any of Claims 1-5, wherein said recombinant alpha galactosidase A is derived from a human alpha galactosidase A.

7. A recombinant alpha galactosidase A comprising the polypeptide sequence of SEQ ID NO: 374, 704, and/or 1022.

8. The recombinant alpha galactosidase A of any of Claims 1-7, wherein said recombinant alpha galactosidase A is more thermostable than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

9. The recombinant alpha galactosidase A of any of Claims 1-8, wherein said recombinant alpha galactosidase A is more stable at pH 7 than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

10. The recombinant alpha galactosidase A of any of Claims 1-9, wherein said recombinant alpha galactosidase A is more stable at pH 4 than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

11. The recombinant alpha galactosidase A of any of Claims 1-10, wherein said recombinant alpha galactosidase A is more stable to exposure to serum than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

12. The recombinant alpha galactosidase A of any of Claims 1-11, wherein said recombinant alpha galactosidase A is more lysosomally stable than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

13. The recombinant alpha galactosidase A of any of Claims 1-12, wherein said recombinant alpha galactosidase A is more readily taken up by cells than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

14. The recombinant alpha galactosidase A of any of Claims 1-13, wherein said recombinant alpha galactosidase A depletes more globotriaosylceramide from cells than the alpha galactosidase A of SEQ ID NO: 2, 374, 704, and/or 1022.

15. The recombinant alpha galactosidase A of any of Claims 1-14, wherein said recombinant alpha galactosidase A is purified.

16. The recombinant alpha galactosidase A of any of Claims 1-15, wherein said recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7; iii) increased tolerance to pH 4; iv) increased tolerance to serum; v) increased uptake into cells; vi) increased depletion of globotriaosylceramide from cells; vii) reduced immunogenicity; or a combination of any of i), ii), iii), iv), v), vi), and/or vii), as compared to a reference sequence.

17. The recombinant alpha galactosidase A of Claim 16, wherein said reference sequence is selected from SEQ ID NO: 374, 704, and/or 1022.

18. A composition comprising at least one recombinant alpha galactosidase A of any of Claims 1-17.

19. A recombinant polynucleotide sequence encoding at least one recombinant alpha galactosidase A set forth in any of Claims 1-18.

20. The recombinant polynucleotide sequence of Claim 19, wherein said polynucleotide sequence is selected from DNA, RNA, and mRNA.

21. The recombinant polynucleotide sequence of Claim 20, wherein said polynucleotide sequence is codon-optimized.

22. An expression vector comprising the recombinant polynucleotide sequence of Claims 19, 20, and/or 21.
23. The expression vector of Claim 22, wherein said recombinant polynucleotide sequence is operably linked to one or more control sequences.
24. The expression vector of Claim 23, wherein said control sequence is a promoter.
25. The expression vector of Claim 24, wherein said promoter is a heterologous promoter.
26. A host cell comprising the expression vector of any of Claims 22-25.
27. The host cell of Claim 26, wherein said host cell is selected from eukaryotes and prokaryotes.
28. The host cell of Claim 26 and/or 27, wherein said host cell is a mammalian cell.
29. A method of producing an alpha galactosidase A variant, comprising culturing said host cell of any of Claims 26-28, under conditions that said alpha galactosidase A encoded by said recombinant polynucleotide is produced.
30. The method of Claim 29, further comprising the step of recovering said alpha galactosidase A.
31. The method of Claim 30, further comprising the step of purifying said alpha galactosidase A.
32. A pharmaceutical composition for the treatment of Fabry disease, comprising the composition of Claim 18.
33. The pharmaceutical composition of Claim 32, further comprising a pharmaceutically acceptable carrier and/or excipient.
34. The pharmaceutical composition of Claims 32 and/or 33, wherein said composition is suitable for parenteral injection or infusion to a human.

35. A pharmaceutical composition comprising the recombinant polynucleotide of any of Claims 19-21.

36. A method for treating and/or preventing the symptoms of Fabry disease in a subject, comprising providing a subject having Fabry disease, and providing the pharmaceutical composition of any of Claims 32-35, to said subject.

37. The method of Claim 36, wherein said symptoms of Fabry disease are ameliorated.

38. The method of Claim 36 and/or 37, wherein said subject is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease.

39. The method of any of Claims 36-38, wherein said subject is an infant or child.

40. The method of any of Claims 36-39, wherein said subject is an adult or young adult.

41. Use of the compositions provided in any of Claims 18, and 32-35.